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 ABSTRACT 
 
The aim of this thesis was to determine the diagnostic accuracy of outpatient endometrial 
evaluation using endometrial biopsy (EB), ultrasound scan (USS) and hysteroscopy (OPH) by 
conducting systematic quantitative reviews of the published literature. The optimum 
diagnostic strategy in terms of cost-effectiveness (cost per life year gained), was then 
established for the investigation of women with post-menopausal bleeding (PMB) for 
endometrial cancer, using the review data in a decision analysis designed to reflect current 
service provision. Meta-analyses showed that a positive test result following EB or OPH was 
more useful for predicting endometrial disease than USS, whereas a negative test result 
following USS was more useful for excluding endometrial disease than EB or OPH. The 
economic model included 12 diagnostic strategies and indicated that a strategy based on initial 
diagnosis with USS, using a 5mm double layer endometrial thickness cut-off, was the most 
cost-effective. Sensitivity analyses showed that initial investigation with EB or USS using a 
4mm cut-off were also potentially cost-effective (incremental cost-effectiveness ratios under 
£30,000 per life year gained) at their most favorable estimates of diagnostic performance, in 
women under 65 years and at disease prevalence of 10% or more. The choice between initial 
testing with EB or USS will therefore depend upon patient age and preference, disease 
prevalence and the availability of high quality USS. In most circumstances women presenting 
for the first time with PMB should undergo initial evaluation with pelvic ultrasound using a 
threshold of 4mm or 5mm to define abnormal results.  
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CHAPTER I 
1  
BACKGROUND 
 
1.1 The underlying problem 
 
Postmenopausal bleeding (PMB), unscheduled bleeding on hormone replacement therapy 
(HRT) and menorrhagia are common gynecological problems.
71
 
310
 The main aim of 
investigations for abnormal uterine bleeding is to exclude serious intrauterine pathology, 
namely endometrial cancer and hyperplasia,
232
 conditions most prevalent in postmenopausal 
women. 
 
Traditional investigation of women with postmenopausal bleeding using inpatient blind 
dilatation of the cervix and curettage of the endometrium (D&C) is now considered out-dated 
practice and has been replaced by initial outpatient endometrial evaluation using miniature 
endometrial biopsy (EB) devices, transvaginal ultrasound scan (USS) and outpatient 
hysteroscopy (OPH).
310
 However, despite the widely accepted advantages of outpatient 
investigation, there is uncertainty regarding the individual value of these tests and the best 
sequence or combination in which to use them. Consequently practice varies throughout 
Europe and North America,
3,59,70,251,296,326
  largely dependent upon prejudice (of individual 
clinicians) and pragmatism (resources available to them).  
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The main aim of investigating women with PMB is to exclude endometrial cancer and its 
precursor, endometrial hyperplasia. The incidence of endometrial cancer has increased during 
the last decade.
251,272
 Unlike other malignancies affecting women, endometrial cancer often 
presents at an early stage with the possibility of curative treatment by hysterectomy.
251
 
Prognosis is increasingly bleak the more advanced the disease. As there have been no recent 
advances in the treatment of endometrial cancer that can be expected to increase survival, the 
importance of accurate and timely diagnosis of endometrial cancer is paramount in order to 
reduce mortality further. 
 
This thesis assesses the diagnostic accuracy of currently available outpatient tests for the 
clinical investigation of women with PMB for endometrial cancer and hyperplasia. Moreover, 
the thesis examines the cost-effectiveness of strategies utilising EB, USS and OPH for the 
diagnosis of endometrial cancer. 
 
1.1.1 Aetiology and epidemiology of postmenopausal bleeding 
PMB is a common clinical problem in both general practice and hospital settings.
1,89,310
 
Women are most likely to present with this symptom in the sixth decade of life
272
 where 
consultation rates in primary care for PMB are 14.3/1000 population.
1,272
 Similarly, in the 
hospital setting, abnormal patterns of uterine bleeding account for more than 70% of all 
gynaecological consultations in the peri- and post-menopausal years.
310
 At the Birmingham 
Women‟s Hospital  (BWH), which serves a female population of 220,000 (of which one can 
assume 80,000 are postmenopausal), approximately 1000 women are seen each year with 
PMB (incidence 12.5/1000 population).  
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In most instances (90-95%), PMB results from benign causes such as intrauterine structural 
pathologies (polyps, fibroids) or prescription of exogenous hormones. Often, bleeding arises 
from apparently normal atrophic endometrium and is thought to be due to superficial petechial 
haemorrhages and mucosal ulceration.
278,342
 However, the main aim of investigations for 
PMB is to exclude endometrial cancer,
232 
which presents with this symptom in over 95% of 
cases.
250
 The probability of endometrial cancer in women presenting with PMB is 
approximately 5-10%
16,146,149,251
 and therefore referral of such women for further investigation 
in secondary care is mandatory. Published recommendations state that women should be seen 
within 2-6 weeks of referral.
251
 On referral, some additional means of endometrial assessment 
are performed, as it is not possible to exclude cancer on clinical assessment alone. 
Traditionally, abnormal uterine bleeding has been investigated with blind D&C under general 
anaesthetic but now there is a trend towards minimally invasive, outpatient investigations 
utilising EB, USS and OPH first (see current service provision below).
251
  
 
Although cervical cancer can present with PMB, most women with this condition present 
below the age of 55 years with intermenstrual bleeding, postcoital bleeding, vaginal discharge 
or pain.
251,259
 The diagnosis is made from clinical examination and cervical biopsy. The 
diagnosis of cervical cancer is not considered further in this thesis.  
 
1.1.2 The epidemiology and management of endometrial cancer 
Endometrial cancer represents the most common female pelvic genital malignancy in the 
western world
136
 and is increasingly common among more affluent populations
272
 and 
increases with the adoption of more westernised lifestyles.
272
 The aetiology of endometrial 
cancer is unknown, but several factors are known to increase or decrease the likelihood of 
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developing endometrial cancer. The most important of these appear to be age, obesity and 
unopposed endogenous or exogenous oestrogen production.
272
  
 
In England and Wales, there are around 4000 new cases of endometrial cancer per annum 
(440 in the West Midlands), representing almost 4% of all cancer cases in women, in whom it 
is ranked 5
th
.
251,272
 Incidence rates are approximately 50 per 100,000 population in women 
over 60 years. The overall age-standardised rate has remained close to 12/100,000 since the 
1970s, but in women aged 55-74 rates have increased slightly in the 1990s.
251
 The lifetime 
risk of developing endometrial cancer has been estimated to be 1.4%. An average general 
practitioner with a list size of 2000 would expect to see 1 new case of endometrial cancer 
every 6 years. In contrast to the trends in incidence, there have been long-term declines in 
mortality from cancer of the uterus. The age-standardised rate has halved – from 6/100,000 in 
1950 to 3/100,000 in 1999. In England and Wales survival was only slightly below the 
European average, but was well below that in the Netherlands, Germany, France and more 
than 10% below rates in the USA.
272
 Overall 5-year survival is around 77%, and improves 
with early stage localised disease. Around 70% of women diagnosed with endometrial cancer 
have early stage disease and 5-year survival is around 87%. Survival is worse for later stage 
disease at around 60% and is as low as 19% with the most advanced stage of disease.
72
 If 
detected at an early stage, endometrial cancer is curable in most cases, usually by surgery 
(hysterectomy) and/or radiotherapy. As there have been no recent advances in the treatment of 
endometrial cancer that can be expected to increase survival, the importance of accurate and 
timely diagnosis of endometrial cancer is paramount in order to reduce mortality further. 
 
 5 
1.1.3 The epidemiology and management of endometrial hyperplasia 
Endometrial hyperplasia is more prevalent than endometrial cancer and affects both pre and 
postmenopausal women.
10,199,206
 The probability of endometrial hyperplasia in women 
presenting with postmenopausal bleeding (with or without HRT) is approximately 15%.
63,206
 
The risk factors for developing hyperplastic endometrium are the same as for endometrial 
cancer and thus relate mainly to unopposed oestrogen exposure. Endometrial hyperplasia is 
categorised histologically by the degree of architectural disruption (simple or complex 
hyperplasia) and by the presence of abnormal cytology (atypia). The importance of 
endometrial hyperplasia relates not only to the symptoms of genital tract bleeding it can 
cause, but to its oncogenic potential. The natural history of endometrial hyperplasia is not 
fully understood.
125
 What is known is that a proportion of simple and complex hyperplastic 
processes will regress without treatment
199
 although the time scale over which such regression 
may occur is unclear. However, a small proportion (estimated to be between 1 and 3%
199
) will 
progress to frank endometrial cancer. The main prognostic factor is the presence of atypical 
cells. Malignant progression has been reported to occur in 30% of atypical endometrial 
hyperplasias if left untreated.
120,175,199
 
 
Management depends upon accurate and timely diagnosis. Endometrial hyperplasia without 
atypia can be managed without the need for treatment as the condition may regress 
spontaneously, but regular endometrial assessment is required to exclude disease 
progression.
120,125,199
 Medical treatments include systemic (oral/parenteral)
120,125,339
 or local 
(intrauterine) progestogens to reverse the oestrogen dominant milieu.
267,288
 Traditional 
treatment is with hysterectomy.
120,339
 In the presence of atypical cells, hysterectomy is usually 
recommended in view of the potential for malignant transformation.
120
 Erroneous diagnosis 
 6 
can thus be detrimental to patients. For example, unnecessary surgery may be performed for 
false positive diagnoses of hyperplastic endometrium whereas false negative diagnoses can 
result in progression to endometrial cancer. 
 
1.2 Investigation of women with postmenopausal bleeding  
 
The traditional investigation for PMB was inpatient dilatation of the cervix and curettage of 
the endometrium (D&C).
152
 This is now considered out dated practice
71
 and has been largely 
replaced by the development of minimally invasive diagnostic tools for use in the outpatient 
setting. These new diagnostic modalities include outpatient endometrial biopsy (EB), 
transvaginal ultrasonography (USS) and outpatient hysteroscopy (OPH). (Table 1-1). 
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Table  1.1 Diagnostic modalities available to detect endometrial cancer and 
hyperplasia in women with postmenopausal bleeding 
 
     
Features Endometrial 
Biopsy 
Ultrasound  Hysteroscopy Prevailing clinical opinion 
     
     
Safety    All safe,
12,62,63,160,303
 endometrial 
biopsy has more potential for 
trauma as it is a blind procedure 
     
Acceptability    All acceptable 
210109,195
, ultrasound 
least painful and invasive, 
endometrial biopsy most painful
320
 
     
Feasibility    Failure rates higher in procedures 
requiring uterine instrumentation. 
Endometrial biopsy higher than 
hysteroscopy.
38,62,63,164
  
     
Other Minimal 
expertise 
required
62
 
Extracavity / 
pelvic 
information
37
 
Directed 
endometrial 
biopsies
134
 
Advances in the technology and 
application of ultrasound
6,33,291
 and 
other radiographic imaging 
techniques
168
 gives this modality 
the greatest future potential in 
diagnosis 
     
 
 invariably   typically  generally 
 
 
Outpatient EB (Figure 1-1) is a blind procedure where the endometrium is sampled using 
small-diameter mechanical or suction devices, which can be easily introduced into the uterine 
cavity without the need for anaesthetic. There is concern however, surrounding the non-
representative nature of these blind procedures, which may be related to the small proportion 
of the endometrial surface sampled
277
 and the non-sampling of focal intrauterine lesions.
157
  
 
 8 
The development of pelvic ultrasound scanning (transabdominal or transvaginal) has allowed 
high resolution imaging inside the uterus enabling measurement of the endometrial thickness. 
(Figure 1-2 to 1-4) 
303
 It has been shown that the endometrial thickness of normal atrophic 
uterus measures on average 2.3 mm
123,146,243,244
.  However, advanced endometrial cancer has 
also been known to occur in cases without noticeable endometrial thickness on ultrasound
96
 
The expertise and availability of ultrasound to gynaecologists varies throughout the UK, 
Europe and North America. Consequently, radiologists or trained radiographers rather than 
gynaecologists often perform USS. In the United Kingdom this situation is likely to change as 
a result of the recent introduction of specialist gynecological training in USS.
280
 
 
Hysteroscopy (Figures 1-5 and 1-7) is an endoscopic technique allowing visualisation of the 
endometrial cavity. Recent advances in instrumentation have allowed hysteroscopy to be 
performed in an outpatient setting, further increasing its use in gynecological practice.
296
 
Various macroscopic features have been suggested as indicative of endometrial disease. 
However, there is no consensus and visual interpretation is subjective and operator 
dependent.
56
 Concerns surrounding the role and value of hysteroscopic diagnosis have 
therefore arisen.
5,25,164,232
  
 
All the forgoing outpatient modalities are generally considered to be safe,
62,63
 simple to use, 
62,63
 and acceptable to patients.
26,109,194,195
 In addition, avoiding the need for an inpatient stay 
potentially reduces health resources utilisation. Such considerations have been examined in 
three published economic evaluations
257,167,119
  (Appendix 2), which were based on imprecise 
data derived from small primary studies. The use of a single outpatient testing strategy in 
comparison to blind inpatient D&C was explored in each study. Two of the studies found 
 9 
outpatient investigation using EB or OPH to be more cost-effective than inpatient D&C in 
terms of complications avoided and additional cases of cancer detected.
257,167 
The study of 
highest quality found EB to be most cost-effective as measured by survival, compared to a 
policy of observation until bleeding recurred, D&C or immediate hysterectomy.
119
 The 
relevance of these studies, is however, questionable given that endometrial assessment using 
D&C as a first-line is now outdated in clinical practice.
71
 So, despite the widely accepted 
advantages of outpatient investigation, there is considerable debate regarding the best way to 
evaluate women with PMB for serious endometrial disease and consequently practice varies 
throughout the United Kingdom
3,59,251,272
 Practice is largely dependent upon individual 
clinician preference and resources available to them. 
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Figure  1-1  Outpatient endometrial biopsy devices 
A variety of outpatient endometrial biopsy devices exist and their common mode of action involves 
mechanically abrading and/or aspirating endometrium from the uterine cavity. 
 
A) Panoramic view 
 
B) Magnified view
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Figure  1-2  Outpatient endometrial biopsy  
 
A) Insertion of endometrial biopsy device into the uterus 
 
B) Endometrial tissue specimen 
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Figure  1-3 Pelvic ultrasound 
A) Transducers suitable for gynaecologic pelvic ultrasound scans: Transabdominal 
and transvaginal probes 
 
B) Transvaginal probe (magnified view).  
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Figure  1-4 Transvaginal ultrasound 
The probe is gently inserted into the vagina with the patient in a semi-recumbent position and an 
empty bladder. The depth of tissue for ultrasound to penetrate is minimal using a transvaginal 
technique thereby allowing the use of higher frequency transducers with improved image resolution. A 
transabdominal scan often precedes the transvaginal approach. 
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Figure  1-5 Endometrial thickness measured by transvaginal ultrasound scan 
 
A) Normal, thin (atrophic) postmenopausal endometrium (3mm thickness) 
 
B) Abnormal thickened postmenopausal endometrium (18mm thickness) 
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Figure  1-6 Hysteroscopy 
Small diameter rigid or flexible endoscopes are used to image directly inside the uterine cavity 
(Reproduced with kind permission of JAMA) . 
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Figure  1-7 Semi-rigid 2.5mm diameter hysteroscopes 
Miniaturisation of endoscopes has facilitated their use in the outpatient setting 
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Figure  1-8 Hysteroscopic views of the endometrium 
A) Normal view showing thin, atrophic postmenopausal endometrium 
 
B) Abnormal view showing thickened, irregular and vascular endometrium. 
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1.3 Current service provision in the United Kingdom 
 
Referral of all women presenting with PMB in the primary care setting for further 
investigation is mandatory
251
 in order to exclude endometrial cancer. All women referred 
should be seen within 2 weeks.
251
 Endometrial assessment is performed on referral, utilising 
the outpatient tests, EB, USS or OPH. This often takes place in a „one stop‟ setting where the 
investigation(s) take place during a single consultation with no planned follow up unless 
test(s) fail or abnormal results are found. Negative findings result in discharge back to 
primary care, whereas a positive diagnosis leads to advanced treatment in most instances. 
Treatment for endometrial cancer varies, although in most instances hysterectomy and 
surgical staging is performed followed by adjuvant non-surgical treatments where necessary. 
279,105 
The typical event pathway is shown in Figure 1-9, which is the essential basis of any 
cost-effectiveness analyses. 
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Figure  1-9  Event pathway (current service provision) for the investigation and management of women with postmenopausal 
bleeding 
 
 
 
 
PMB = postmenopausal bleeding, GP = General Practitioner 
* Some combination of endometrial biopsy, pelvic ultrasound and hysteroscopy 
** Surgery (hysterectomy) with or without adjuvant radiotherapy / chemotherapy 
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1.4 Existing evidence on accuracy of diagnostic tools 
 
The bibliographic databases MEDLINE (1966-2001) and EMBASE (1982-2001) were 
searched for existing published evidence addressing the accuracy of investigative tools used 
in PMB. This showed that in the last decade, there have been many publications indicating 
that outpatient EB, ultrasound measurement of endometrial thickness and ambulatory 
hysteroscopy may be useful in predicting endometrial cancer and hyperplasia. However, 
individual studies addressing accuracy of these minimally invasive diagnostic tools, are small 
leading to imprecise and heterogeneous estimates of accuracy.
51
 In addition, many studies 
have used measures of diagnostic accuracy that are not clinically intuitive. The generation of 
conflicting and confusing data has thus hampered clinical interpretation. The absence of a 
uniform strategy for the investigation of women with PMB has resulted because of a 
deficiency in the rigorous assessment of these newer diagnostic tools. 
 
No systematic reviews of EB, USS or OPH were available at the outset of the research 
forming this thesis. However, during the course of my research program, two systematic 
reviews of USS and one of EB were published. The results and conclusions of all these 
reviews are of limited validity due to potential biases in their methodological approach as 
discussed later in the thesis (see section 4.4). I was unable to identify any systematic reviews 
addressing the diagnostic accuracy of hysteroscopy. Therefore the need to conduct 
comprehensive high quality reviews in this field was clear.  
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1.5 Existing economic evidence  
 
The bibliographic databases MEDLINE (1966-2001) and EMBASE (1988-2001) were 
searched for existing published economic evidence addressing the cost-effectiveness of 
investigative tools currently used in PMB for detecting endometrial cancer. The search 
strategy used is shown in Appendix 1. In addition, the NHS Economic Evaluation Database 
(EED) held at the Centre for Reviews and Dissemination at the University of York and the 
Cochrane Library were also searched. Following the electronic searches of MEDLINE and 
EMBASE, there were 26 potentially eligible studies identified of which one
337
 was selected 
after obtaining the full manuscripts. No manuscripts were selected from the EED out of 22 
potentially eligible studies. No relevant studies were found from the Cochrane Library.  
 
This study addressed outpatient investigation using USS or EB, and concluded that initial 
evaluation with USS was less costly than initial evaluation with EB in relation to test 
feasibility.
337
 No study was identified that evaluated the cost-effectiveness of all 
contemporary outpatient modalities (i.e. EB, USS and OPH) used in sequence or combination 
for the investigation of postmenopausal bleeding for endometrial cancer (Appendix 2). 
Therefore there is a need to conduct a rigorous economic evaluation of diagnostic tools 
current used in investigating women with PMB for endometrial cancer.  
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1.6 Research questions 
1.6.1 Questions addressed by this thesis 
The following questions were posed in this thesis. 
 
In women presenting with postmenopausal bleeding: 
1. What is the accuracy of outpatient endometrial biopsy in the diagnosis of endometrial 
cancer and hyperplasia and what are the rates of failure and complications?  
2. What is the accuracy of outpatient endometrial ultrasound in the diagnosis of endometrial 
cancer and hyperplasia? 
3. What is the accuracy of outpatient hysteroscopy in the diagnosis of endometrial cancer 
and hyperplasia and what are the rates of failure and complications? 
4. Which of the above three tests and their combination is most cost effective in outpatient 
diagnosis of endometrial cancer? 
 
1.6.2 Framing questions 
Careful formulation of focussed research questions is necessary to aid the appropriate design 
of systematic reviews and cost-effectiveness analyses so that specific answers can be 
provided. The components of research questions in diagnosis are generally a population, a test 
and a reference standard against which the accuracy of the test will be measured. Some other 
outcome of interest may also be specified. Breaking down a question into these component 
parts facilitates the precise identification of problems needing to be addressed.
186
 The factors 
considered when formulating the questions posed in this thesis are discussed below: 
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1.6.2.1 Question 1 
What is the accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer 
and hyperplasia in women with postmenopausal bleeding and what are the rates of failure and 
complications? 
 
 
 
      
 
 
 
 
 
Endometrial cancer and its precursor, endometrial hyperplasia, are the most important 
diagnoses to exclude in women with abnormal uterine bleeding. These conditions are more 
common in postmenopausal women, although they can occur in pre-menopausal women, 
where menstrual dysfunction is prevalent and also in perimenopausal women with 
unscheduled bleeding whilst taking hormone replacement therapy (HRT). Endometrial biopsy 
is performed in both pre and postmenopausal women and so in order to maximise the 
information about test accuracy, the population was not restricted to postmenopausal women. 
However, where possible, data was stratified according to menopausal status and HRT use.  
 
Miniature endometrial biopsy devices have been designed for use in the conscious patient in 
an outpatient setting and various devices are now available. Although they can be used in the 
unconscious inpatient, they are almost always used in the conscious outpatient and therefore 
 
Population:     Women with abnormal pre or postmenopausal uterine bleeding  
 
Test:          Outpatient endometrial biopsy 
 
Reference standard: Histology of endometrial cancer and hyperplasia of a specimen obtained by an 
independent method (e.g. hysterectomy) 
 
Other outcomes:   Failure to successfully complete the test 
         Complications attributable to the test 
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the question of diagnostic performance was restricted to the outpatient setting, where it is 
most relevant. Both the test and reference standard (inpatient endometrial curettage or 
hysterectomy specimen) involve histological examination of obtained endometrial tissue. 
Therefore the disease outcomes of interest (endometrial cancer and hyperplasia) could be 
directly compared with one another facilitating ease of data abstraction. This also allowed the 
impact of the severity of endometrial hyperplasia on the diagnostic performance of 
endometrial biopsy to be examined, by stratifying data according to the presence or absence 
of abnormal cytology (atypical cells). Non-endometrial uterine malignancies were not 
considered in any of the reviews and where they occurred were excluded from analysis. 
 
Good diagnostic performance depends upon test feasibility and safety in addition to 
diagnostic accuracy. This is especially true for tests designed for use in the outpatient setting, 
where patient factors may limit successful completion of the test. Unsuccessful sampling 
using outpatient endometrial biopsy was categorised as either failed procedures (i.e. failure to 
correctly position the device in the uterine cavity) or as histologically inadequate specimens 
(failure to obtain adequate endometrial tissue for histological diagnosis from a correctly sited 
device within the uterine cavity). Failed procedures may occur because of technical 
difficulties (usually unfavourable uterine anatomy) or pain resulting from the outpatient 
procedure. Histologically inadequate specimens are important because they may reflect the 
normal atrophic postmenopausal endometrial state where obtaining endometrial tissue would 
not necessarily be expected, rather than poor test performance. This consideration is important 
in clinical practice as it presents problems of interpretation. Failure to successfully complete 
the test was thus defined as both including and excluding histologically inadequate specimens 
(see data abstraction in chapter 3). Complications were categorised according to whether they 
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arose directly from the test procedure itself (e.g. visceral damage, haemorrhage, infection, 
vaso-vagal episodes) or indirectly (e.g. exacerbation of existing health problem such as 
angina) and by severity (potentially life threatening or not).    
 
1.6.2.2 Question 2 
What is the accuracy of pelvic ultrasound in the diagnosis of endometrial cancer and 
hyperplasia in women with postmenopausal bleeding? 
 
 
 
 
 
 
   
 
 
 
Measurement of endometrial thickness by pelvic ultrasound can be performed using 
transabdominal probes or more recently using transvaginal probes allowing better image 
resolution.
128
 The procedure is rarely, if ever, required as an inpatient admission. 
Measurement of endometrial thickness is useful in postmenopausal women because oestrogen 
dependent endometrial thickening does not occur and so thin endometrium is considered 
normal. In contrast, thickened endometrium may represent the important diagnoses of cancer 
and hyperplasia as well as other benign conditions such as endometrial polyps. There is 
considerable debate regarding what constitutes an abnormally thickened endometrium and so 
various measurement cut-offs have been used.
160,303,319
 Different methods for measuring 
endometrial thickness by ultrasound exist (e.g. single layer and double layer measurement) 
 
Population:     Women with abnormal pre or postmenopausal uterine bleeding  
 
Test:          Endometrial thickness measured by pelvic ultrasound 
 
Reference standard: Histological confirmation of endometrial cancer and disease (cancer + 
hyperplasia) 
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and this has complicated the situation further. For the purposes of this review, all studies of 
symptomatic postmenopausal women undergoing pelvic ultrasound were included, but data 
were grouped according to the type of ultrasound probe, cut-off level for abnormality and 
measurement method used. 
 
Pelvic ultrasound is not confined to use in postmenopausal women, but is widely employed in 
pre-menopausal women with abnormal menstrual bleeding. This is because patient acceptance 
is almost universal
128,303
 and the modality allows the myometrium and ovaries to be imaged, 
in addition to the uterine cavity and endometrium. Consequently, the most commonly 
occurring gynaecologic pathology in women of reproductive age, uterine fibroids
340
 and 
benign ovarian cysts,
28
 can be diagnosed with a high degree of accuracy.
105,176
 However, 
measurement of endometrial thickness to diagnose endometrial cancer or hyperplasia is of 
limited use in this population.
80,92,102,104,106,268
 This is because a thickened endometrium is 
normally seen in pre-menopausal women as a result of ovarian oestrogen production and the 
extent of endometrial thickening varies in accordance with the stage of the menstrual cycle.
242
 
Furthermore, the prevalence of endometrial cancer is very low in premenopausal women with 
menstrual dysfunction
27,219,271
 and benign endometrial polyps, which cause focal endometrial 
thickening, are far more common.
20,103
 The population in my research question was therefore 
restricted to postmenopausal women with vaginal bleeding. Exogenous oestrogen given to 
postmenopausal women as part of HRT may cause endometrial proliferation to a varying, but 
lesser degree than in pre-menopausal women.
147
 Thus, symptomatic postmenopausal women 
on HRT were also included in the population, although data was stratified according to HRT 
usage. 
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The review of endometrial biopsy was conducted first, where the diagnostic reference 
standard was endometrial histology obtained by inpatient sampling (endometrial curettage, 
directed biopsy, endometrial resection and hysterectomy specimens). However, a significant 
proportion of primary studies assessing diagnostic accuracy of ultrasound (and hysteroscopy) 
used outpatient endometrial biopsy devices to obtain histological samples. The results of the 
review of outpatient endometrial biopsy showed high diagnostic accuracy (see chapter IV). 
Bias due to misdiagnosis by endometrial biopsy, though considered unlikely to be a 
significant problem, was explored with subgroup analyses based on variation in histological 
reference standard (see chapter III). In contrast to the research question posed for endometrial 
biopsy, the condition of endometrial hyperplasia was not considered, but instead it was 
included together with endometrial cancer under the heading „endometrial disease.‟ This 
approach was used because ultrasonic (and hysteroscopic) features of hyperplasia are not 
clearly distinct from those of endometrial cancer
56
 and such an approach has previously been 
used.
134,303
 
 
The safety of ultrasound has been well established
12
 and a previous systematic review
303
 has 
reported negligible failure rates and so these outcomes were not considered. 
 
1.6.2.3 Question 3 
What is the accuracy of hysteroscopy in the diagnosis of endometrial cancer and hyperplasia 
in women with postmenopausal bleeding and what are the rates of failure and complications? 
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Hysteroscopy can be carried out as an inpatient test under general anaesthetic or as an 
outpatient test in the conscious patient. The research question relates to outpatient 
investigative tools in women with postmenopausal uterine bleeding. However, as with 
endometrial biopsy, hysteroscopy is performed in both pre and postmenopausal women and so 
in order to maximise the information about test accuracy, the population was not restricted to 
postmenopausal women. However, where possible, data was stratified according to the setting 
and menopausal status. Diagnosis of the conditions endometrial cancer or disease was 
considered (see question formulation for pelvic ultrasound – see section 1.6.2.2). Where 
cancer or hyperplasia was suspected within a focal abnormality, these were categorised under 
cancer and/or disease.  
 
Hysteroscopic procedures failing to make a final diagnosis because of technical aspects (e.g. 
cervical stenosis, anatomical factors, structural abnormalities), inadequate visualization (e.g. 
obscured by bleeding, endometrial debris) or patient factors (e.g. pain, intolerance) were 
categorized as failed procedures. Complications were categorised in the same way as for 
endometrial biopsy (see section 1.6.2.1). 
 
Population:     Women with abnormal pre or postmenopausal uterine bleeding  
 
Test:          Hysteroscopy 
 
Reference standard: Histological confirmation of endometrial cancer and disease (cancer + 
hyperplasia) 
 
Other outcomes:   Failure to successfully complete the test 
         Complications attributable to the test 
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1.6.2.4 Question 4 
What is the most cost-effective outpatient test or combination of outpatient tests for the 
diagnosis of endometrial cancer in women with postmenopausal bleeding? 
 
 
 
 
  
 
 
 
     
 
Endometrial cancer is the most important diagnosis to exclude in women with abnormal 
uterine bleeding. This potentially life-threatening diagnosis is invariably made in association 
with postmenopausal bleeding (PMB), where endometrial cancer is found in 5-10% of such 
women.
16,146,149,251
 Additional means of outpatient endometrial assessment is mandatory
251
 
(traditional investigation with inpatient dilatation and curettage as a first-line is considered 
outdated practice),
71
 but which test or combination of tests is best to use is not established and 
consequently is the focus of clinical debate and the reason for eclectic hospital 
practice.
3,59,251,272
 Endometrial hyperplasia is not considered to be premalignant unless found 
in association with abnormal cytology.
120,175,199
 The hyperplastic process is usually reversed 
with simple hormonal treatment.
120,267,288,339
 Endometrial cancer is the only diagnosis 
considered to significantly affect survival and therefore the management of this condition has 
been chosen for the cost-effectiveness analysis, where effectiveness is measured in terms of 
life years gained.  
 
Population:    Women with postmenopausal uterine bleeding  
 
Test:         Diagnostic approaches utilising various combinations of outpatient endometrial 
biopsy, ultrasound and hysteroscopy  
 
Clinical outcome:  Survival following diagnosis and treatment of endometrial cancer  
 
Economic outcome: Costs incurred in testing and in treating endometrial cancer  
        (NHS hospital perspective) 
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The benefits and costs of using an intervention to treat a disease depend upon whose 
perspective it is (i.e. patient, hospital, payer, society etc.) The societal perspective is the most 
comprehensive one (and encompasses all other perspectives), as it considers all costs and 
benefits irrespective of who pays and who benefits. This is of use to government and policy 
makers who are interested in allocating resources to improve population welfare.
231
 However, 
our main concern related to maximising health (as opposed to welfare) in the symptomatic, 
postmenopausal female population undergoing mandatory investigation for abnormal uterine 
bleeding. For this reason we chose to take the perspective of the health service provider (NHS 
healthcare system) and considered direct medical costs appropriate to the NHS. 
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CHAPTER II 
2 MET 
METHODS 
 
This research presented in this thesis was undertaken with two aims: 
 
(1) To summarise the current evidence on the diagnostic accuracy of outpatient endometrial 
evaluation using endometrial biopsy (EB), ultrasound scan (USS) and outpatient 
hysteroscopy (OPH) using systematic reviews 
 
(2) To determine the most cost-effective combination of these tests for the investigation of 
women with post-menopausal bleeding (PMB) for endometrial cancer using decision-
analytic modeling. 
 
2.1 Systematic review methods 
 
To determine the accuracy of the outpatient diagnostic tests used in PMB to predict 
endometrial cancer and hyperplasia, quantitative systematic reviews of endometrial biopsy 
(EB), pelvic ultrasound (USS) and hysteroscopy (OPH) were conducted. The methodology 
used was common to all three reviews, it was based on a prospective protocol considering 
widely recommended methods,
66,183,189
 and followed the stages given below.  
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2.1.1 Identification of studies 
General bibliographic databases, MEDLINE and EMBASE, were searched. Language 
restrictions were not applied. The electronic search strategies targeted the relevant diagnostic 
procedures exclusively, studies addressing the relevant clinical problem (abnormal uterine 
bleeding which encompasses both pre and postmenopausal bleeding) were then identified on 
completion of the initial search phase by examining all the retrieved citations. Pilot searches 
suggested that the chosen search strategies gave reasonable precision without compromising 
sensitivity. These search strategies are detailed in Appendices 3 to 5. 
 
In addition, the Cochrane Library and relevant specialist registers of the Cochrane 
Collaboration were searched. Reference lists of all known reviews and primary studies were 
checked and direct contact with manufacturers of outpatient EB devices and hysteroscopes 
was also made.  
 
2.1.2 Selection criteria 
The reviews focused on prospective observational studies or comparative cross-sectional 
studies in which the results of the diagnostic test of interest were compared with the results of 
a reference standard. The following criteria were used to select articles for inclusion: 
 
Population:    Women with abnormal pre or postmenopausal bleeding. 
Diagnostic tests:  Outpatient endometrial biopsy, endometrial thickness 
measurement using ultrasound imaging and hysteroscopy. 
Reference Standard: Endometrial cancer and endometrial hyperplasia confirmed 
histologically. 
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Two reviewers identified the studies in a two-stage process independently (see 
Acknowledgments). The titles and abstracts identified as being potentially relevant from the 
computer database searches or inspection of bibliographies were scanned and provisionally 
included, unless they could definitely be excluded as not addressing the accuracy of EB, USS 
or OPH. The full texts of all provisionally included articles from the first stage were retrieved. 
The authors and journal titles were removed from the retrieved citations thereby blinding the 
reviewers. Final inclusion/exclusion decisions were made with reference to a checklist, the 
items of which were based on the selection criteria above. The checklists were piloted and the 
repeatability of their use tested and confirmed. The checklists used for each review are shown 
in Appendices 6 to 8. Disagreements about inclusion/exclusion were initially resolved by 
consensus and where this was not possible it was resolved using arbitration by a third 
reviewer (see Acknowledgements). The agreement statistics between reviewers were 
computed using percentage agreement and weighted kappa statistics.
67
 The kappa statistic 
provides measurement of agreement obtained beyond chance and weights provide credit for 
partial agreement.
55
 
 
2.1.3 Quality assessment 
All papers meeting the eligibility criteria were assessed for their methodological quality. 
Quality was defined as the confidence that the study design, conduct and analysis minimized 
bias in the estimation of diagnostic accuracy. Based on existing checklists,
66,107,163,207,230
 
quality assessment involved scrutinizing study designs and the relevant features of population, 
intervention and outcome. These included method of data collection and patient selection, 
details relating to type of abnormal bleeding and menopausal status, description of the 
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diagnostic test and histological reference standard, and presence of verification bias and 
blinding (Table 2-1).
189
 This approach is in line with the recently published STARD criteria 
for reporting test accuracy studies
34,35
 and the recently developed „QUADAS tool‟ for 
assessing quality of test accuracy studies (personal communication – see Chapter 4).
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 Table  2.1 Quality assessment and definitions 
  
Feature Quality assessment  
  
  
Study design 
 
Studies where the diagnostic test and reference standard were performed on the same occasion were defined as cross-sectional or simultaneous 
studies and considered ideal. Observational series where the intervention and reference standard were not carried out simultaneously were 
defined as sequential studies whereas case-control studies encompassed those studies where a subset of the population was already known to 
have endometrial cancer or hyperplasia. These latter designs were considered second best.  
 
Data collection 
 
Prospective collection of data from the study population was considered ideal whereas retrospective collection was considered second best.  
 
Patient selection 
 
Consecutive recruitment of eligible women was considered ideal and convenience sampling, i.e. arbitrary recruitment or non-consecutive 
recruitment was deemed second best. In the absence of any explicit information in the manuscript on the method of data collection or 
recruitment, the article was categorised as unclearly reported.  
 
Population details 
 
Population details were considered adequate if the menopausal status and type of abnormal uterine bleeding of women enrolled was reported 
and inadequate if not reported.  
 
Population spectrum* Population spectrum was considered wide if patients with and without Hormone Replacement Therapy (HRT) were included. Those excluding 
women on HRT were considered narrow and inadequate if not reported.  
 
Definition of menopause* Length of amenorrhoea indicating that the woman was menopausal was considered ideal if it was >/=12 months, and inadequate if it was < 12 
months or unreported. 
 
Diagnostic test:  
Endometrial biopsy The description of the use of the outpatient biopsy device was considered ideal if the methodology was reported in sufficient detail to allow 
replication by other researchers. In the absence of the above information, the diagnostic intervention was considered as unclearly reported.  
 
Ultrasound The description of the ultrasound test was considered ideal if the method of obtaining the ultrasound image (i.e. transvaginal or 
transabdominal) was reported along with the frequency of the transducer used.  Whether one or both layers of the endometrium were measured 
for thickness was also assessed.  Information on the cut-off level for an abnormal test result was also sought.  If the cut-off level for an 
abnormal result was determined a priori it was considered ideal.  If any of the above information was not present then the diagnostic test was 
classified as unclearly reported. 
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Table 2-1 continued 
  
Hysteroscopy The description of the hysteroscopic technique and the definition of the hysteroscopic features constituting a diagnosis of endometrial disease 
were considered adequate if the methodology was reported in sufficient detail or referenced to allow replication by other researchers. For 
hysteroscopic technique to be deemed adequate the method used to inspect the uterine cavity had to be explicit in addition to describing the 
setting, type of hysteroscope, distension medium, and imaging system. In the absence of the above information, description of the diagnostic 
intervention was considered as inadequate.  
 
Reference standard 
 
For confirmation of diagnosis by a reference standard, histology obtained from inpatient endometrial sampling (hysterectomy, directed biopsy 
or D&C were considered ideal and histology obtained from blind outpatient sampling was considered second best (USS and OPH). For the 
reviews of EB confirmation of diagnosis by a reference standard, hysterectomy, directed biopsy and dilatation and curettage under anaesthesia 
were considered adequate, in that order of importance. 
 
Verification bias† Verification bias was considered to be present if the application of the reference test was dependent upon the result of the hysteroscopy 
(differential verification) or if <90% patients originally tested had diagnosis verified (incomplete or partial verification)  
 
Timing of verification‡ The verification of diagnosis following the index test was either performed at the same time (simultaneous) or after a short delay (sequential). 
Simultaneous verification was considered ideal whereas sequential verification was considered second best. 
 
Blinding Blinding was considered present if it was clearly reported that the pathologists providing histological diagnoses were kept unaware of the test 
(endometrial biopsy, ultrasound or hysteroscopy) diagnosis. If the diagnosis following the test was divulged to the pathologists or in the 
absence of any such reporting, blinding was categorized as absent. 
 
Follow up Greater than 90% follow up of the original study population was considered ideal and less than 90% follow up as second best. 
 
 
* Ultrasound review only 
† Ultrasound and hysteroscopy reviews only 
‡ Hysteroscopy review only
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Analysis of these items was used to develop a hierarchy of evidence in diagnostic test studies, 
shown in Table 2-2. 
 
Table  2.2 Hierarchy of evidence for primary research on diagnostic accuracy 
 
  
Level Description 
  
  
1 An independent, blind comparison with reference standard among an appropriate population 
of consecutive patients. 
  
2 An independent, blind comparison with reference standard among an appropriate population 
of non-consecutive patients or confined to a narrow population of study patients. 
  
3 An independent, non-blind comparison with reference standard among an appropriate 
population of consecutive patients.  
  
4 An independent, non-blind comparison with reference standard among an appropriate 
population of non-consecutive patients or confined to a narrow population of study patients. 
  
5 An independent, blind comparison among an appropriate population of patients, but 
reference standard not applied to all study patients. 
  
6 Reference standard not applied independently or expert opinion with no explicit critical 
appraisal, based on physiology, bench research or first principles. 
  
 
 
Study levels 1-3 were considered to be high quality and levels 4-5 low quality. Level 6 studies 
were not eligible for inclusion in the reviews and were excluded. A piloted checklist was used 
to identify and record items of study quality. The assessment was performed independently, in 
duplicate for the reviews of EB and USS. In the hysteroscopy review, the assessment of 
English language papers was performed by one reviewer and foreign language papers by two 
reviewers independently following translation where necessary. Any disagreements were 
resolved by consensus.  
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2.1.4 Data abstraction 
Data were extracted independently and in duplicate. Data abstraction forms are given in 
Appendices 6 to 8. 
 
2.1.4.1 Diagnostic accuracy data extraction 
Three outcomes were considered: endometrial cancer, endometrial hyperplasia and normal 
(functional or atrophic endometrium and benign focal abnormalities e.g. intrauterine polyps 
and fibroids) for the review of EB. As discussed in section 1.6.2.2, endometrial disease, 
defined as including cancer and/or hyperplasia, was examined rather than endometrial 
hyperplasia for the reviews of USS and hysteroscopy. Non-endometrial uterine malignancies 
were excluded from analysis.  
 
Endometrial cancer was considered the most important diagnosis and, to analyse its 
prediction, data were abstracted as two by two tables of the diagnostic test under scrutiny, 
result (positive or negative for cancer) and the results of the reference standard histology 
(benign or cancer). Similarly contingency tables were produced for USS and hysteroscopy 
results and endometrial disease (benign or disease), and EB and endometrial hyperplasia 
(hyperplasia or non-hyperplasia). In the review of ultrasound measurement of endometrial 
thickness, different cut-off levels for an abnormal test result were adopted by the different 
selected studies and 2x2 tables were produced according to these cut-off levels (see also 
section 1.6.2.2). 
 
To examine the impact of the severity of endometrial hyperplasia on the diagnostic 
performance of EB, endometrial hyperplasia data were stratified by the presence or absence of 
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atypical cells (abnormal cytology) as part of a secondary analysis (as discussed in section 
1.6.2.1). This involved constructing two sets of 2x2 tables comparing EB and reference 
standard histology. The target disorder (histology) for the first table was hyperplasia without 
atypia (normal / negative test result being absence of hyperplasia) and in the second table the 
target disorder was hyperplasia with atypia (normal / negative test result being absence of 
hyperplasia with atypia). A final analysis was then conducted for endometrial cancer or 
precancer (complex or atypical hyperplasia). In this analysis, data were abstracted as 2x2 
tables of the outpatient biopsy result (positive or negative for endometrial cancer + precancer) 
and the results of the reference standard histology (endometrial cancer/precancer or non-
endometrial cancer/precancer). 
2.1.4.2 Secondary outcomes data extraction 
Data pertaining to complications, inadequate specimens (EB only) and failures associated 
with testing were recorded (see section 1.6). Failures were excluded from two by two tables, 
whereas inadequate specimens (precluding a definitive diagnosis following the reference test 
in the case of hysteroscopy) were used in sensitivity analyses including them along with 
negative results. This is because the inability to obtain a specimen is generally considered a 
negative result.
19,24
 Information on menopausal status, the number of women recruited, and 
those whose outcome data were known was also sought from the manuscripts. In addition, the 
setting (outpatient or inpatient) and technical details pertaining to the hysteroscopic 
examination were sought. 
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2.1.5 Quantitative data synthesis 
2.1.5.1 2x2 tables 
The tables were constructed as detailed in section 2.1.4.1. True positive rate (sensitivity), false 
positive rate (1-specificity) and likelihood ratios (LRs) were calculated for each study along 
with their 95% confidence intervals (CIs). Where 2x2 tables contained zero cells, 0.5 was 
added to each cell to enable our calculations.
287
  
 
2.1.5.2 Heterogeneity 
Heterogeneity of results between different studies was formally assessed in all reviews 
graphically, using sensitivity and specificity plots in addition to the χ2 test. In order to explore 
for clinical sources of heterogeneity, the potential explanatory variables were defined a 
priori.
64
 In view of the potential influence of spectrum variability,
276,331
 menopausal status 
and setting were considered to be important. In addition, examination of the impact of study 
quality on estimation of accuracy according to individual quality items (patient selection, 
reference standard, completeness of verification and blinding) and also according to an overall 
quality level (1-5) incorporating these items, was planned.
62
  
 
2.1.5.2.1 Subgroup and meta-regression analysis 
Statistical examination was performed to assess whether estimation of accuracy was different 
in the subgroups. This was done by examining if the impact of an explanatory variable on the 
log of diagnostic odds ratio (dOR), a measure which accommodates LRs for both positive and 
negative test results, in meta-regression analysis.
305,311
 Univariable analyses were initially 
performed followed by multivariable modeling, which controlled for confounding between 
41 
variables.
305
 In the review of ultrasound, meta-analyses were performed separately for 
subgroups of studies with the same cut-off level for abnormality and the same measurement 
techniques (single or both endometrial layers). The effect of HRT use on diagnostic accuracy 
was also evaluated by subgroup analysis. Sources of heterogeneity were explored for by 
univariate subgroup analyses according to the pre-specified possible explanatory variables 
population spectrum (HRT use) and study quality items. Additional subgroup analyses were 
performed, stratifying studies according to variation in specific study characteristics (e.g. 
population, intervention, and outcome).
82,305
 Multivariable modeling was then performed as 
described for hysteroscopy below. 
 
In the review of hysteroscopy, the models produced by multivariable analysis included 
menopausal status (postmenopausal vs. pre-menopausal and mixed population) and clinical 
setting (office vs. inpatient) as explanatory variables. The models were adjusted for the effect 
of study quality. For this quality was used as a binary variable (levels 1-3 vs. 4-5), which 
avoided problems of co-linearity between quality items. By testing only three variables in 
meta-regression analysis, it was hoped to avoid spurious results due to “overfitting”. 311 This 
approach is in keeping with published recommendations, which advocate a cautious 
examination of potential reasons for heterogeneity by specification of a small number of 
subgroup analyses in advance. 
64,69,82
 
 
For the hysteroscopy review, additional post hoc analyses to explore for causes of 
heterogeneity were conducted alongside those planned in advance, when certain variables 
were considered to be informative or recommended by the peer reviewers. Following 
univariable analyses, multivariable meta-regression analyses were performed to evaluate the 
42 
effect of the explanatory variables on log dOR observed among individual studies.
305
 The 
models produced by multivariable analysis included the independent variables description of 
test (adequate vs. inadequate), complications (present vs. absent), timing of verification 
(simultaneous vs. sequential), method of data collection (prospective vs. other) and 
completeness of follow up (greater than 90% vs. less than 90%), in addition to the variables 
defined a priori. The findings of these post hoc analyses were, however, considered in the 
context of hypothesis generation. 
 
2.1.5.3 Meta-analysis 
Meta-analysis to produce summary pooled estimates of sensitivity and specificity were 
performed if these measures were found to behave independently
83,170
 as indicated by lack of 
statistical correlation between them. However, estimates of sensitivity and specificity have 
limited value in clinical interpretation.
86,162,174,283
 Therefore summary likelihood ratios (LRs) 
were generated as the principal measures of diagnostic accuracy based on the 
recommendations of the various Evidence-based Medicine Groups.
82,84,86,150,173,174
 The LRs 
indicate by how much a given hysteroscopy finding raises or lowers the probability of having 
endometrial cancer or disease.
21
 This is important in clinical decision making because the 
estimated probability of disease (or not having disease) is a prime factor determining whether 
to withhold treatment, undertake further diagnostic testing or treat without further testing.
264
 
Thus the generation of LRs and post-test probabilities represents a more relevant method of 
establishing the utility of a test and reduces the risk of erroneous inferences being 
drawn.
162,185
.  
 
43 
Pooling of LRs was performed by weighting the log LR from each study in inverse proportion 
to its variance. The clinical implications of the LRs generated for diagnostic accuracy were 
examined to determine post-test probabilities using Bayes‟ theorem using the formula: post-
test probability = likelihood ratio x pre-test probability/[1-pre-test probability x (1-likelihood 
ratio)].  An estimate of pre-test probability was obtained by calculating the prevalence of 
pathology in the population studied.  The post-test probability of endometrial pathology, in 
the presence of a particular test result, refers to the probability of this outcome being present 
conditional on this test result.  In this way, a more clinically useful measure of the diagnostic 
performance of the test is obtained as it relates to the actual test result before the presence or 
absence of pathology is known.  In order to deal with the uncertainty in the estimation, 95% 
confidence intervals (CI) around the point estimates were generated.  Approximate variance 
for the post-test odds were obtained by adding the variances of the combined LRs and pre-test 
odds, enabling the calculation of its 95% CI.  The 95% CIs for the post-test probabilities were 
then generated by converting the limits of the post-test odds to their respective probabilities.  
Inferences according to strength of evidence were generated considering estimate of accuracy, 
homogeneity of results and study quality.
188
 
 
2.1.5.3.1 Fixed and random effects models 
When heterogeneity was encountered within subgroup meta-analysis for hysteroscopy or 
ultrasound, results were initially pooled from individual studies using both a fixed effects and 
random effects model. In the presence of heterogeneity across studies, a random effects model 
may be considered preferable
64,69,82,91
 in meta-analysis, as this approach produces wider CIs. 
However, this benefit has to be balanced against the potential disadvantage that by weighting 
smaller studies preferentially, it may produce biased point estimates of accuracy.
82
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Examination for such bias in meta-analyses was carried out and results reported with a fixed 
effects model where a random effects model was associated with higher estimates of 
accuracy. This allowed more conservative interpretation of the results. Furthermore, if 
heterogeneity remained within the pre-specified clinical subgroups, interpretations were based 
on inferences from high quality studies (levels 1-3). 
 
2.1.5.4 Sensitivity analysis 
In order to ascertain how uncertainty arising from underlying assumptions influence review 
results, sensitivity analyses were conducted where indicated. A sensitivity analysis was 
carried out in the review of hysteroscopy, considering inadequate histological specimens, 
precluding a definitive diagnosis following the reference test, as negative results. This is 
because insufficient tissue samples are generally taken to mean absence of pathology.
19,24
 
Intrauterine polyps were also excluded and fibroids as part of a sensitivity analysis, in order to 
examine whether the presence of these focal lesions affected estimates of diagnostic accuracy. 
 
2.1.5.5 Publication bias 
For all reviews, exploration for publication bias was carried out, by producing funnel plots 
(scatter plot of individual study accuracy against some measure of study information
186
) of 
diagnostic odds ration (dOR) against corresponding inverse of variance. When no publication 
bias is present the plots will be shaped like a funnel because studies of smaller size are 
expected to have increased variation in the estimates of accuracy.
318
 The bigger the study 
variance, the lower the weighting of the study and the less information it provides. This means 
that in addition to small sample size of included primary studies, those studies reporting very 
45 
high accuracy (few false positive or negative diagnoses) will also have a relatively big 
variance and thus be weighted less. The adjusted rank correlation method was used to test the 
correlation between estimated LRs and their standard errors.
23,23
  
 
 
2.2 Economic analysis methods 
 
The cost-effectiveness analysis was based on modeling the costs and outcomes of patients 
with PMB investigated using various diagnostic strategies. Survival in terms of life years 
gained (LYG) was the outcome and cost per LYG was the measure of cost-effectiveness. This 
approach is widely used in health economics
137,231,262,327
 and was conducted according to 
recommended methods.
99,111,231,240,253,301
  
 
2.2.1 The model  
A decision model
114,198,294
 was constructed to reflect current service provision (Figure 2-1). As 
there is no consensus regarding how best to investigate women with PMB for endometrial 
cancer, initial investigation utilising all tests either alone or in combination were included in 
the model. For strategies involving USS, both 4mm and 5mm cut-offs were used to define 
abnormal endometrial thickening. This was done to address the ongoing clinical debate 
regarding what constitutes the best USS cut-off for abnormal endometrial thickening (4mm or 
5mm) and also to reflect varying clinical practice.
160,303,319
 A further option, of withholding 
immediate investigation at initial presentation and only instituting diagnostic work-up if PMB 
recurred, was also considered. Thus, 12 outpatient strategies for the clinical investigation of 
women with PMB for endometrial cancer were evaluated based on initial evaluation with: 
46 
 
1. EB 
2. USS (4mm) 
3. USS (5mm) 
4. OPH 
5. USS (4mm) and OPH 
6. USS (5mm) and OPH 
7. USS (4mm) and EB 
8. USS (5mm) and EB 
9. EB and OPH 
10. USS (4mm) and EB and OPH 
11. USS (5mm) and EB and OPH 
12. No initial evaluation 
 
 
In cases of test failure, the default diagnostic procedure was inpatient evaluation of the 
endometrium under general anaesthetic utilising blind or directed dilatation of the cervix and 
curettage of the endometrium (D&C) (Figures 2-2 to 2-10). As discussed in section 1.2, initial 
endometrial assessment by inpatient D&C is outmoded, but is still employed when outpatient 
modalities fail.  
 
The model used estimates of probabilities for various test results, life expectancy, direct 
medical cost and computed cost-effectiveness as a function of age cohorts (45 years, 55 years, 
65 years, 75 years and greater than 80 years of age). Endometrial cancer was divided into 
47 
localised (FIGO stage I) and more advanced (FIGO stages II-IV) disease. The model also 
considered costs arising from morbidity associated with diagnosis by D&C.
152
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Figure  2-1 Decision analytic model: Strategy utilising initial evaluation with endometrial biopsy (EB) for the investigation of 
postmenopausal bleeding for endometrial cancer  
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Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, Neg = negative test result, OPH =outpatient hysteroscopy, Pos = positive test result, PMB = postmenopausal bleeding, Rep = 
represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability, # = complementary  probability  
Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
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Figure  2-2 Decision analytic model: Strategy utilising initial evaluation with pelvic ultrasound scan (USS) using a cut-off of 
4mm to signify abnormal endometrial thickness for the investigation of postmenopausal bleeding for endometrial 
cancer  
 
 
Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, Neg = negative test result, OPH =outpatient hysteroscopy, Pos = positive test result, PMB = postmenopausal bleeding, Rep = 
represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability., # = complementary  probability, Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
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Figure  2-3 Decision analytic model: Strategy utilising initial evaluation with pelvic ultrasound scan (USS) using a cut-off of 
5mm to signify abnormal endometrial thickness for the investigation of postmenopausal bleeding for endometrial 
cancer  
 
 
 
Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, Neg = negative test result, OPH =outpatient hysteroscopy, Pos = positive test result, PMB = postmenopausal bleeding, Rep = 
represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability, # = complementary  probability. 
Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
TAH 
cUSS+cEB+cTAH+cCancerIMM EB Pos 
pEBtprifUSSPos 
TAH 
cUSS+cEB+cRep+cTAH+cCancerDEL Represent Discharge EB Neg 
# 
EB Success 
pEBsuccessafterUSS 
TAH 
cUSS+cEBfail+cDC+cTAH+cCancerIMM D&C Pos 
pDCtpr 
TAH 
cUSS+cEBfail+cDC+cRep+cTAH+cCancerDEL Represent Discharge D&C Neg 
# 
EB Failure 
# 
USS Pos 
pUSS5mmtpr 
TAH 
cUSS+cRep+cTAH+cCancerDEL Represent Discharge USS Neg 
# 
Success 
pUSSsuccess 
TAH 
cUSS+cDC+cTAH+cCancerIMM D&C Pos 
pDCtpr 
TAH 
cUSS+cDC+cRep+cTAH+cCancerDEL Represent Discharge D&C Neg 
# 
Failure 
# 
Cancer 
TAH 
cUSS+cEB+cTAH EB Pos 
pEBfpr 
DISCHARGE 
cUSS+cEB EB Neg 
# 
EB Success 
pEBsuccessafterUSS 
TAH 
cUSS+cEBfail+cDC+cTAH D&C Pos 
pDCfpr 
DISCHARGE 
cUSS+cEBfail+cDC D&C Neg 
# 
EB Failure 
# 
USS Pos 
pUSS5mmfpr 
DISCHARGE 
cUSS USS Neg 
# 
Success 
pUSSsuccess 
TAH 
cUSS+cDC+cTAH D&C Pos 
pDCfpr 
DISCHARGE 
cUSS+cDC D&C Neg 
# 
Failure 
# 
No Cancer 
USS 5mm 
51 
Figure  2-4 Decision analytic model: Strategy utilising initial evaluation with outpatient hysteroscopy (OPH) for the 
investigation of postmenopausal bleeding for endometrial cancer  
 
 
 
 
Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, Neg = negative test result, OPH =outpatient hysteroscopy, Pos = positive test result, PMB = postmenopausal bleeding, Rep = 
represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability, # = complementary  probability. 
Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
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Figure  2-5 Decision analytic model: Strategy utilising initial evaluation with a combination of pelvic ultrasound and outpatient 
hysteroscopy (USS_OPH) for the investigation of postmenopausal bleeding for endometrial cancer (both 4mm 
and 5mm ultrasound cut-offs used to signify abnormal endometrial thickness) 
 
Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, GOPD = gynaecology outpateint department visit (additional), Neg = negative test result, OPH =outpatient hysteroscopy, 
Pos = positive test result, PMB = postmenopausal bleeding, Rep = represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability, # = complementary  probability. Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
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Figure  2-6 Decision analytic model: Strategy utilising initial evaluation with a combination of pelvic ultrasound and 
endometrial biopsy (USS_EB) for the investigation of postmenopausal bleeding for endometrial cancer (both 
4mm and 5mm ultrasound cut-offs used to signify abnormal endometrial thickness) 
 
 
 
 
Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, GOPD = gynaecology outpateint department visit (additional), Neg = negative test result, OPH =outpatient hysteroscopy, 
Pos = positive test result, PMB = postmenopausal bleeding, Rep = represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability, # = complementary  probability. 
Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
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Figure  2-7 Decision analytic model: Strategy utilising initial evaluation with a combination of endometrial biopsy and 
outpatient hysteroscopy (EB_OPH) for the investigation of postmenopausal bleeding for endometrial cancer  
 
 
 
 
 
Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, GOPD = gynaecology outpateint department visit (additional), Neg = negative test result, OPH =outpatient hysteroscopy, 
Pos = positive test result, PMB = postmenopausal bleeding, Rep = represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability. # = complementary  probability 
Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
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Figure  2-8 Decision analytic model: Strategy utilising initial evaluation with a combination of pelvic ultrasound, endometrial 
biopsy and outpatient hysteroscopy (USS_EB_OPH) for the investigation of postmenopausal bleeding for 
endometrial cancer (both 4mm and 5mm ultrasound cut-offs used to signify abnormal endometrial thickness) 
 
 
 
 
Cancer IMM = endometrial cancer treatment following immediate diagnosis, Cancer DEL = endometrial cancer treatment following delayed diagnosis, D&C or DC = dilatation and 
curettage, EB = endometrial biopsy, fpr = false positive rate, GOPD = gynaecology outpateint department visit (additional), Neg = negative test result, OPH =outpatient hysteroscopy, 
Pos = positive test result, PMB = postmenopausal bleeding, Rep = represent, TAH = total abdominal hysterectomy, tpr = true positive rate, USS = ultrasound scan.  
Prefix c = cost, prefix p = probability. # = complementary  probability 
Represent = a combination of all three tests performed (USS and EB and OPH) – see text for details 
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Figure  2-9 Decision analytic model: Strategy of no initial evaluation (i.e. diagnostic work-up only if symptoms recurred) for 
the investigation of postmenopausal bleeding for endometrial cancer 
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cRep+cTAH+cCancerDEL
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DISCHARGE
(No Payoff)
No Cancer
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Cancer DEL = endometrial cancer treatment following delayed diagnosis, Rep = represent, TAH = total abdominal hysterectomy,  
Prefix c = cost,  
Represent = a combination of all three tests performed (ultrasound, outpatient endometrial biopsy and hysteroscopy) – see text for details 
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2.2.2 Data sources and modeling assumptions for decision analysis  
 
In the first instance it was assumed that the hypothetical presentation with postmenopausal 
bleeding represented the first episode. No postmenopausal woman was assumed to be less 
than 45 years old and no other significant aetiology (e.g. other genital tract malignancy) was 
considered. The woman was considered to be otherwise healthy with a normal age-adjusted 
life expectancy. The probability of endometrial cancer in women presenting with 
postmenopausal bleeding is between 5 and 10%
16,251
 and women are most likely to present 
with this symptom in the seventh decade of life.
272
 Therefore, a 65 year old woman presenting 
with PMB and a 5% prevalence of malignant disease were used for the base case analysis.  
 
The initial investigation(s) used in each strategy were assumed to take place in a „one stop‟ 
setting (i.e. one initial consultation only with no planned follow up unless test(s) failed or 
abnormal results were found). It was assumed that a consultant grade specialist performed all 
diagnostic and surgical procedures. For the base case analysis it was assumed that an 
additional return visit was required following a positive USS in order to perform endometrial 
sampling. The impact of performing EB following a positive USS at the same visit was 
examined as part of a sensitivity analysis, to reflect the practice of gynaecologists with 
expertise in ultrasound. Expert clinical opinion was then obtained independently about 
decision-making conditional upon positive or negative test results (i.e. the need for any further 
testing or therapeutic intervention). An expert clinical panel was then convened to reach 
consensus in cases of disagreement. In this manner a representative body of opinion was 
obtained regarding current management pathways in the diagnosis of PMB. It was agreed that 
invasive surgery (hysterectomy) for endometrial cancer would not be performed without 
58 
histological confirmation, whether by EB or inpatient sampling (D&C). Once the decision for 
hysterectomy had been made, additional pre-operative investigation by examination under 
anaesthesia, fractional curettage, cystoscopy, magnetic resonance imaging and other 
radiographic modalities was assumed not to have been necessary in accordance with current 
clinical practice.
279
 Radiotherapy and chemotherapy were assumed to have been provided by 
the same medical oncologist. 
 
2.2.2.1 Diagnostic Tests 
Failed diagnostic procedures led to investigation by inpatient endometrial assessment under 
general anaesthesia (D&C). In the case of outpatient endometrial biopsy, failed procedures 
were considered to be cases where technical problems meant that an endometrial specimen 
could not be obtained. Histologically inadequate specimens were considered to be negative 
tests for both EB and D&C.
19,62
 Inpatient D&C was assumed to have no technical failure 
rate.
219
 Data for failure rates and estimates of diagnostic accuracy were obtained from high 
quality published systematic quantitative reviews of the diagnostic literature for EB, USS and 
OPH (presented in this thesis – Appendix 9).62 Failure rates for initial strategies utilising test 
combinations were estimated by the consensus panel based on the definition of a failed 
strategy as any test making up the strategy failing and on available failure rate data from 
individual tests.
62
 
63,160,303
 Similarly, failure rates were also adjusted for tests performed in a 
diagnostic strategy conditional on the success of preceding tests. The base case true positive 
rates for diagnostic tests carried out conditional on a preceding test result were also adjusted 
as part of a sensitivity analysis to take account of plausible changes in accuracy due to lack of 
complete test independence (Appendix 9).
16
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As over 95% of women with endometrial 
cancer present with PMB,
250
 it was assumed that all women who were erroneously discharged 
59 
following the initial presentation (i.e. false negatives) remained symptomatic. The interval to 
representation was thus taken to be short and all these women were then assumed to undergo 
reinvestigation with all outpatient tests where perfect test success and accuracy was assumed.  
 
No serious morbidity was assumed to be associated with any of the ambulatory procedures 
(ultrasound, hysteroscopy and endometrial biopsy) based on evidence from systematic 
reviews of the available literature.
62,63,160,303
 For D&C the major complication rate was 
assumed to be 1.4% (included haemorrhage 0.4%, infection 0.3%, perforation 0.6% and 
emergency laparotomy 0.1%).
152
 Costs associated with morbidity arising from complications 
were incorporated into the model, but no adjustment to life expectancy was made (Appendix 
10). Mortality rates were assumed to be negligible for all the diagnostic tests.
62,63,152,160,303
 The 
mortality rate for abdominal hysterectomy in endometrial cancer was assumed to increase 
with age (0.4% in a woman aged 45 years, 0.8% at 55 years, 1.4% at 65 years and 3.5% at 75 
years)
344
  and adjustments to survival were made accordingly. 
 
2.2.2.2 Treatment 
For the base case analysis, it was assumed that all women not discharged underwent initial 
treatment by total abdominal hysterectomy (TAH) and bilateral salpingo-oophorectomy with 
or without pelvic node sampling (i.e. all were fit for surgery and none had primary radical 
radiotherapy). All women were therefore assumed to be surgically staged.
72
 There is some 
variation in practice in the treatment of endometrial cancer regarding the relative roles of 
surgery, radiotherapy / chemotherapy.
72,279
 The treatment pathways in this model were based 
on published recommendations and reports of current practice.
2,245,251,279,309
 All 
epidemiological statistics relating to endometrial cancer were taken from the latest annual 
60 
report from the International Federation of Obstetrics and Gynaecology (FIGO) of results of 
treatments of gynaecological cancers.
72
  For the base case analysis, the cost of treating a 
woman correctly diagnosed with endometrial cancer on first presentation was based on the 
assumption that 70% of such women had localised (FIGO stage I) disease and 30% advanced 
(FIGO stages II-IV) disease.
72
 To account for delayed diagnosis experienced by women with 
endometrial cancer who were erroneously discharged initially (false negatives) it was 
estimated that this group of women had a 5% increased probability of advanced stage 
endometrial cancer (stage II-IV) in the absence of relevant data (Appendix 9). Those with 
advanced disease (stages II, III or IV) underwent radiotherapy (adjuvant /palliative) and/or 
chemotherapy.
2,245,251,279
 Women with stage Ic disease or poorly differentiated (histological 
grade 3) stage Ia or Ib disease were assumed to have adjuvant radiotherapy.
251
 The proportion 
of women undergoing additional non-surgical treatment is shown in Figure 2-10. 
 
 
Figure  2-10 Decision analytic model (common pathway for further treatment of 
endometrial cancer following initial hysterectomy) 
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Standardised radiotherapy and chemotherapy regimens were assumed regardless of disease 
stage, radiotherapy consisted of a 5-week course of external beam radiotherapy giving a total 
dose of 50-55 grays in 20-28 fractions.  Chemotherapy consisted of standard cytotoxic and/or 
hormonal therapies.
2,245,251,279
 Compliance with treatment was assumed to be 100%. It was 
assumed that hormonal treatment using long term oral progestogens was not employed given 
there is no evidence of benefit in terms of survival.
226
 The 5 year survival rates were assumed 
to be 87% for stage I disease and 60% for advanced (stage II-IV) disease.
72
   
 
2.2.3 Cost data 
Costs were estimated from the perspective of my base National Health Service (NHS) hospital 
and from NHS data provided by the Department of Health. The analysis included all direct 
medical costs in UK pounds sterling (Appendix 10). Data for the base case and sensitivity 
analyses were obtained from local sources (Birmingham Women‟s Hospital data for 
uncomplicated procedures 2000-2001) and national sources (Department of Health, National 
Schedule of Reference Costs for the United Kingdom 2000
252
  and Unit Costs of Health and 
Social Care 2000/2001
247
). Drug costs were obtained from the British National Formulary 
2002. Costs for outpatient investigation included the clinic appointment and other hospital 
charges, the relevant procedures (endometrial biopsy, ultrasound scan or outpatient 
hysteroscopy) and the specialist(s) fee (consultant gynaecologist +/- consultant pathologist). 
Costs for inpatient endometrial assessment under general anaesthesia (hysteroscopy/D&C) 
took into account hospital costs for a day-case surgical procedure in addition to the 
specialists‟ fees for a consultant gynaecologist and anaesthetist. In addition, a cost associated 
with complications arising from D&C was estimated and incorporated (included costs of 
unexpected inpatient stay and antibiotic treatment for haemorrhage, uterine infection, 
62 
perforation and unplanned emergency laparotomy – see Appendix 10). The costs of 
reinvestigation by all three outpatient modalities incurred in those women representing after 
initial erroneous discharge were included in the model. Hysterectomy was classed as a 
complex major laparotomy and costed according to the base hospital charges taking into 
account uncomplicated inpatient hospital stay, operating theatre costs and specialist fees. 
Radiotherapy charges were estimated from charges for standard outpatient treatment charges 
(12-24 fractions of external beam radiotherapy) using national data.
252
 Chemotherapy was 
costed according to national data for day-case treatment of the female reproductive system.
252
 
No adjustments to costs were made for the effects of inflation. 
 
2.2.4 Clinical Outcomes 
Baseline values of the probabilities of each test result and treatment outcome, together with 
the costs of each diagnostic intervention, were estimated and incorporated into the decision 
tree (DATA Professional 2001, Treeage software inc, 1075 Main Street, Williamstown, 
United States, MA 01267 [www.treeage.com]. The cost and effectiveness for each of the 12 
strategies were calculated. The effectiveness of each competing diagnostic strategy was 
determined by comparing survival using the outcome measure cost per life year 
gained.
137,231,262
  
 
Age specific life expectancies were calculated in the following way. For “true negative” 
results, normal actuarial age/sex specific death rates
177
 were used to calculate life expectancy. 
For women with stage I or stage II-IV endometrial cancer, international 5-year survival data
72
 
were compared with the expected survival for the general population. The resulting hazard 
ratio was assumed to apply constantly over 12 years, after which survival is equivalent to the 
63 
normal population.
166
 Finally, for “false positive” results, an age-specific immediate mortality 
was applied for the effect of the unnecessary hysterectomy
344
, after which the general 
population life expectation was used. The base case analysis used an age of 65 years.
272
 This 
age was chosen as endometrial cancer has its peak incidence in this decade.
272
 
 
The costs, effect in terms of additional life year saved and average cost-effectiveness ratios 
(cost per additional life year saved) were determined for each diagnostic strategy.
137,231,262,327
 
Incremental cost-effectiveness ratios were then generated by using the ratio of cost compared 
to change in life expectancy relative to the cheapest strategy. In this way improvements in life 
expectancy per extra pound spent could be determined.
99,253,301
 In accordance with Treasury 
guidelines, future years of life were discounted at 1.5% per year.
88,325
 Discounting costs was 
not relevant as all costs were assumed to occur in the first year. 
 
2.2.5 Sensitivity Analyses 
Extensive sensitivity analyses were performed for all strategies found to be potentially cost-
effective following the base case analysis. One-way analyses were performed over ranges of 
age at presentation, disease prevalence, test failure rates, estimates of diagnostic accuracy and 
upstaging of endometrial cancer due to delayed diagnosis to explore the robustness of the 
analytic model (Appendices 6 and 7). For treatment of endometrial cancer, the costs of local 
(FIGO Stage 1) and advanced (FIGO stage II-IV) disease were varied together. 
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CHAPTER III 
3 RESULTS 
RESULTS 
 
3.1 Results of systematic review of endometrial biopsy 
3.1.1 Question 
What is the accuracy of outpatient endometrial biopsy in the diagnosis of endometrial cancer 
and hyperplasia and what are the rates of failure and complications?  
 
3.1.2 Study Selection 
The electronic search generated 1369 citations and of these there were 39 
articles
8,22,32,42,78,93,100,101,113,117,121,126,135,139,143,157,161,169,181,190,192,201,202,209,213,214,254,257,261,284,289,298
,299,312,313,317,332,346,349
 which both reviewers thought were relevant: 37 were published in 
English, one in French and one in Spanish. A further 13 
articles
24,30,124,133,138,182,196,204,206,307,314,315,333 
were identified through examination of the 
reference lists of the known primary publications and review articles. After independent 
review of the 52 manuscripts, 12 articles (11 English,
22,24,78,117,133,138,161,192,314,317,332
 one French
 
284
) were considered to be eligible for inclusion in the review (Figure 3-1). Agreement 
regarding eligibility was 90% (weighted kappa 0.7). The lists of references supplied by the 
manufacturers contacted did not add anything to the above search. Excluded studies are listed 
in Appendix 11. 
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Figure  3-1 Study selection process for systematic review of outpatient EB 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant studies identified and screened for 
retrieval 
(citations in electronic search)   n=1369 
Diagnostic test studies included in meta-analysis  
          n=12 
   
(Endometrial cancer data only   n= 5 
Endometrial hyperplasia only   n=1 
Endometrial cancer and hyperplasia data n=6) 
 
Diagnostic test studies excluded: 
 
Population:  Restricted recruitment (endometrial cancer)
1-7  
n=7 
     Intrauterine abnormalities data only
8-9   
n=2 
     Asymptomatic women
10         
n=1 
     Subtotal            n=10 
 
Diagnostic  Performed under general anaesthetic
11-18
  
 
n=8 
 
Intervention:Cytological outpatient device
19      
n=1 
     
No convincing gold standard
20-28     
n=9 
     Subtotal            n=18 
 
Outcome:  Differential verification
29-30
        n=2 
     Lack of data to construct 2x2 table 
31-37
 
  
n=7 
     Lack of original data / reviews
38-40     
n=3 
     Subtotal            n=12 
 
Total excluded
1-40
             n=40 
 
   
Studies excluded              n=1330 
(Inappropriate population, intervention or outcome – see text) 
Diagnostic test studies retrieved for more detailed 
evaluation: 
from electronic search      n=39 
from reference lists       n=13 
Total           n=52 
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There were 1337 subjects in 14 diagnostic evaluations reported in 12 primary studies, which 
assessed the diagnostic accuracy of EB in detecting serious endometrial disease: 40 women in 
a single evaluation of the Accurette® device,
138
 70 women in a single evaluation of the 
Gynoscann® device,
317
 176 women in a single evaluation of the Novak® curette,
314
 865 
women in 8 evaluations of the Pipelle® device,
22,24,78,133,161,192,284,332
 
104 women in 2 evaluations of the Vabra® aspirator
138,314
 and 77 women in a single 
evaluation of the Z-sampler®
117
 device. Of the 12 included studies, 11 studies (1013 women) 
assessed the diagnosis of endometrial cancer. Seven of these evaluations contained data 
exclusively about postmenopausal women,
22,78,117,138,161,332
 four about pre and postmenopausal 
women
24,192,284,317
 and in three menopausal status was unclear
133,314
. Postmenopausal women 
represented 36% of the populations studied. 
 
3.1.3 Study quality 
The observer agreement for various items of study quality ranged from 73 to 100%. Kappa 
values were 0.5 for population enrolment, 1.0 for biopsy technique description, 0.9 for 
blinding of test results and 1.0 for description of outcomes. The methodological quality 
criteria of the studies selected for meta-analyses are detailed in Appendix 12 and summarised 
in Table 3-1. 
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Table  3.1 Methodological quality of outpatient EB studies included in meta-
analyses 
 
  
Quality Criteria  No. of Studies  
  
  
Population  
Data Collection  
Adequate (prospective) 9/12 (75%) 
Inadequate (retrospective)  3/12 (25%) 
Patient Selection  
Adequate (consecutive)  4/12 (33%) 
Inadequate (arbitrary/unreported) 8/12 (67%) 
Population Details  
Complete 8/12 (67%) 
Inadequate   4/12 (33%) 
  
Intervention  
Biopsy technique description  
Adequate    9/12 (75%)  
Inadequate    3/12 (25%) 
  
Outcome  
*Reference standard  
Hysterectomy  6/12 
Directed Biopsy/Transcervical resection   2/12 
D&C      10/12 
Blinding of Test Results  
Adequate    2/12 (17%) 
Unreported  10/12 (83%) 
Use of reference standard regardless of test result  
Adequate (>90%)    12/12 (100%) 
  
 
 
Study recruitment was prospective in nine (75%) of the studies, patient details were complete 
in 8 (67%) studies, but patient selection was consecutive in only 4 (33%) of the studies. The 
description of the interventions were adequate in 9 (75%) of the studies. The assessment of 
outcome data shows that in only 2 (17%) of the studies were the outpatient test results 
reported to be masked from the pathologist interpreting the reference standard. Thus 2 
studies
22,78
 (17%) were level 1, a further 2 studies
117,332
 (17%) were level 3 and 8 
studies
24,133,138,161,192,284,314,317
 (66%) were level 4 in quality. 
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3.1.4 Data synthesis 
3.1.4.1 Accuracy in predicting endometrial cancer 
Amongst adequate specimens, outpatient EB failed to diagnose three endometrial cancers. 
Figure 3-2 presents the sensitivity and specificity of EB in the diagnosis of endometrial 
cancer. The overall pooled sensitivity was 94.1% (95% CI 83.8% to 98.8%) and specificity 
was 99.6% (95% CI 98.8% to 99.9%). In view of the lack of an association between 
sensitivity and specificity, a summary receiver operating characteristic curve was not 
generated.
83
 The pooled LRs for endometrial cancer were 66.48 (95% CI 30.04-147.13) and 
0.14 (95% CI 0.08-0.27) for positive and negative outpatient test results respectively. The pre-
test probability increased from 6.3% (95% CI 4.7% to 8.2%) to 81.7% (95% CI 59.7% to 
92.9%) with a positive result. It decreased to 0.9% (95% CI 0.4% to 2.4%) with a negative 
result (Table 3-2). 
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Figure  3-2 Sensitivity and specificity of endometrial biopsy in the diagnosis of 
endometrial cancer and hyperplasia  
Results sorted according to estimated sensitivity and presented with 95% confidence 
interval   
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Table  3.2 Pooled estimates of pre-test probabilities, likelihood ratios and post-test 
probabilities for diagnostic accuracy of outpatient biopsy in detecting 
endometrial cancer in women with abnormal uterine bleeding 
 
    
Device & Population Pre-test Probability Post-test Probability % (range) 
 % (95% CI) Test + Test – 
    
All devices    
All Women 6.3 (4.7-8.2) 81.7 (59.7-92.9) 0.9 (0.4-2.4) 
Postmenopausal 
Women 
6.9 (4.4-10.1) 83.1 (58.0-94.3) 1.0 (0.4-2.9) 
Pipelle©    
All Women 6.3 (4.7-8.2) 81.3 (52.4-94.4) 0.7 (0.2-2.4) 
Postmenopausal 
Women 
6.9 (4.4-10.1) 82.7 (50.7-95.5) 0.8 (0.2-3.1) 
    
 
An estimate of the pre-test probability was obtained by calculating the prevalence of the outcome event in the population 
studied. The following equation was used for calculating post-test probability: post-test probability = likelihood ratio x pre-
test probability / [1-pre-test probability x (1-likelihood ratio)], where Likelihood Ratios (95% CI) for all devices are LR+ 
66.5 (30.0-147.1) / LR- 0.14 (0.1-0.3) and Likelihood Ratios (95% CI) for pipelle® device are LR+ 64.6 (22.3-187.1) / LR- 
0.1 (0.04-0.28) 
Ranges of post-test probability were calculated by using lower and upper limits of 95% confidence intervals of pre-test 
probabilities and likelihood ratios. 
 
 
 
 
If inadequate samples were regarded as negative results then LRs for all devices were 87.24 
(95% CI 38.87-195.79) and 0.15 (95% CI 0.08-0.27) for positive and negative outpatient test 
results respectively. In this case the pre-test probability increased from 5.50% (95% CI 4.13% 
to 7.15%) to 83.6% (95% CI 62.4% to 93.8%) with a positive result and decreased to 0.9% 
(95% CI 0.3% to 2.1%) with a negative result. Homogeneity of diagnostic performance was 
confirmed across all studies by a non-significant (p=0.99) χ2 test. Subgroup analyses stratified 
for study quality did not affect the pooled LR estimates.  
 
A funnel plot showing the distribution of effect sizes according to inverse of variance (Figure 
3-3), indicated that larger studies tend to report better diagnostic test performance, though the 
correlation was not statistically significant  (rank correlation r=0.4, p=0.17).  
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Figure  3-3  Funnel plot endometrial biopsy and cancer 
     
 
3.1.4.2 Accuracy in predicting endometrial hyperplasia 
Diagnostic accuracy was lower for endometrial hyperplasia than endometrial cancer. The 
weighted overall sensitivity was 66.0% (95% CI 47.0% to 81.0%) and specificity was 95.0% 
(95% CI 91.0%to 98.0%). The pooled LRs for endometrial hyperplasia were 12.0 (95% CI 
7.8-18.6) and 0.2 (95% CI 0.1-0.3) for positive and negative outpatient test results 
respectively (Table 3-3). The pretest probability increased from 10.2% (95% CI 8.2%-12.5% 
to 57.7% (95% CI 41.1% to 72.7%) with a positive result. It decreased to 2.2% (95% CI 0.9% 
to 4.1%) with a negative result. If inadequate samples were regarded as negative results then 
LRs were 15.7 (95% CI 9.7-25.5) and 0.4 (95% CI 0.3-0.5) for positive and negative EB 
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results respectively. In this case the pretest probability increased from 12.9% (95% CI 10.7% 
to 15.3%) to 70.0% (95% CI 53.7% to 82.2%) with a positive result and decreased to 5.6% 
(95% CI 3.7% to 8.1%) with a negative result. For studies of postmenopausal women, the 
pretest probability was increased from 14.3% (95% CI 8.6%-21.9%) to 66.7% (95% CI 42.3% 
to 83.9%) with a positive result and decreased to 3.2% (95% CI 0.9% to 7.8%) with a 
negative result.  
 
Heterogeneity of diagnostic performance was confirmed across all studies for endometrial 
hyperplasia by a significant (p = 0.0001) χ2 test. Sensitivity analyses stratified for items of 
study quality did affect the heterogeneity of diagnostic performance. Prospective recruitment 
(p=0.9), clear population details (p=0.9) and the exclusive use of one particular reference 
standard (D&C or hysterectomy, p=0.9) removed significant heterogeneity of diagnostic test 
performance and thereby provided a possible explanation for the overall observed 
heterogeneity. A funnel plot (Figure 3-4) indicated that smaller studies tend to report better 
diagnostic test performance (Spearman rank correlation r= 0.83, p=0.02) and publication bias 
is therefore likely. 
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Figure  3-4 Funnel plot endometrial biopsy and hyperplasia 
 
3.1.4.2.1 Severity of endometrial hyperplasia 
The data were separated for the presence of endometrial hyperplasia with or without atypia. 
Table 3-3 shows the pooled LRs, pre and posttest probabilities for positive and negative 
results for these subgroups along with the overall pooled result for comparison. Significant 
heterogeneity of diagnostic test performance was present. Possible explanations for this 
related to study design and type of reference standard as sensitivity analyses excluding 
retrospective studies and studies using more than one reference standard produced 
homogeneity of diagnostic performance. In addition the data was analysed to determine the 
diagnostic accuracy of outpatient biopsy in detecting premalignant (complex and atypical 
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hyperplasia) or malignant endometrial pathology. Homogeneity of diagnostic performance 
was confirmed across all studies by a non-significant (p = 0.43) χ2 test. 
 
3.1.5 Secondary outcomes 
3.1.5.1 Failure rate and inadequate specimen rate 
The overall failure rate for outpatient biopsy was 68/1337 representing 5% (95% CI 4%-6%) 
of all attempted biopsies. Pipelle®, the most frequently evaluated device, had a failure rate of 
5% (43/870, 95% CI 4%-7%). Histologically inadequate samples (no specimen obtained or 
insufficient for adequate assessment) were reported in 148/1269 (12% 95% CI 10%-14%) 
samples overall and in 64/822 (8% 95% CI 6%-10%) of Pipelle® samples. Among the 7 
evaluations of exclusively postmenopausal women, the failure rates and inadequate sampling 
rates were higher than that found in all studies combined. There were 58/486 (12% 95% CI 
9%-15%) failures and 93/428 (22% 95% CI 17.9-25.9) inadequate samples.  One case of 
cancer was found in all the inadequate specimens (Appendix 13).  
 
3.1.5.2 Complication rate 
No cases of potentially serious complications (e.g. life threatening haemorrhage or systemic 
illness, uterine trauma, visceral damage) were reported out of 1269 successful procedures. 
However, ascertainment of serious complications may be suboptimal as only 5/12 (42%) 
studies, which included 251 successful procedures, explicitly stated the intention to report or 
actually reported complications.  
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Table  3.3 Sensitivity analyses for meta-analysis of the diagnostic accuracy of outpatient endometrial biopsy in endometrial 
hyperplasia with or without atypia and its diagnostic accuracy in detecting endometrial cancer with or without 
premalignant complex/atypical endometrial hyperplasia  
 
        
Device (No. Evaluations)  Positive test Negative test LR positive LR negative  Pretest probability Posttest probability  
&Study (Year published) (Sensitivity) (1-Specificity) (95% CI) (95% CI) (95% CI) +ve test (95% CI) -ve test (95% CI) 
        
        
Endometrial hyperplasia (all 8 evaluations)        
        
Total 
21,26,40,44,61,66
 82/126 38/679 12.0 (7.8-18.6)  0.2 (0.1-0.3) 10.2% (8.%-12.5%)  57.7% (41.1 - 72.7%) 2.2% (0.9 to 4.1%) 
        
Endometrial hyperplasia without atypia (4 evaluations)        
        
Total
 21,26,40,44 
55/90 26/427 10.7 (6.1-18.9) 0.45 (0.35-0.57) 15.7% (12.6-19.1%) 86.7% (72.8 to 3.9%) 7.7% (4.8 to 11.9%) 
        
Endometrial hyperplasia with atypia (1 evaluation)        
        
Total 
44 
 2/3 1/51 34 (4.2-277.4) 0.3 (0.07-1.7) 5.6 (1.2-15.4%) 66.9% (48.5 to 8.1%) 2.6% (0.4 to 9.4%) 
        
Endometrial cancer +/- complex/atypical endometrial hyperplasia (8 evaluations)     
        
Total 
21,26,40,44,61,66 
34/37 2/768 95.1 (41.2-219.4) 0.1 (0.07-0.3) 4.5% (3.2 to 6.1%) 81.8% (57.7 to 93.4%) 0.5% (0.2 to 1.9%) 
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3.2 Results of systematic review of endometrial thickness 
measurement by ultrasound 
 
3.2.1 Question 
What is the accuracy of outpatient endometrial ultrasonography in the diagnosis of 
endometrial cancer and hyperplasia? 
 
3.2.2 Study Selection 
The initial electronic searches generated 551 citations, in which observer agreement was 
518/551 (94%) with a kappa of 0.80.  Eighty-two articles were thought to be relevant by both 
reviewers and 33 articles were considered relevant by one reviewer.  The full manuscripts of 
these 115 articles were obtained for review.  Another 30 articles were obtained from scanning 
the reference lists of known primary and review articles in my personal files.  After reviewing 
the full manuscripts of a total of 145 articles, 35 
English,
4,14,18,36,42,48,53,54,78,94,96,122,130,135,142,146,147,151,154,159,161,164,179,216,223,224,229,238,243,244,304,328,334
,338,345
 7 German,
85,132,165,234,269,290,295
 4 Italian,
227,285,321,348
 2 French,
258,281
 2 Chinese,
155,205
 2 
Bulgarian,
172,323
 1 Spanish,
237
 1 Polish,
316
 1 Turkish,
9
 and 1 Dutch
43
 articles were selected for 
inclusion in the overview.  There were 6 articles in which the two reviewers initially 
disagreed on eligibility but this was resolved easily by consensus.  These instances of 
disagreement were the result of an oversight by one of the reviewers.  Agreement concerning 
eligibility was 96% (kappa = 0.91).  Characteristics of the 57 studies selected for meta-
analysis are shown in Appendix 14. 
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The reasons for excluding the remaining 88 manuscripts (Figure 3-5 and Appendix 15) 
included inappropriate study design (18 studies), inappropriate study population (31 studies), 
inappropriate clinical outcomes being reported (5 studies), and the inability to extract data 
precluding construction of 2x2 tables (31 studies).  Three articles were also excluded due to 
duplicate publication.  
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Figure  3-5 Study selection process for systematic review of ultrasound scan 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2.3 Study quality 
The observer agreement for the various components of study quality was 89-100%, kappa 
values were 0.64 for population enrolment, 1.0 for description of amenorrhoea and HRT use, 
1.0 for description of analytical test and cut-off level, 0.88 for number of endometrial layers 
used in the ultrasonic measurement of endometrial thickness, 0.69 for blinding of test results 
Potentially relevant studies identified and screened for 
retrieval (citations in electronic search)  n=551 
Diagnostic test studies included in meta-analysis  
          n=57 
Diagnostic test studies excluded: 
 
Inappropriate study design (not accuracy)     n=18 
 A7,9,12,25,26,28,33,36,45,49,51,67,70,74,80,85,86,88
  
 
Inappropriate study population       n=31 
A1,4-6,11,14,16-19,31,32,35,39,46,48,54-56,59,62,64,66,68,69,73,75-77,79,83 
 
Inappropriate outcomes (not cancer)
A3,22,40,72,87  
n=5 
 
Inability to extract for 2x2 table       n=31 
A2,8,10,13,15,20,21,23,24,27,29,30,34,37,38,42-44,47,50,53,58,60,61,63,65,71,78,81,82,84
 
Duplicate publication
A41,52,57       
n=3 
 
Population:  Restricted recruitment (endometrial cancer) 
5,18-
20,24-25,30 
n=7 
Intrauterine abnormalities data only 
29,56  
n=2 
Asymptom tic women 
43    
n=1 
 
Subtotal      n=10 
 
Diagnostic Performed under general anaesthetic 
22,41,48,50,54-55,60-61
n=8 Intervention:Cytological outpatient device 
59   
n=1
No convincing gold standard 
13,15-16,23,26,28,31,33,58  
n=9 
 
Subtotal      n=18 
 
Outcome:      
 
Differential verification 
14,27
    n=2 
Lack of data to construct 2x2 table 
34-36,42,45-46,49,53 
n=8 
Lack of original data / reviews 
21,32,51   
n=3 
 
Subtotal      n=13 
 
TTotal excluded 
5,13-17,18-35,38,41-43,45-46,48-51,53-56,58-61    
 n=88
 
 
      
   
Studies excluded          n=406       
(Inappropriate population, intervention or outcome – see text) 
Diagnostic test studies retrieved for more detailed 
evaluation: 
from electronic search     n=115 
from reference lists      n=30 
Total          n=145 
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and 1.0 for completeness of verification.  The instances of disagreement were the result of an 
oversight on of one of the reviewers, and were resolved easily by consensus.  The main 
features of the methodological qualities of those studies selected for meta-analysis are 
summarised in Table 3-4.  A majority of the studies were quality level 4-5.  
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Table  3.4 Methodological quality of selected primary studies 
 
  
Quality criteria* Number of Studies (%) 
  
  
Population   
Recruitment  
Consecutive 5/56 (9.0) 
Arbitrary 2/56 (3.5) 
Unclearly reported 49/56 (87.5) 
Spectrum  
With and without HRT 13/56 (23.0) 
Narrow 27/56 (48.0) 
Unreported 16/56 (29.0) 
  
Diagnostic test  
Determination of scanning method and transducer frequency 
Ideal 55/56 (98.2) 
Unclearly reported 1/56 (1.8) 
Determination of method of measuring endometrial thickness 
Ideal 48/56 (85.7) 
Unclearly reported 8/56 (14.3) 
Description of cut-off level for  4 mm only 
A priori 4/9 (44.4) 
Post hoc 5/9 (55.6) 
Description of cut-off level for  5 mm only 
A priori 7/21 (33.3) 
Post hoc 14/21 (66.7) 
  
Outcome  
Reference Standard  
1 0/56 (0) 
2                        Ideal 38/56 (67.8) 
3 3/56 (5.4) 
1,2 3/56 (5.4) 
2,3                     Non-ideal 10/56 (17.8) 
1,2,3 2/56 (3.6) 
  
Blinding of test results  
Blinded 7/56 (12.5) 
Unclearly reported 49/56 (87.5) 
Verification of diagnosis  
>90% 50/56 (89.4) 
81-90% 3/56 (5.3) 
<80% 3/56 (5.3) 
  
Quality levels*  
1 0/56 
2 5/56 (8.9) 
3 1/56 (1.8) 
4 45/56 (80.4) 
5 5/56 (8.9) 
 
HRT = hormone replacement therapy, Reference Standard: 1- Hysterectomy / directed biopsy under hysteroscopic vision, 2 - 
Inpatient Dilatation and Curettage (D&C), 3 - Outpatient biopsy e.g. Pipelle, Novak 
*See Methods section for details 
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3.2.4 Data synthesis  
3.2.4.1 Accuracy in predicting endometrial cancer 
The commonest cut-off levels for abnormality were based on the measurement of both layers 
of endometrial thickness - 4 mm (9 studies) and 5 mm (21 studies). Figure 3-6 and 3-7 
presents the sensitivity and specificity of ultrasound in the diagnosis of endometrial cancer 
using 4mm and 5mm cut-offs respectively. The overall sensitivity was 99.2% (95% CI 97.2% 
to 99.9%) and specificity was 48.6% (95% CI 46.4% to 50.8%) according to the 9 studies of 
ultrasound using an endometrial thickness cut-off for endometrial cancer of 4mm. Taking the 
5mm cut-off, pooled sensitivity was 97.3% (95% CI 95.0% to 98.8%) and specificity was 
55.2% (95% CI 52.9% to 57.4%) for endometrial cancer. In view of the lack of an association 
between sensitivity and specificity, a summary receiver operating characteristic curve was not 
generated.
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Figure  3-6 Sensitivity and specificity of ultrasound 4mm in the diagnosis of 
endometrial cancer and disease  
Results sorted according to estimated sensitivity and presented with 95% confidence 
interval   
     
 
Endometrial Cancer            Endometrial Disease* 
 
*Endometrial disease is endometrial cancer or endometrial hyperplasia (see section 1.6.2.2 for an explanation)  
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Figure  3-7 Sensitivity and specificity of ultrasound 5mm in the diagnosis of 
endometrial cancer and disease  
Results sorted according to estimated sensitivity and presented with 95% confidence 
interval   
     
 
Endometrial Cancer             Endometrial Disease* 
 
*Endometrial disease is endometrial cancer or endometrial hyperplasia (see section 1.6.2.2 for an explanation) 
 
 
 
Estimates of LRs for individual studies for the various reported cut-off levels are shown in 
Appendix 16.  Pooled estimates of pre-test probability, LRs and post-test probability are 
shown in Table 3-5.  There were 1243 cases of endometrial cancer among 8890 patients 
giving a pre-test probability of 14.0% (95% CI 13.3 – 14.7%). As shown in Table 3-5, a 
negative test result reduced the post-test probability of cancer to 1.2% (95% CI 0.4-2.9) at  4 
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mm and 2.3% (95% CI 1.2-4.8) at  5 mm.  The pooled estimates for  4 mm negative results 
were homogeneous (p=0.65), although none of the 9 studies using the  4 mm cut-off level 
were of good quality. The pooled estimates of LRs for  5 mm were heterogeneous (p=0.0001 
and p=0.02 for positive and negative test respectively), sensitivity analyses failed to produce 
an explanation as the confidence intervals of the LRs for the various subgroups overlapped 
(Table 3-6). The pre-specified subgroups population spectrum and patient selection were 
found to be significant explanatory variables for heterogeneity in univariable analyses. A 
narrow population spectrum (i.e. not explicitly including postmenopausal women on HRT) 
and the quality item non-consecutive patient selection were associated with significantly 
higher accuracy of ultrasound. Of the additional exploratory variables, a lower ultrasound 
probe transducer frequency (giving reduced image resolution) and a  5 mm cut-off level for 
abnormal endometrial thickening defined post hoc in advance were also predictive of higher 
accuracy. However, the effect of these features on diagnostic accuracy was not confirmed 
with multivariable analysis (Table 3-7). There were only 4 studies out of the 21 studies using 
the  5 mm cut-off level that employed the best quality criteria.  Using the pooled estimates 
from these 4 studies only, a negative test result reduced the post-test probability of cancer to 
2.5% (95% CI 0.9-6.4). 
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Table  3.5 Pooled estimates of pre-test probability, likelihood ratio and post-test 
probability for ultrasound measurement of endometrial thickness in 
predicting endometrial cancer 
 
Method of measurement and cut-off level 
for abnormality 
 
Pre-test probability 
% (95% CI) 
Likelihood ratio 
(95% CI) 
Post-test probability 
% (95% CI) 
    
Measurement of both layers ET thickness    
3 mm (n = 2 studies)    
Positive test result 14.0 (13.3-14.7) 2.1 (1.9-2.3) 25.3 (22.8-27.9) 
Negative test result 14.0 (13.3-14.7) 0.04 (0.01-0.19) 0.7 (0.2-3.2) 
4 mm (n = 9 studies)    
Positive test result 14.0 (13.3-14.7) 1.96 (1.60-2.4)* 24.2 (19.7-29.2) 
Negative test result 14.0 (13.3-14.7) 0.08 (0.03-0.17) 1.2 (0.4-2.9) 
5 mm (n = 21 studies)    
Positive test result 14.0 (13.3-14.7) 2.17 (1.75-2.68)* 26.1 (21.1-31.6) 
Negative test result 14.0 (13.3-14.7) 0.15 (0.08-0.29)* 2.3 (1.2-4.8) 
6 mm (n = 2 studies)    
Positive test result 14.0 (13.3-14.7) 2.5 (2.0-3.1) 28.5 (23.1-34.5) 
Negative test result 14.0 (13.3-14.7) 0.2 (0.08-0.5) 3.2 (1.2-7.9) 
8 mm (n = 1 study)    
Positive test result 14.0 (13.3-14.7) 2.0 (1.0-4.0) 24.6 (13.3-40.8) 
Negative test result 14.0 (13.3-14.7) 0.3 (0.02-4.55) 5.1 (0.3-4.4) 
15 mm (n = 1 study)    
Positive test result 14.0 (13.3-14.7) 7.0 (3.7-13.4) 53.4 (36.2-69.8) 
Negative test result 14.0 (13.3-14.7) 0.2 (0.06-0.7) 3.3 (0.9-11.0) 
    
Single layer ET measurement    
2 mm (n = 3 studies)    
Positive test result 14.0 (13.3-14.7) 2.4 (2.0-3.0) 28.4 (23.5-33.8) 
Negative test result 14.0 (13.3-14.7) 0.15 (0.1-0.3) 2.4 (1.1-5.2) 
3 mm (n = 6 studies)    
Positive test result 14.0 (13.3-14.7) 1.9 (1.7-2.2)* 24.0 (20.5-27.9) 
Negative test result 14.0 (13.3-14.7) 0.3 (0.2-0.5)* 5.1 (3.0-8.5) 
4 mm (n = 2 studies)    
Positive test result 14.0 (13.3-14.7) 1.8 (1.6-2.0) 22.8 (20.0-25.6) 
Negative test result 14.0 (13.3-14.7) 0.08 (0.02-0.27) 1.3 (0.3-4.5) 
10 mm (n = 1 study)    
Positive test result 14.0 (13.3-14.7) 29.2 (4.1-208.0) 82.6 (38.6-97.3) 
Negative test result 14.0 (13.3-14.7) 0.17 (0.03-1.0) 2.7 (0.5-15.1) 
    
Unreported number of layers for ET measurement 
4 mm (n = 4 studies)    
Positive test result 14.0 (13.3-14.7) 1.9 (1.8-2.1) 23.9 (21.6-26.4) 
Negative test result 14.0 (13.3-14.7) 0.1 (0.06-0.2) 1.6 (0.9-2.9) 
5 mm (n = 2 studies)    
Positive test result 14.0 (13.3-14.7) 2.3 (1.8-3.1)* 27.4 (21.2-34.6) 
Negative test result 14.0 (13.3-14.7) 0.04 (0.01-0.2)* 0.7 (0.2-3.5) 
6 mm (n = 1 study)    
Positive test result 14.0 (13.3-14.7) 3.3 (2.5-4.2) 34.7-28.0-41.9) 
Negative test result 14.0 (13.3-14.7) 0.04 (0.00-0.6) 0.7 (0.1-9.2) 
7 mm (n = 1 study)    
Positive test result 14.0 (13.3-14.7) 2.7 (1.9-3.7) 30.1 (22.8-38.7) 
Negative test result 14.0 (13.3-14.7) 0.04 (0.00-0.6) 0.7 (0.0-9.8) 
ET = endometrial thickness, *heterogeneity P<0.05 (chi-squared test for heterogeneity used) 
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Table  3.6 Sensitivity analyses: Studies of ultrasound measurement of both layers  4 mm or  5 mm endometrial thickness 
for endometrial cancer or disease with pooled LRs stratified according to study characteristics and quality 
 
  Cancer  Disease (hyperplasia and/or cancer) 
   4 mm   5 mm   4 mm   5 mm 
Quality Criteria*  
n 
Positive test  
LR (95% CI) 
 
n 
Positive test  
LR (95% CI) 
Negative test  
LR (95% CI) 
 
n 
Positive test  
LR (95% CI) 
 
n 
Positive test  
LR (95% CI) 
Negative test  
LR (95% CI) 
           
POPULATION           
Recruitment           
Consecutive 0 - 2 3.5 (2.4-5.6) 0.3 (0.1-0.6) 0 - 2 4.0 (2.5-6.4) 0.3 (0.2-0.6) 
Arbitrary 0 - 0 - - 0 - 0   
Unclearly reported 9 1.83 (1.76-1.9) 19 1.9 (1.8-2.1) 0.08 (0.05-0.14) 9 2.1 (1.95-2.2) 17 2.5 (2.3-2.9) 0.1 (0.06-0.2) 
           
Length of amenorrhoea           
 12 months 3 1.5 (1.4-1.6) 7 1.8 (1.6-2.1) 0.1 (0.03-0.2) 3 1.7 (1.6-1.8) 6 2.4 (2.0-2.9) 0.15 (0.1-0.4) 
< 12 months 2 
2.0 (1.9-2.1) 
3 
2.1 (2.0-2.3) 0.1 (0.07-0.2) 
2 
2.3 (2.2-2.5) 
3 
2.6 (2.3-2.8) 0.1 (0.1-0.2) 
Unreported 4 11 4 10 
           
Spectrum           
With and without HRT 4 1.8 (1.75-1.9) 5 1.8 (1.6-2.0) 0.2 (0.1-0.4) 4 2.0 (1.9-2.1) 5 1.9 (1.7-2.2) 0.2 (0.1-0.3) 
Narrow 4 1.8 (1.6-2.0) 10 2.0 (1.8-2.1) 0.06 (0.03-0.12) 4 2.1 (1.9-2.4) 9 2.9 (2.6-3.3) 0.06 (0.03-0.1) 
Unreported 1 1.9 (1.6-2.2) 6 2.6 (2.1-3.1) 0.2 (0.1-0.4) 1 2.3 (1.9-2.8) 5 2.8 (2.4-3.4) 0.2 (0.1-0.3) 
           
DIAGNOSTIC TEST           
Cut-off level for abnormality           
A priori 4 1.46 (1.37-1.54) 7 2.0 (1.8-2.3) 0.1 (0.05-0.2) 4 1.5 (1.4-1.7) 6 2.9 (2.4-3.5) 0.16 (0.1-0.3) 
Post-hoc 5 2.2 (2.0-2.3) 14 2.0 (1.8-2.1) 0.1 (0.06-0.2) 5 2.5 (2.3-2.7) 13 2.5 (2.2-2.7) 0.1 (0.07-0.2) 
           
OUTCOME           
Reference Standard           
1 0  0   0 - 0 - - 
2                                   Ideal 4 2.0 (1.9-2.1) 15 1.9 (1.8-2.0) 0.12 (0.07-0.2) 4 2.3 (2.2-2.5) 14 2.5 (2.3-2.7) 0.1 (0.08-0.2) 
1,2 0  3   0 - 2   
3 1  1   1  1   
2,3                         Non-ideal 4 1.6 (1.5-1.7) 1 3.6 (2.8-4.5) 0.05 (0.01-0.2) 4 1.7 (1.6-1.9) 1 3.0 (2.4-3.7) 0.1 (0.06-0.3) 
1,2,3 0  1   0 - 1   
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Table 3-6 continued 
    
  Cancer  Disease (hyperplasia and/or cancer) 
   4 mm   5 mm    4 mm   5 mm  
Quality Criteria*  
n 
Positive test  
LR (95% CI) 
 
n 
Positive test  
LR (95% CI) 
Negative test  
LR (95% CI) 
 
n 
Positive test  
LR (95% CI) 
 
n 
Positive test  
LR (95% CI) 
Negative test  
LR (95% CI) 
           
Blinding of test results           
Blinded 0 - 3 2.9 (2.4-3.4) 0.1 (0.02-0.3) 0 - 3 5.0 (3.9-6.4) 0.03 (0.01-0.1) 
Unclearly reported 9 1.83 (1.76-1.9) 18 1.9 (1.8-2.0) 0.1 (0.07-0.2) 9 2.1 (1.95-2.2) 16 2.2 (2.0-2.4) 0.015 (0.1-0.2) 
           
Verification of diagnosis           
>90% 9 1.83 (1.76-1.9) 17 2.0 (1.9-2.1) 0.1 (0.05-0.2) 9 2.1 (1.95-2.2) 15 2.9 (2.6-3.2) 0.1 (0.05-0.1) 
81-90% 0 - 2 
2.0 (1.7-2.3) 0.2 (0.1-0.4) 
0 - 2 
1.9 (1.7-2.2) 0.2 (0.1-0.4) 
<80% 0 - 2 0 - 2 
           
Quality Level           
I-III 0 - 4 2.8 (2.3-3.3) 0.16 (0.06-0.4) 0 - 4 4.7 (3.7-6.0) 0.08 (0.03-0.2) 
IV-VI 9 1.83 (1.76-1.9) 17 1.9 (1.8-2.1) 0.09 (0.05-0.2) 9 2.1 (1.95-2.2) 15 2.2 (2.0-2.4) 0.13 (0.09-0.2) 
           
Reference Standard and Quality Level         
Ideal and I-III 0 - 4 2.8 (2.3-3.3) 0.16 (0.06-0.4) 0 - 4 4.7 (3.7-6.0) 0.08 (0.03-0.2) 
Ideal and IV-VI 4 2.0 (1.9-2.1) 14 1.8 (1.6-1.9)  0.1 (0.06-0.2) 4 2.3 (2.2-2.5) 12 2.05 (1.9-2.3) 0.1 (0.09-0.2) 
Non-ideal and IV-VI 5 1.6 (1.5-1.7) 3 3.6 (2.8-4.5) 0.05 (0.01-0.2) 5 1.7 (1.6-1.9) 3 3.0 (2.4-3.7) 0.1 (0.06-0.3) 
           
 
Reference Standard: 1- Hysterectomy / directed biopsy under hysteroscopic vision, 2 - Inpatient D&C (D&C), 3 - Outpatient biopsy e.g. Pipelle, Novak, *see Methods section for details
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Table  3.7 Exploration of heterogeneity in estimation of accuracy of ultrasound (5mm double layer endometrial thickness) 
for diagnosis of endometrial cancer and disease: Results of meta-regression analysis  
 
 
    
Outcome  
Explanatory variables 
Univariable analysis Multivariable analysis I 
(Hypothesis testing) 
Multivariable analysis II 
(Hypothesis generating) 
 Coefficient 
(standard error)† 
P value Coefficient 
(standard error)† 
 
P value Coefficient 
(standard error)† 
 
P value 
       
ENDOMETRIAL CANCER       
       
Clinical features       
Population spectrum (Wide vs. narrow)* -0.34 (0.14) 0.02 -0.06 (0.25) 0.80 -0.37 (0.80) 0.65 
       
Study quality‡       
Items:       
Patient selection (Consecutive vs. non-consecutive) -0.48 (0.15) 0.01 - - - - 
Reference standard (Outpatient biopsy vs. other) 1.17 (0.91) 0.21 - - - - 
Complete verification (Present vs. absent) 0.38 (0.14) 0.02 - - - - 
Blinding (Blind vs. not blind) 0.14 (0.24) 0.56 - - - - 
Levels: (1-3 vs. 4-5) 0.08 (0.20) 0.69 -0.13 (0.32) 0.68 -0.28 (0.99) 0.78 
       
Ultrasonic procedure       
Transducer frequency(high (>5MHz) vs. low (5MHz)) -0.35 (0.14) 0.02 - - -0.43 (0.75) 0.57 
       
Additional items of study quality       
Length of amenorrhoea (Adequate vs. inadequate)
#
 0.11 (0.17) 0.53 - - -0.13 (0.80) 0.88 
Definition of abnormal result (5mm) (A-priori vs. post hoc) -0.34 (0.14) 0.02 - - 0.13 (0.91) 0.89 
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Table 3-7 continued 
Outcome  
Explanatory variables 
Univariable analysis Multivariable analysis I 
(Hypothesis testing) 
Multivariable analysis II 
(Hypothesis generating) 
 Coefficient 
(standard error)† 
P value Coefficient 
(standard error)† 
 
P value Coefficient 
(standard error)† 
 
P value 
       
ENDOMETRIAL DISEASE       
       
Clinical features       
Population spectrum (Wide vs. narrow)* -0.98 (0.60) 0.12 -0.22 (0.83) 0.80 -0.57 (0.93) 0.54 
       
Study quality‡       
Items:       
Patient selection (Consecutive vs. non-consecutive) -0.33 (0.82) 0.69 - - - - 
Reference standard (Outpatient biopsy vs. other) 0.40 (0.77) 0.61 - - - - 
Complete verification (Present vs. absent) 1.17 (0.58) 0.06 - - - - 
Blinding (Blind vs. not blind) 1.24 (1.07)  0.26 - - - - 
Levels: (1-3 vs. 4-5) -0.04 (0.89) 0.96 0.30 (0.94) 0.75 0.12 (1.07) 0.91 
       
Ultrasonic procedure       
Transducer frequency(high (>5MHz) vs. low (5MHz)) 0.40 (0.64) 0.54 - - 0.55 (0.87) 0.52 
       
Additional items of study quality       
Length of amenorrhoea (Adequate vs. inadequate)† 0.57 (0.82) 0.50   -0.52 (0.87) 0.55 
Definition of abnormal result (5mm) (A-priori vs. post hoc) 0.55 (0.65) 0.41   -0.50 (1.03) 0.63 
       
 
* Wide population spectrum meant that the study population included postmenopausal women on HRT, whereas studies categorised as having a narrow population spectrum did not 
include postmenopausal women on HRT or where the use of HRT was unreported. 
†The dependent variable is the log diagnostic odds ratio, a positive coefficient means that the diagnostic accuracy as measured by the odds ratio is increased and a negative coefficient 
means that it is reduced in relation to the variable. P values <0.05 considered statistically significant. 
‡ Quality levels (1-5) rather than individual quality items used for multivariable analysis62 (see text)  
# The length of amenorrhoea indicating that the woman was menopausal was considered ideal if it was  12 months, and inadequate if it was < 12 months or unreported. 
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Statistical tests (rank correlation) to explore for publication and related biases, found that 
funnel plot asymmetry (Figure 3-8) was not statistically significant (p=0.82) 
 
Figure  3-8  Funnel plot of ultrasound ( 5 mm double layer) and endometrial cancer  
   
 
 
3.2.4.2 Accuracy in predicting endometrial disease 
Estimates of LRs for individual studies are shown in Appendix 17.  Pooled estimates of 
pretest probability, LRs and posttest probability are shown in Table 3-8.  There were 1887 
cases of endometrial disease among 7270 patients giving a pretest probability of 26.0% (95% 
CI 25.0 – 27.0%).  The commonest cut-off levels for abnormality were based on the 
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measurement of both layers of endometrial thickness - 4 mm (9 studies) and 5 mm (19 
studies).  As shown in Table 3-8, a negative test result reduced the posttest probability of 
cancer to 2.4% (95% CI 1.3-3.9) at  4 mm and 5.0% (95% CI 2.9-9.1) at  5 mm.  The 
pooled estimates for  4 mm negative results were homogeneous. However, none of the 9 
studies using the  4 mm cut-off level were of good quality.  Although the pooled estimates of 
LRs for  5 mm were heterogeneous (p<0.05), sensitivity analyses failed to produce an 
explanation as the confidence intervals of the LRs for the various subgroups overlapped 
(Table 3-6). An explanation for heterogeneity was not provided by the population spectrum or 
items of study quality (Table 3-7) when examined using both univariable and multivariable 
analysis. Similarly, the other potential explanatory variables considered did not appear to 
influence diagnostic accuracy. There were only 4 studies out of the 21 studies using the  5 
mm cut-off level that employed the best quality criteria.  Using the pooled estimates from 
these 4 studies only, a negative test result reduced the posttest probability of endometrial 
disease to 2.7% (95% CI 0.9-6.9). 
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Table  3.8 Pooled estimates of pretest probability, likelihood ratio and posttest 
probability for ultrasound measurement of endometrial thickness in 
predicting endometrial disease (hyperplasia and/or cancer) 
 
Method of measurement and cut-off level 
for normality 
Pretest probability 
% (95% CI) 
Likelihood ratio 
(95% CI) 
Posttest probability 
% (95% CI) 
    
    
Measurement of both layers ET thickness    
3 mm (n = 1 study)    
Positive test result 26.0 (25.0-27.0) 2.5 (1.95-3.2) 46.7 (39.4-54.0) 
Negative test result 26.0 (25.0-27.0) 0.03 (0.0-0.4) 1.0 (0.0-12.9) 
    
4 mm (n = 9 studies)    
Positive test result 26.0 (25.0-27.0) 2.17 (1.73-2.73)* 43.3 (36.6-46.7) 
Negative test result 26.0 (25.0-27.0) 0.07 (0.04-0.11) 2.4 (1.3-3.9) 
    
5 mm (n = 19 studies)    
Positive test result 26.0 (25.0-27.0) 2.62 (2.03-3.38)* 47.9 (40.4-55.6) 
Negative test result 26.0 (25.0-27.0) 0.15 (0.09-0.27)* 5.0 (2.9-9.1) 
    
6 mm (n = 2 studies)    
Positive test result 26.0 (25.0-27.0) 1.4 (1.0-1.9)* 32.8 (25.4-41.3) 
Negative test result 26.0 (25.0-27.0) 0.8 (0.6-1.0)* 21.3 (16.4-27.0) 
    
Single layer ET measurement    
2 mm (n = 3 studies)    
Positive test result 26.0 (25.0-27.0) 2.6 (2.0-3.4) 47.9 (40.5-55.4) 
Negative test result 26.0 (25.0-27.0) 0.14 (0.07-0.27) 4.7 (2.3-9.1) 
    
3 mm (n = 5 studies)    
Positive test result 26.0 (25.0-27.0) 2.1 (1.9-2.6) 43.7 (38.1-49.3) 
Negative test result 26.0 (25.0-27.0) 0.3 (0.2-0.4)* 9.0 (6.5-12.6) 
    
4 mm (n = 2 studies)    
Positive test result 26.0 (25.0-27.0) 1.9 (1.7-2.2) 40.5 (36.7-44.5) 
Negative test result 26.0 (25.0-27.0) 0.07 (0.02-0.2) 2.4 (0.7-6.9) 
    
10 mm (n = 1 study)    
Positive test result 26.0 (25.0-27.0) 21.9 (1.3-364.1) 88.5 (30.6-99.3) 
Negative test result 26.0 (25.0-27.0) 0.6 (0.4-0.9) 17.4 (11.8-25.2) 
    
Unreported number of layers for ET measurement   
4 mm (n = 3 studies)    
Positive test result 26.0 (25.0-27.0) 2.7 (2.1-3.4) 48.5 (41.4-55.6) 
Negative test result 26.0 (25.0-27.0) 0.08 (0.05-0.1) 2.7 (1.6-4.9) 
    
5 mm (n = 2 studies)    
Positive test result 26.0 (25.0-27.0) 2.3 (1.8-2.9) 44.4 (37.2-51.6) 
Negative test result 26.0 (25.0-27.0) 0.03 (0.0-0.15) 1.0 (0.0-5.3) 
    
6 mm (n = 1 study)    
Positive test result 26.0 (25.0-27.0) 4.7 (3.4-6.7) 62.4 (52.8-71.1) 
Negative test result 26.0 (25.0-27.0) 0.02 (0.0-0.3) 0.7 (0.0-9.4) 
 
ET = endometrial thickness, *heterogeneity P<0.05 (chi-squared test for heterogeneity used) 
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3.3 Results of systematic review of hysteroscopy 
 
3.3.1 Question 
What is the accuracy of outpatient hysteroscopy in the diagnosis of endometrial cancer and 
hyperplasia and what are the rates of failure and complications? 
 
3.3.2 Study selection   
A total of 65 primary studies (20 non-English studies), including 26,346 women, assessed the 
diagnostic accuracy of hysteroscopy in detecting serious endometrial disease and met the 
criteria for inclusion (Figure 3-9 and Appendix 18).  
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Figure  3-9 Study selection process for systematic review of hysteroscopy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Potentially relevant studies identified and screened for 
retrieval (citations in electronic search) n=3484 
2846 
Diagnostic test studies excluded: 
Population:  duplicate publication / more complete data sets
A1-9
 n= 9 
     Indeterminable
A10
          n=1 
     Restricted recruitment (endometrial cancer)
A11-13
 n=3 
     Subtotal            n=13 
Intervention:Hysteroscopy findings not presented
A14-21
   n=8  
Outcome:  Lack of data to construct 2x2 table
A22-59
   n=38 
     Histology not separated from hysteroscopy
A60-67
 n=8 
     Not correlated with histology
A68-98
      n=31 
     No cases of cancer/hyperplasia 
A99-101
   n=12  
     Lack of original data = reviews, letter
A111-137
  n=27 
     Subtotal            n=116 
Design:   Case report
A138
          n=1 
Other:   Unobtainable*
A139-143
         n=5 
Total excluded              n=143 
* Manuscripts not obtained despite electronic, local, national and international 
library searches, and writing to authors and colleagues in relevant countries.  
  
      
Diagnostic test studies excluded: 
Population:  duplicate publication / more complete data sets
A1-6
 n=6 
Indeterminable
A7
     n=1 
Restricted recruitment (endometrial cancer)
A8-10
  n=3 
Subtotal      n=10 
Intervention:
 
Hysteroscopy findings not presented
A11-18
  n=8 
Outcome: Lack of data to construct 2x2 table
A19-53
  n=35 
Histology not separated from hysteroscopy
A54-60
  n=7 
Cannot separate cancer and hyperplasia
A61
  n=1 
Not correlated with histology
A62-92
    n=31 
Studies excluded (Duplicates or inappropriate population,  
intervention or outcome – see text)         n=3280 
 
Diagnostic test studies retrieved for more detailed 
evaluation: 
from electronic search (above)   n=204 
from reference lists      n=4 
          n=208  
   190 
 
Diagnostic test studies included in  
meta-analysis (see main text)    n=6554 
 
(Endometrial cancer data only    n= 2421 
Endometrial hyperplasia data only   n=97 
Endometrial cancer and hyperplasia data  n=3226) 
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Agreement regarding eligibility was 96% (weighted kappa 0.8). Of the 65 included studies, 56 
studies (24,649 women) assessed the diagnosis of endometrial cancer. Postmenopausal 
women represented 29% of the populations studied.  
 
3.3.3 Study quality 
Details of the participants, interventions, outcomes and study quality criteria of the studies 
selected for meta-analyses are summarized in Appendices 19 and 20. There was a single study 
of the highest methodological quality (level 1), one study was classified as level 2, ten studies 
(15%) were level 3, 42 studies (65%) were level 4 and 11 studies (17%) were level 5 in 
quality. 
 
3.3.4 Data synthesis 
3.3.4.1 Accuracy in predicting endometrial cancer 
Figure 3-10 presents the sensitivity and specificity of hysteroscopy in the diagnosis of 
endometrial cancer. The variations in sensitivity were much greater than the variations in 
specificity and there was no significant association between sensitivity and specificity 
(Spearman‟s correlation coefficient r=-0.06, P=0.65). Weighted by the number of cases, the 
overall sensitivity was 86.4% (95% CI 84.0% to 88.6%) and specificity was 99.2% (95% CI 
99.1% to 99.3%) according to 56 studies of hysteroscopy for endometrial cancer. In view of 
the lack of an association between sensitivity and specificity, a summary receiver operating 
characteristic curve was not generated.
83
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Figure  3-10 Sensitivity and specificity of hysteroscopy in the diagnosis of 
endometrial cancer and disease  
     Results sorted according to estimated sensitivity and presented with 95% confidence 
interval.   
     
  Endometrial Cancer         Endometrial Disease* 
 
  
*Endometrial disease is endometrial cancer or endometrial hyperplasia (see section 1.6.2.2 for an explanation) 
 
 
 
 
The pooled LRs for endometrial cancer are shown in Table 3-9. The pretest probability 
(prevalence) increased from 3.9% (95% CI 3.7%-4.2%) to 71.8% (95% CI 67.0%-76.6%) 
with a positive result and decreased to 0.6 % (95% CI 0.5%-0.8%) with a negative result. 
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Heterogeneity of diagnostic performance between studies was present as confirmed by a 
statistically significant χ2 test and this remained within the pre-specified clinical subgroups 
(setting and menopausal status). An explanation for heterogeneity was not provided by the 
study setting, menopausal status or study quality (Table 3-10). Neither did the other potential 
explanatory variables defined post hoc significantly influence diagnostic accuracy. The 
reported occurrence of complications was associated with reduced accuracy on univariable 
analysis, but this was not confirmed on multivariable analysis.  
 
Statistical tests (rank correlation) to explore for publication and related biases, found that 
funnel plot asymmetry (Figure 3-11) was not statistically significant (p=0.34) 
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Table  3.9 Pooled estimates of pretest probabilities, likelihood ratios and posttest probabilities for diagnostic accuracy of 
hysteroscopy in detecting endometrial cancer and disease in women with abnormal uterine bleeding   
 
   
    
Outcome (pretest probability with 95% CI) Positive Likelihood Negative Likelihood Posttest Probability % (range) 
Population sub group (number of studies) Ratio (95% CI) Ratio (95% CI) Test + Test – 
     
     
ENDOMETRIAL CANCER (3.9% (3.7%-4.2%))     
     
All studies (61) 60.9 (51.2-72.5) 0.15 (0.13-0.18) 71.8 (67.0-76.6) 0.6 (0.5-0.8) 
     
Quality (High vs. low quality)*     
High quality studies (11) 34.8 (25.6-47.3) 0.21 (0.15-0.28) 58.6 (49.6-67.5) 0.8 (0.6-1.2) 
Low quality studies (50) 73.5 (59.5-90.8) 0.14 (0.12-0.17) 74.9 (69.6-79.9) 0.6 (0.5-0.7) 
     
Setting (Outpatient vs. inpatient)     
Outpatient setting (31) 82.5 (64.9-105.0) 0.13 (0.10-0.16) 77.0 (71.4-82.2) 0.5 (0.4-0.7) 
High quality studies  (4) 119.2 (63.0-225.7) 0.16 (0.11-0.24) 82.8 (70.7-90.8) 0.7 (0.4-1.0) 
Low quality studies  (27) 76.5 (59.0-99.2) 0.12 (0.09-0.15) 75.6 (69.4-81.3) 0.5 (0.3-0.7) 
Inpatient setting (16) 21.9 (15.9-30.2) 0.28 (0.21-0.37) 47.1 (37.9-57.0) 1.1 (0.8-1.6) 
High quality studies  (5) 8.6 (5.4-13.6) 0.36 (0.23-0.54) 25.8 (17.2-37.4) 1.4 (0.9-2.3) 
Low quality studies  (11) 58.6 (33.5-102.7) 0.25 (0.17-0.35) 70.4 (56.3-81.8) 1.0 (0.7-1.5) 
     
Menopausal status (Postmenopausal vs. mixed)     
Postmenopausal women (16) 38.3 (26.1-56.1) 0.13 (0.09-0.18) 60.9 (50.1-71.1) 0.5 (0.4-0.8) 
High quality studies  (2) 45.4 (9.7-211.5) 0.09 (0.02-0.44) 64.8 (27.2-90.3) 0.4 (0.08-1.9) 
Low quality studies  (14) 37.8 (25.5-56.0) 0.13 (0.09-0.19) 60.5 (49.5-71.1) 0.5 (0.3-0.8) 
Pre/post menopausal women (45) 72.5 (59.7-88.1) 0.16 (0.13-0.19) 74.6 (69.6-79.4) 0.6 (0.5-0.8) 
High quality studies  (9) 34.0 (25.1-46.1) 0.22 (0.16-0.29) 58.0 (49.1-66.9) 0.9 (0.6-1.3) 
Low quality studies  (36) 104.7 (80.7-135.9) 0.14 (0.12-0.18) 81.0 (75.6-85.6) 0.6 (0.5-0.7) 
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Table 3-9 continued 
    
     
     
Outcome (pretest probability with 95% CI) Positive Likelihood Negative Likelihood Posttest Probability % (range) 
Population sub group (number of studies) Ratio (95% CI) Ratio (95% CI) Test + Test – 
     
     
ENDOMETRIAL DISEASE (10.6% (10.2%-11.0%))     
     
All studies (71) 10.4 (9.7-11.1) 0.24 (0.22-0.25) 55.2 (52.4-57.8) 2.8 (2.4-3.0) 
     
Quality (High vs. low quality)*     
High quality studies (12) 5.5 (4.8-6.3) 0.31 ((0.27-0.37) 39.4 (35.3-43.8) 3.5 (3.0-4.4) 
Low quality studies (59) 12.6 (11.5-13.7) 0.22 (0.1-0.24) 59.9 (56.6-62.3) 2.5 (1.1-2.9) 
     
Setting (Outpatient vs. inpatient)     
Outpatient setting (36) 13.9 (12.6-15.3) 0.21 (0.19-0.23) 62.2 (58.9-65.4) 2.4 (2.1-2.8) 
High quality studies  (4) 8.3 (6.9-10.1) 0.29 (0.24-0.35) 49.6 (43.9-55.5) 3.3 (2.7-4.2) 
Low quality studies  (32) 16.2 (14.5-18.2) 0.20 (0.17-0.22) 65.7 (62.2-69.2) 2.3 (1.9-2.7) 
Inpatient setting (18) 4.6 (4.0-5.3) 0.39 (0.34-0.44) 35.3 (31.2-39.6) 4.4 (3.7-5.2) 
High quality studies  (5) 2.4 (2.0-2.9) 0.45 (0.34-0.59) 22.1 (18.5-26.4) 5.1 (3.7-6.8) 
Low quality studies  (13) 7.0 (5.6-8.6) 0.37 (0.32-0.43) 45.4 (38.9-51.5) 4.2 (3.5-5.1) 
     
Menopausal status (Postmenopausal vs. mixed)     
Postmenopausal women (18) 20.4 (15.7-26.6)  0.14 (0.11-0.19) 70.8 (64.1-76.7) 1.6 (1.2-2.3) 
High quality studies  (2) 71.5 (9.8-522.9) 0.09 (0.02-0.41) 89.5 (52.7-98.5) 1.1 (0.2-4.8) 
Low quality studies  (16) 19.6 (15.0-25.6) 0.15 (0.11-0.19) 69.9 ((63.0-76.0) 1.8 (1.2-2.3) 
Pre/post menopausal women (53) 9.6 (9.0-10.4) 0.25 (0.23-0.27) 53.2 (50.1-56.2) 2.9 (2.6-3.2) 
High quality studies  (10) 5.2 (4.6-6.0) 0.28 (0.23-0.34) 38.1 (34.3-42.6) 3.2 (2.6-4.0) 
Low quality studies  (43) 11.8 (10.8-12.9) 0.20 (0.18-0.22) 58.3 (55.1-61.5) 2.3 (2.0-2.7) 
     
 
An estimate of the pretest probability was obtained by calculating the prevalence of the outcome event in the overall population in the 65 included studies. 
The following equation was used for calculating post-test probability: posttest probability = likelihood ratio x pretest probability/[1-pretest probability x (1-likelihood ratio)]. 
Ranges of posttest probability were calculated by using lower and upper limits of 95% confidence intervals of pretest probabilities and likelihood ratios.  
* High quality studies (levels 1-3), low quality studies (levels 4-5) – see Methods section for details 
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Table  3.10 Exploration of heterogeneity in estimation of accuracy of hysteroscopy for diagnosis of endometrial cancer and 
disease: Results of meta-regression analysis  
 
    
Outcome  
Explanatory variables 
Univariable analysis Multivariable analysis I 
(Hypothesis testing) 
Multivariable analysis II 
(Hypothesis generating) 
 Coefficient 
(standard error)† 
P value Coefficient 
(standard error)† 
 
P value Coefficient 
(standard error)† 
 
P value 
       
ENDOMETRIAL CANCER       
       
Defined a priori       
       
Clinical features       
Setting (Outpatient vs. inpatient) 0.60 (0.44) 0.18 0.52 (0.47) 0.26 0.89 (0.51) 0.09 
Menopausal status (Postmenopausal vs. mixed)  -0.64 (0.69) 0.36 -0.41 (0.72) 0.57 -0.55 (0.75) 0.47 
       
Study quality‡       
Items:       
Patient selection (Consecutive vs. non-consecutive) -0.08 (0.46) 0.86 - - - - 
Reference standard (Outpatient biopsy vs. other) 0.45 (0.61) 0.46 - - - - 
Complete verification (Present vs. absent) -0.14 (0.47) 0.77 - - - - 
Blinding (Blind vs. not blind) -0.39 (2.1) 0.85 - - - - 
Levels: (1-3 vs. 4-5) -0.18 (0.52) 0.73 -0.12 (0.52) 0.82 -0.35 (0.70) 0.62 
       
Defined post hoc       
       
Hysteroscopic procedure       
Description of diagnostic test (Adequate vs. inadequate) -1.11 (0.57) 0.06 - - -1.02 (0.77) 0.19 
Complications (Present vs. absent) -1.71 (0.67) 0.01 - - -1.28 (0.87) 0.15 
       
Items of study quality       
Timing of verification (Sequential vs. simultaneous) 0.13 (0.48) 0.78 - - 0.07 (0.66) 0.91 
Data collection (Prospective vs. other) -0.36 (0.55) 0.52 - - 0.01 (0.60) 0.99 
Follow up (>90% vs. < 90%) -0.28 (0.99) 0.98 - - 0.35 (1.03) 0.73 
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Table 3-10 continued 
Outcome  
Explanatory variables 
Univariable analysis Multivariable analysis I 
(Hypothesis testing) 
Multivariable analysis II 
(Hypothesis generating) 
 Coefficient 
(standard error)† 
P value Coefficient 
(standard error)† 
 
P value Coefficient 
(standard error)† 
 
P value 
       
ENDOMETRIAL DISEASE       
       
Defined a priori       
Clinical features       
Setting (Outpatient vs. inpatient) 1.18 (0.37) 0.002 1.25 (0.33) 0.001 0.54 (0.38) 0.15 
Menopausal status (Postmenopausal vs. mixed)  1.41 (0.69) 0.045 1.54 (0.60) 0.013 1.05 (0.56) 0.06 
       
Items of study quality‡       
Items:       
Patient selection (Consecutive vs. non-consecutive) -1.08 (0.38) 0.005 - - - - 
Reference standard (Outpatient biopsy vs. other) 0.36 (0.50) 0.48 - - - - 
Complete verification (Present vs. absent) 0.57 (0.46) 0.22 - - - - 
Blinding (Blind vs. not blind) 1.81 (2.77)  0.52 - - - - 
Levels: (1-3 vs. 4-5) -1.10 (0.41) 0.009 -1.28 (0.37) 0.001 -1.69 (0.60) 0.006 
       
Defined post hoc       
Hysteroscopic procedure       
Description of diagnostic test (Adequate vs. inadequate) 1.61 (0.82) 0.05 - - 1.22 (0.73) 0.10 
Complications (Present vs. absent) -2.12 (0.64) 0.001 - - -1.15 (0.73) 0.12 
       
Items of study quality       
Timing of verification (Sequential vs. simultaneous) 0.002 (0.43) 1.0 - - 0.88 (0.57) 0.13 
Data collection (Prospective vs. other) 0.82 (0.52) 0.12 - - 0.58 (0.43) 0.19 
Follow up (>90% vs. < 90%) 1.59 (0.53) 0.004 - - 1.78 (0.52) 0.001 
       
 
* Results are based on data from 61 data points presented in the 56 studies of endometrial cancer and 71 data points presented in the 65 studies of endometrial disease. In some studies, 
data could be extracted for both postmenopausal and premenopausal women, thus, there are more data points than studies. 
†The dependent variable is the log diagnostic odds ratio, a positive coefficient means that the diagnostic accuracy as measured by the odds ratio is increased and a negative coefficient 
means that it is reduced in relation to the variable. P values <0.05 considered statistically significant. 
‡ Quality levels (1-5)  rather than individual quality items used for multivariable analysis (see Methods section for details) 
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Figure  3-11 Funnel plot of hysteroscopy and endometrial cancer 
 
 
 
3.3.4.2 Accuracy in predicting endometrial disease 
As observed with endometrial cancer, the variation in sensitivity was much greater than the 
variation in specificity and there was no significant association between sensitivity and 
specificity (correlation coefficient r=0.05, P= 0.70). Diagnostic accuracy was lower for 
endometrial disease than endometrial cancer. The weighted overall sensitivity was 78.0% 
(95% CI 76.3% to 79.6%) and specificity was 95.8% (95% CI 95.6% to 96.1%). The 
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increased from 10.6% (95% CI 10.2%-11.0%) to 55.2% (95% CI 52.4%-57.8%) with a 
positive result and decreased to 2.8% (95% CI 2.4%-3.0%) with a negative result (Table 3-9).  
 
There was heterogeneity in the overall and subgroup meta-analyses (Table 3-9). Clinical 
setting and menopausal status were significant explanatory variables for heterogeneity in 
univariable analyses as was the quality item, patient selection (Table 3-10). Poor study 
quality, the office setting and postmenopausal women were associated with significantly 
higher accuracy of hysteroscopy. The effect of these features on diagnostic accuracy was 
confirmed with multivariable analysis (Table 3-10). Of the variables defined post hoc, only 
follow up greater than 90% was associated with higher accuracy on both univariable and 
multivariable analyses (Table 3-10). 
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3.3.5 Sensitivity analysis 
In 12 (18%) studies it was not possible to determine the rate of inadequate specimen due to a 
lack of clear reporting and the rate was assumed to be zero for the purpose of analysis. This 
gave an inadequate specimen rate on the reference test of 1196/25409 (4.7%, 95% CI 4.5%-
5.0%). The pooled LRs were not altered if inadequate samples were regarded as negative 
results. There were 4622 focal lesions (intrauterine polyps of fibroids) detected in 25409 
hysteroscopies (prevalence 18%) reported in 55/65 primary studies. In 152 of the 4622 focal 
anomalies (prevalence 3%) endometrial cancer (17) or hyperplasia (135) was present. 
Estimates of accuracy for endometrial cancer were not affected when focal abnormalities 
were excluded as part of a sensitivity analysis (LR for positive and negative test 59.3 (49.2-
71.6) and 0.14 (0.12-0.16). 
 
3.3.6 Secondary outcomes 
3.3.6.1 Failure rate 
Failure rates were clearly reported in 36/65 (55%) studies. The overall failure rate was 
937/26346 (3.6%, 95% CI 3.3%-3.8%) when considering all studies and 937/19323 (4.9%, 
95% CI 4.6-5.2%) when studies with unclear reporting were excluded. In those studies 
performed exclusively in one setting, the failure rate for an ambulatory procedure was 
755/18126 (4.2%, 95% CI 3.9-4.5%) compared to 86/2526 (3.4%, 95% CI 2.7-4.2%) for an 
inpatient procedure. However, the underlying reasons for failure varied between settings. 
Failed hysteroscopies in the office setting resulted from technical problems (e.g. cervical 
stenosis, anatomical factors, structural abnormalities) or patient factors (e.g. pain, intolerance) 
more often than in inpatient setting (79% v 9%). By contrast, inadequate visualization (e.g. 
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obscured by bleeding, debris) was more common in the inpatient setting as a reason for failure 
(3% v 0.7%). Endometrial cancer was found in 8/927 (0.8%, 95% CI 0.4%-1.7%) failed 
procedures reported in the 56 cancer studies and endometrial disease was found in 25/937 
(2.7%, 95% CI 1.7%-3.9%) failures reported in all included studies. In those studies where 
data for postmenopausal women could be separated, the failure rate of hysteroscopy (67/1948, 
3.4%, 95% CI 2.7%-4.4%) was comparable to the overall rate (Appendix 20).  
 
3.3.6.2 Complication rate 
Eight cases of potentially serious complications (pelvic infection, uterine perforation (4), 
bladder perforation, and precipitation of a hypocalcaemic crisis and an anginal episode) were 
reported out of 25,409 successful procedures. However, ascertainment of serious 
complications may be suboptimal as only 19/65 (29%) studies, which included 9413 
successful procedures, explicitly stated the intention to report or actually reported 
complications.  
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3.4 Results of economic analysis 
 
3.4.1 Question 
Which of the three available tests (EB, USS and OPH) and their combinations is most cost 
effective in outpatient diagnosis of endometrial cancer? 
 
3.4.2  Base case results  
Life expectancies adjusted for age, surgery and presence of endometrial cancer are shown in 
Appendix 21. All strategies for diagnostic work-up were associated with improved survival 
when compared with a strategy of undertaking no initial investigation of women with PMB. 
However, there was little difference in expected survival between diagnostic strategies. The 
strategies OPH, EB + OPH and USS+EB+OPH were dominated by other strategies (i.e. in 
each case there was an alternative strategy that was both cheaper and more effective – 
Appendix 22). Incremental cost-effectiveness ratios (ICERs) comparing the cost-effectiveness 
of strategies with no initial investigation are shown in Table 3-11. 
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Table  3.11 Investigation of postmenopausal bleeding: Incremental cost-
effectiveness ratios for diagnostic strategies, compared in each case to 
no initial investigation 
 
     
Strategy Incremental 
cost (£) 
Life Years 
Gained (LYG) 
Average days extra 
survival/ patient 
ICER (£/LYG)* 
     
     
USS 5mm 211.94 0.018477 6.74 11,470 
USS 4mm 225.57 0.018839 6.88 11,974 
EB 231.89 0.018845 6.88 12,305 
OPH 239.32 0.016647 6.08 14,376 
USS 5mm+EB 371.69 0.019706 7.19 18,862 
USS 4mm+EB 383.07 0.019724 7.20 19,422 
USS 5mm+OPH 386.91 0.019853 7.25 19,489 
EB+OPH 399.06 0.019731 7.20 20,225 
USS 4mm+OPH 399.07 0.019883 7.26 20,071 
USS+EB+OPH 453.06 0.019731 7.20 22,962 
     
 
Survival discounted at a rate of 1.5% 
*The incremental cost-effectiveness ratios are calculated in each case by comparison with no initial investigation. 
EB = endometrial biopsy, ICER = incremental cost-effectiveness ratio, £/LYG = UK pound sterling per life year gained, 
OPH = outpatient hysteroscopy, USS = transvaginal ultrasound.  
 
 
 
The strategy based on USS using a 5mm cut-off was the least expensive. Incremental cost-
effectiveness ratios (ICERs) comparing the cost-effectiveness of non-dominated strategies 
with USS 5mm are shown in Table 3-12.  
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Table   3.12 Investigation of postmenopausal bleeding: Incremental cost-
effectiveness ratios for the non-dominated strategies, compared in each 
case to a strategy of ultrasound (5mm cut-off) 
 
     
Strategy Incremental cost 
(£) 
Life Years 
Gained (LYG) 
Average days extra 
survival/patient 
ICER (£/LYG* 
     
     
USS 4mm 13.63 0.000362 0.13 37,652 
EB 19.95 0.000368 0.13 54,212 
OPH 27.38 -0.00183 -0.67 D 
USS 5mm+EB 159.76 0.001229 0.45 129,992 
USS 4mm+EB 171.13 0.001246 0.45 137,343 
USS 5mm+OPH 174.97 0.001376 0.50 127,158 
EB+OPH 187.12 0.001254 0.46 149,219 
USS 4mm+OPH 187.13 0.001405 0.51 133,189 
     
 
Survival discounted at a rate of 1.5% 
*The incremental cost-effectiveness ratios are calculated in each case by comparison with a strategy of initial investigation 
with ultrasound using a 5mm endometrial thickness cut-off. 
D=dominated, EB = endometrial biopsy, ICER = incremental cost-effectiveness ratio, £/LYG = UK pound sterling per life 
year gained, OPH = outpatient hysteroscopy, USS = transvaginal ultrasound.  
 
 
 
The ICERs compared to no initial investigation reduced for USS 5mm (£11,470), USS 4mm 
(£11,974) and OPH (£12,305) strategies when the model was altered to allow for EB to be 
performed following a positive test on the same visit, rather than a subsequent one. In these 
circumstances, the ICERs compared to USS 5mm, increased for all diagnostic strategies apart 
from USS 4mm (£27,873) (Appendix 23). 
 
3.4.3 Other age-groups 
Table 3-13 shows the ICERs of diagnostic strategies compared to USS 5mm for women 
presenting at different ages. At older ages of presentation, more strategies became dominated. 
The ICERs increased for all strategies that remained non-dominated with increasing age. The 
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general patterns of dominance were the same when survival effects were not discounted 
although ICERs were generally lower (Appendix 24). 
 
Table  3.13 Investigation of postmenopausal bleeding at different ages of 
presentation: Incremental cost-effectiveness ratios of strategies 
compared to ultrasound (5mm cut-off) 
 
  
Strategy ICER compared to USS5mm for starting age (years) 
 45 55 65 75 80+ 
      
      
USS 4mm 24,940 26,401 37,652 75,493 191,431 
EB 24,336 29,039 54,212 D(USS5) D(USS5) 
OPH D(USS5) D(USS5) D (USS5) D(USS5) D(USS5) 
USS 5mm+EB 78,078 85,417 129,992 375,287 D(USS5) 
USS 4mm+EB 82,616 90,324 137,343 392,722 D(USS5) 
USS 5mm+OPH D(USS+EB) 91,993 127,158 222,326 428,949 
EB+OPH 89,786 98,171 149,219 D (USS5+OPH) D(USS5) 
USS 4mm+OPH D(EB+OPH) 95,407 133,189 D (USS5+OPH) D (USS5+OPH) 
      
 
Survival discounted at a rate of 1.5% 
EB = endometrial biopsy, OPH = outpatient hysteroscopy, USS = transvaginal ultrasound.  
D(USS5) = dominated by USS 5mm cut-off.  D(USS+EB) = dominated by USS+OPH  strategy. D(EB+OPH) = dominated 
by EB+OPH strategy. D(U5+OPH) = dominated by USS 5mm cut-off+OPH strategy. 
 
 
 
3.4.4 Results of sensitivity analyses 
Univariate sensitivity analyses for the strategies involving two initial tests applied over ranges 
of diagnostic feasibility, accuracy and disease prevalence had little effect on overall cost-
effectiveness. However, the assumed effect of delayed diagnosis on increasing disease stage 
from local (FIGO stage I) to advanced (FIGO stages II-IV) endometrial cancer (“upstaging”) 
did reduce the ICERs for all strategies substantially (See Table 3-14). The ICERs for the 
strategies based on initial investigation with USS 4mm or EB reduced to under £30,000 per 
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life year gained when the probability of upstaging endometrial cancer following delay was 6% 
and 8% respectively.   
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Table  3.14 Sensitivity analysis: The effect of delayed diagnosis on the incremental 
cost-effectiveness ratios of combination strategies compared to 
ultrasound (5mm cut-off) 
 
   
Strategy ICERs (£/LYG) stratified according to the probability of 
upstaging endometrial cancer as a result of delayed diagnosis  
   
   
 0.05 0.3 
USS 5mm+EB 129,992 18,909 
USS 4mm+EB 137,343 20,005 
USS5mm +OPH 127,158 20,946 
EB+OPH 149,219 21,747 
USS 4mm+OPH 133,189 21,662 
   
 
0.05 assumes a 5% increase in stage of endometrial cancer as a result of delayed diagnosis following erroneous initial 
discharge, 0.3 assumes a 30% „upstage‟ of disease. 
EB = endometrial biopsy, OPH = outpatient hysteroscopy, USS = transvaginal ultrasound. 
ICER (£/LYG) = incremental cost-effectiveness ratio (£/life year gained). 
 
 
 
 
 
The potentially most cost-effective strategies were those based on initial investigation with 
USS (4 and 5mm) or EB alone. Factors influencing the cost and effectiveness of these three 
diagnostic strategies were varied in order to determine how sensitive the base case results 
were to changes in the underlying assumptions. Figure 3-12 shows the four quadrants of the 
cost-effectiveness plane
11,31,41
 and the results of the sensitivity analyses comparing USS 4mm, 
USS 5mm and EB are shown graphically in this format (Figures 3-13 to 3-15, tabulated data 
is given in Appendices 25 to 27). These results show that there is not yet sufficient data to 
determine which of these strategies is preferred on cost-effectiveness grounds (data points 
appear in all four quadrants of the respective graphs). 
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Figure  3-12 The cost-effectiveness plane 
 
 
 
 
 
 
The cost-effectiveness space is incremental such that the comparison strategy (C) is the origin in the figure and the horizontal 
and vertical axes relate to effect and cost differences respectively 
 
Quadrants I and III represent the situation where one of the strategies is both more effective and more costly. The decision 
regarding cost-effectiveness is unclear and a judgement must be made concerning whether the additional costs of the more 
expensive strategy are justified by the additional effectiveness associated with the particular strategy. A maximum acceptable 
incremental cost-effectiveness ratio (ICER) can be explicitly set to aid decision making. This is represented by the dashed 
line. Datapoints to the right of the line suggest that strategy in question is cost-effective, while points to the left of the line are 
associated with cost-ineffective strategies.41 
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Figure  3-13 Results of univariate sensitivity analysis on extra cost and survival of 
USS 4mm compared to USS 5mm 
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Each datapoint represents one parameter change, all others remaining at base case values. Parameters varied were test failure 
rates, test accuracy estimates for true and false positive rate, the adjustments to true positive rates conditional on previous test 
results and the probability of upstaging endometrial cancer due to delayed diagnosis. 
Line represents £30,000/additional life year gained threshold.274 The strategy USS 4mm may be considered potentially cost-
effective compared with USS 5mm when the data points (representing increased upstaging  probability  to 30%, endometrial 
cancer prevalence increased to 10% and true positive rate of USS 5mm reduced to 94%) are to the right of the line. The 
strategy USS5mm dominates when no endometrial cancer upstaging is assumed. 
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Figure  3-14 Results of univariate sensitivity analysis on extra cost and survival of 
EB compared to USS 5mm 
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Each datapoint represents one parameter change, all others remaining at base case values. Parameters varied were test failure 
rates, test accuracy estimates for true and false positive rate, the adjustments to true positive rates conditional on previous test 
results and the probability of upstaging endometrial cancer due to delayed diagnosis. 
Line represents £30,000/additional life year gained threshold.274 The strategy EB may be considered potentially cost-effective 
compared with USS 5mm when the data points (representing increased upstaging probability to 30%, endometrial cancer 
prevalence increased to 10%, true positive rate of USS 5mm reduced to 94%, and false positive rate and failure rate of EB 
reduced to 0% and 9%  respectively) are to the right of the line. The strategy USS5mm dominates when no endometrial 
cancer upstaging is assumed. 
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Figure  3-15 Results of univariate sensitivity analysis on extra cost and survival of 
EB compared to USS 4mm 
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Each datapoint represents one parameter change, all others remaining at base case values. Parameters varied were test failure 
rates, test accuracy estimates for true and false positive rate, the adjustments to true positive rates conditional on previous test 
results and the probability of upstaging endometrial cancer due to delayed diagnosis. 
Line represents £30,000/additional life year gained threshold.274 These results show that there is not yet sufficient data to 
determine which of these strategies is preferred on cost-effectiveness grounds (data points appear in all four quadrants of the 
graph). 
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3.5 Summary of Results 
3.5.1 Summary of results of systematic reviews 
 
 The literature was of relatively poor methodological quality. 
 
 There was statistical heterogeneity in pooling of likelihood ratios, for USS and OPH, but 
an explanation for this could not be found in spectrum composition and study quality. 
 
 A positive test result on EB diagnosed endometrial cancer with a pooled LR of 66.48 
(95% CI 30.04-147.13) while a negative test result had a pooled LR of 0.14 (95% CI 0.08-
0.27). 
 
 The commonest USS cut-offs to define abnormal endometrial thickness were 4mm and 
5mm, measuring both endometrial layers. Using a 4mm cut-off, a positive test result on 
USS diagnosed endometrial cancer with a pooled LR of 1.96 (95% CI 1.6-2.4) while a 
negative test result had a pooled LR of 0.08 (95% CI 0.03-0.17). The LRs for positive and 
negative ultrasound results for diagnosing endometrial cancer using a 5mm cut-off were 
2.17 (95% CI 1.75-2.68) and 0.15 (95% CI 0.08-0.29) respectively. 
 
 A positive test result on OPH diagnosed endometrial cancer with a pooled LR of 60.9 
(95% CI 51.2-72.5) while a negative test result had a pooled LR of 0.15 (95% CI 0.13-
0.18). 
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3.5.2 Summary of results of economic analysis 
 
 Life expectancies were comparable for all diagnostic strategies, but costs varied.  
 
 For all ages economic modeling indicated that the strategy based on initial diagnosis with 
USS was the least expensive for the investigation of women with PMB.  
 
 Strategies based on initial investigation with OPH or all tests combined were dominated 
by other strategies, in that in each case there was an alternative strategy that was cheaper 
and more effective.  
 
 When compared to initial investigation with USS 5mm for a woman aged 65 (base case - 
decade of peak incidence of endometrial cancer), the ICERs for the non-dominated 
strategies ranged between £37,652 for the initial strategy USS 4mm and  £149,219 for the 
strategy EB + OPH per additional LYG.  
 
 The ICERs increased when considering older ages at presentation and reduced for lower 
ages. However, the ICERs were still well above generally recognised thresholds for all 
strategies with the exception of USS 4mm and EB under the age of 65 years. 
 
 Initial investigation with EB is potentially a cost-effective strategy (ICER reduced below 
£30,000 per LYG)) compared to USS, if EB performs at the more favourable estimates of 
accuracy and USS at the least favourable estimates of accuracy. Similarly, the ICER 
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reduced for EB compared to USS 4mm or 5mm as the probability of upstaging of 
endometrial cancer with delayed diagnosis increased.  
 
 The strategies involving initial evaluation with two tests (combination strategies) could 
become more cost-effective if the effect on life expectancy of a delayed diagnosis is much 
greater than is assumed in the base case. 
 
 
Table  3.15 Summary of results of economic evaluation: cost-effectiveness of each 
strategy compared with ultrasound scan (5mm cut-off) 
 
 
  
Comparator Ultrasound scan 
(5mm cut-off) 
  
  
No initial investigation A 
Ultrasound scan (4mm cut-off) I 
Endometrial biopsy I 
Outpatient hysteroscopy G 
Ultrasound scan + outpatient hysteroscopy I 
Ultrasound scan + endometrial biopsy I 
Endometrial biopsy + outpatient hysteroscopy I 
Ultrasound scan + endometrial biopsy + outpatient hysteroscopy I 
  
 
 
Possible permutations for results of economic evaluation
82
 
A Trade off  Higher costs but better outcomes (incremental cost-effectiveness analysis required) 
B Reject   Higher costs and no difference in outcomes 
C Reject   Higher costs and poorer outcomes 
D Accept   No difference in costs and improved outcomes (partial dominance) 
E Neutral   No difference in costs and no difference in outcomes 
F Reject   No difference in costs and poorer outcomes 
G Accept   Lower costs and improved outcomes (extended dominance) 
H Accept   Lower costs and no difference in outcomes (partial dominance) 
I Trade off  Lower costs but poorer outcomes (incremental cost-effectiveness analysis required) 
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CHAPTER IV 
4 DISCUSSION AND CONCLUSIONS 
DISCUSSION AND CONCLUSIONS 
 
4.1 Diagnostic reviews 
4.1.1 Test accuracy in the diagnosis of endometrial cancer 
The reviews of diagnostic hysteroscopy and endometrial biopsy show them to be safe 
procedures with a low incidence of serious complications.
62,63
 Although the review of 
ultrasound did not record this data, primary studies have not reported these procedures to be 
associated with significant side effects.
12
 When the uterine cavity is adequately visualised, 
hysteroscopy is highly accurate, and thereby clinically useful in the diagnosis of endometrial 
cancer. Moreover, performance of the test does not appear to be significantly altered by the 
clinical setting or menopausal status. Endometrial biopsy is also highly accurate when 
adequate specimens are obtained. For both these diagnostic tests, a positive test result is 
highly accurate but a negative test result is of more limited accuracy and thereby only 
moderately useful.
21,174
 As the diagnosis of endometrial cancer is very important, the high 
likelihood ratio for a positive test should raise most pre-test probabilities over any threshold 
for advanced management.
264
 In contrast, the likelihood ratio for a negative test may not be 
low enough to negate the need for further diagnostic testing (i.e. malignant pathology can be 
missed by outpatient biopsy and hysteroscopy), thereby reducing the utility of outpatient 
biopsy or hysteroscopy in isolation for excluding cancer.  
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In contrast, these results suggest that ultrasonic measurement of endometrial thickness has 
limited diagnostic prediction for endometrial cancer but is a good test for exclusion of 
malignancy. A  4 mm or  5 mm cut-off level measuring both layers, can be used to rule out 
endometrial cancer with good certainty, as a negative test result reduced the post-test 
probability substantially (less than 0.5% using 4mm and less than 1% using 5mm, assuming a 
5% pre-test probability). The marginally greater reduction in post-test probability, and the 
statistical homogeneity of the pooled LR for a negative test result, may favour use of the  
4mm double layer cut-off level. However, all 9 included studies at this cut-off were of poor 
methodological quality. The tangible reduction in post-test probability of endometrial cancer 
observed at a  5 mm cut-off level remained (4.2% assuming a 5% prevalence) when pooling 
only the best quality studies, although no explanation for heterogeneity was found. As the 
exclusion of endometrial cancer is very important, one should be wary of relying on the 
pooled estimates of only 4 studies, despite them being of good quality. This illustrates the 
poor methodological quality of the majority of primary studies on this topic. These findings 
concur with a recent Consensus Conference statement, which has also concluded that, an 
endometrial thickness greater than 5 mm should be considered as abnormal,
141
 similar to a 
previous systematic review
303
 (see below).  
 
4.1.2 Test accuracy in the diagnosis of endometrial disease 
Abnormal postmenopausal endometrial thickening is a feature of endometrial hyperplasia as 
well as endometrial cancer. It is not surprising therefore, that the diagnostic performance of 
ultrasound is similar for both conditions and the inferences remain the same i.e. ultrasonic 
measurement of endometrial thickness has limited diagnostic prediction for endometrial 
hyperplasia or cancer but it is a good test for exclusion of endometrial pathology. However, 
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the diagnostic accuracy of EB and OPH is reduced in endometrial disease (cancer and/or 
hyperplasia) compared with estimates of accuracy for endometrial cancer. The modest 
estimates of accuracy in diagnosing endometrial disease reduce the usefulness of these two 
outpatient modalities in informing clinical decision-making.
21
 Further testing will be 
indicated, especially if symptoms persist or intrauterine structural abnormalities are suspected, 
as endometrial disease cannot be ruled in or excluded with a high level of certainty.  
 
Items of poor study quality (retrospective recruitment, unclear reporting) appear to explain the 
observed heterogeneity of diagnostic test performance of EB in hyperplasia. Separating the 
data for the presence of atypia changed the estimates of diagnostic accuracy, although not 
significantly. Diagnostic accuracy was reduced for endometrial hyperplasia without atypia 
and increased when atypical cells were present. The presence of complex hyperplasia with 
atypia is important in clinical practice, because approximately 33% will progress to 
malignancy.
199
 Simple hyperplasia on the other hand, rarely progresses and the hyperplastic 
process can be reversed with local or systemic progestogens.
125
 Moreover, this review 
demonstrates that outpatient endometrial biopsy is highly accurate in diagnosing either 
premalignant or malignant endometrial pathology. A positive test result was more accurate 
than a negative test result. It is encouraging that the more clinically significant the 
endometrial pathology, the better the diagnostic accuracy of outpatient endometrial biopsy 
and hence the more clinically useful the test. In contrast to the findings for endometrial 
cancer, hysteroscopy is more accurate for the diagnosis of endometrial disease in 
postmenopausal women and when undertaken in the office setting. In this review (OPH), 
statistically significant differences between these clinical subgroups are quantitative rather 
than qualitative. Invariably such differences only explain part of the heterogeneity. Therefore, 
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it may be argued that the overall average estimates may provide the best summary of the 
available evidence.
347
 However, cautious interpretation would demand that one considers the 
test‟s performance to vary according to setting and menopausal status. Therefore, inferences 
are based on these clinical subgroups and methodological quality in the case of endometrial 
disease.  
 
4.1.3 Test feasibility 
The results of these systematic reviews show outpatient endometrial biopsy and hysteroscopy 
to be successful procedures.
62,63
 Ultrasonography is the least invasive investigation and has 
previously been shown to be associated with a negligible failure rate.
303
 Failure rates and 
inadequate sampling rates were higher for EB in postmenopausal women compared with 
premenopausal women. Inadequate endometrial samples, despite successful outpatient 
procedures, may result from poor patient compliance or biopsy technique, inherent problems 
with non-representative sampling, varied pathological interpretation or be consistent with the 
underlying atrophic endometrial state. The review of EB found that single cases of cancer and 
hyperplasia were found in inadequate EB specimens, although sensitivity analysis showed 
that the effect of these missed cases on overall accuracy estimates was minimal. However, 
further means of endometrial evaluation should be considered, particularly when endometrial 
imaging or menopausal status is inconsistent with the finding of inadequate tissue. 
Hysteroscopy is a successful procedure in both pre and postmenopausal women although the 
lack of an effect of menopausal status may be the result of reporting bias, as recording of 
failures was unclear in some studies. The office setting appears to have a marginally higher 
failure rate compared to the inpatient setting. This is attributable to anatomical and patient 
factors rather than inadequate visualization, which is more common in the inpatient setting. 
123 
The failure rate of office hysteroscopy may represent an underestimate because of more 
favourable patient selection. However, selection bias is unlikely to have affected diagnostic 
performance in endometrial disease because the ease of visualisation, and hence diagnosis, is 
not readily predictable prior to hysteroscopy. Furthermore, the trend towards improved 
diagnostic performance was confirmed on multivariable analysis, which adjusted for 
menopausal status. Technical failure in performing the EB or OPH should lead to other means 
of endometrial assessment. 
 
 
4.2 Validity of reviews 
 
The strength of this overview is based on its compliance with criteria for performing rigorous 
systematic reviews.
66,170,235,260
 The study focused on explicit research questions and a clear 
prospective protocol was formulated. The search strategies were broad and data that were 
subject to duplicate publication were excluded from the reviews.  Articles were included that 
were published in non-English languages. Furthermore, the assessment of methodological 
quality and data extraction was performed in a valid
107,207
 and reproducible fashion.  The 
evidence was quantitatively summarised and summary LRs were used based on the 
recommendations of the various Evidence-based Medicine Working Group's.
84,86,150,174
 Using 
LRs and Bayes‟ theorem allowed the generation of clinically meaningful post-test 
probabilities thereby facilitating clinical decision making.
174
 Since the completion of the 
reviews included in this thesis, recommendations have been published for the optimal 
reporting of primary studies of diagnostic accuracy.
34,35
 The vast majority of information 
advocated in this „STARD‟ statement has been extracted and presented. 
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4.2.1 Heterogeneity 
Sensitivity analyses were performed to investigate for possible sources of heterogeneity, 
which were planned a priori. Heterogeneity relates to the presence of differences in results 
between individual studies. Homogeneity of results from study to study is one of the criteria 
for meta-analysis, but presence of inconsistency itself does not always invalidate a meta-
analysis. In this situation, it is important to consider possible reasons for heterogeneity and so 
try and explain it. Exploration for sources of heterogeneity was performed as thoroughly as 
possible in accordance with published guidelines,
69,82,91
  taking into account differences in 
methodological quality and study characteristics, using both univariable and multivariable 
analytic techniques. However, this approach did not explain the observed variation in the 
reviews of ultrasound and hysteroscopy. Such analyses are often restricted due to the number 
of available studies.
322,341
 Although the reviews included numerous studies, the exploration of 
underlying sources of heterogeneity may be limited without access to individual patient 
data.
110
 Cautious interpretation of the pooled findings for hysteroscopy and ultrasound is 
recommended in this situation. However, in view of the lack of satisfactory explanations for 
heterogeneity between studies it may be reasonable to base inferences on the overall pooled 
results.
347
  
 
The methodological quality of the primary studies included in the reviews were generally 
poor. Frequent methodological shortcomings included non-consecutive population enrolment 
and unclear reporting of patient‟s menopausal status. Another potential source of bias in the 
review of ultrasound was the manner in which the cut-off level for abnormal endometrial 
thickness was determined. In a majority of studies using the  4 and  5 mm cut-off level, this 
125 
was determined post hoc i.e. retrospectively following the conduct of the test and outcome 
examinations.  This would explain the large number of studies in which there was no 
incidence of endometrial cancer in the presence of a negative test result.  Ideally, the cut-off 
level at which a test will perform most optimally should be determined prior to conducting a 
study to assess its diagnostic performance.
148
 Such potential biases may contribute to 
heterogeneity, but in this review they did not account for the inconsistency of the results 
across studies.  
 
4.2.2 Sources of bias 
4.2.2.1 Reference standard 
In the reviews of USS and OPH, choice of histological reference standard and lack of blinding 
in its assessment could potentially introduce bias. Hysterectomy specimens are regarded as 
the „gold‟ standard for verification of endometrial disease, but the exclusive use of this 
reference standard in a diagnostic test study is not feasible. Therefore it is not surprising that 
many studies included in these reviews obtained endometrial tissue using other methods. It is 
worth noting that any test applied in clinical practice to finally direct patient management can 
serve as a reference standard. However, evaluating diagnostic tests compared to reference 
tests instead of a „gold‟ standard (in this case hysterectomy), will generally underestimate 
diagnostic accuracy as a result of misclassification on true disease status by the reference test 
chosen.
236
 Bias due to misdiagnosis by these methods is however, unlikely to be a significant 
problem in this thesis. This is because outpatient endometrial sampling methods are 
considered to be highly accurate for endometrial cancer.
61,62
 Moreover, both subgroup 
analyses did not show the type of reference standard or blinding to be significant predictors 
126 
for diagnostic performance. Blinding in this overview may be less important than in other 
diagnostic test studies. This is because the histological diagnosis of endometrial cancer, the 
primary outcome measure, is an objective one
215
 and consequently not as susceptible to 
expectation bias.  
 
4.2.2.2 Publication bias 
The impact of publication bias is another important consideration in all systematic reviews, as 
diagnostic accuracy may be overestimated as a result. Here studies with negative or non-
significant results may have been less likely to be published. However, this was only 
suggested by funnel plot asymmetry
82,306
 in the review of EB in endometrial hyperplasia. 
Removal of the smaller studies that reported the highest estimates of diagnostic accuracy as 
part of a sensitivity analysis did not materially alter the results although it did reduce the 
estimates of accuracy slightly, suggesting that the pooled results are reliable. 
 
 
4.3 Comparison with other reviews and guidelines 
4.3.1 Reviews 
Two systematic reviews of ultrasound and one review of EB have been recently 
published.
303,319
 Methodological deficiencies arising from the review of EB
95
 compromise the 
internal and external validity of their review findings. These deficiencies include the use of a 
limited search and the inappropriate inclusion of data derived from studies restricted to 
women known to have endometrial cancer, asymptomatic women, cytological devices and 
procedures carried out under general anaesthetic in overall data synthesis. Estimates of 
127 
diagnostic performance are thus likely to be affected to an unknown degree. However, despite 
these limitations, the pooled detection rates and false positive rates for endometrial cancer 
were comparable with those derived from the EB review included in this thesis (95% and 
0.5% vs. 94% and 1% respectively).  The reviews of ultrasound
303,319
 also had methodological 
problems such as restricting the searching to just one database, which is associated with 
literature retrieval bias
306
 and lack of study quality assessment.
207
 One of the USS reviews
303
 
suggested that an endometrial thickness of  5 mm can reliably exclude endometrial 
pathology in postmenopausal women (detection rate 96% for a 39% false positive rate 
compared with 97% and 45% respectively for the review in this thesis). They recommended 
that a negative test result avoided the need for endometrial sampling for histological 
examination. However, the potential biases in the review process raised concerns that this 
conclusion was over optimistic and therefore required testing as part of a decision analysis 
(see below).  
 
In contrast, the other recently published USS review
319
 recommended that histological 
sampling (D&C) was still required following a negative USS (detection rate 96% for a 50% 
false positive rate). The authors used individual patient data from a few centres to demonstrate 
that the median USS endometrial thickness in postmenopausal women with and without 
endometrial cancer varied between them. They argued that a universal, optimum endometrial 
thickness cut-off was not appropriate, but such cut-offs should be individualized according to 
local data. The findings of this review are potentially biased because of a narrow and outdated 
search restricted to the English language, use of a small data sample and lack of any attempt 
to explore the reasons for variation in endometrial thickness measurements (the 
reproducibility of this measurement has been demonstrated by others
116
) and accuracy 
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between centres. Indeed, 9 of the 11 included centres reported median endometrial thickness 
of  5 mm for unaffected women and all reported median endometrial thickness greater than 
this for endometrial cancer, in keeping with the findings of both Smith-Bindman et al
303
 and 
the USS review included in this thesis. Applying the accuracy estimates from all three USS 
reviews, assuming a 5% pre-test probability of cancer and USS endometrial thickness cut-offs 
of 4 or 5mm, the posterior probability of cancer following a negative USS is between 0.4 and 
0.8%. Thus, the inference that USS is a good test for exclusion of endometrial malignancy in 
PMB remains regardless of which pooled estimate of accuracy is applied. I was unable to 
identify any systematic reviews addressing the diagnostic accuracy of hysteroscopy. 
 
4.3.2 Guidelines 
The Scottish Intercollegiate Guidelines Network (SIGN) published a clinical guideline for the 
investigation of post-menopausal bleeding in September 2002.
293
 No other such guideline was 
identified following searches of electronic bibliographic databases and relevant internet health 
sites. This guideline favoured the use of transvaginal ultrasound because of the “…..greater 
quantity and higher quality of evidence supporting its use compared with other methods.” 
Although the guideline was developed using a standard methodology,
292
 the acquisition of 
evidence was incomplete and important recommendations have been made without due regard 
to the supporting evidence, thereby undermining the strength of contained recommendations. 
For example, the findings from systematic reviews of pelvic ultrasound
160,303
 were included in 
the SIGN guideline, but those of endometrial biopsy were not.
61,62,95
 Furthermore, the review 
of hysteroscopy presented in this thesis
63
 was not published until the month following 
publication of the SIGN guideline. These omitted reviews show there to be an even greater 
quantity of available primary research for other outpatient modalities compared with 
129 
transvaginal ultrasound that is of a similar quality. The SIGN guideline recommended using 
ultrasound as the first-line investigation in PMB, taking a 3mm cut-off (unless on sequential 
hormone replacement therapy where a 5mm cut-off was taken as the pre-test risk of cancer 
was assumed to be lower). Endometrial tissue sampling combined with hysteroscopy was 
recommended following a positive ultrasound result. This recommendation was based on a 
high pre-test risk of endometrial cancer (10%) and accuracy data obtained from the ultrasound 
review presented as part of this thesis.
160
 However, only two studies assessed ultrasound 
diagnostic performance using a 3mm double-layer endometrial thickness cut-off (Table 3-8). 
The recommendations of the SIGN guideline may therefore be prone to bias toward the use of 
ultrasound. 
 
 
4.4 Applicability of reviews 
 
The prevalence of endometrial cancer in women with postmenopausal bleeding has been 
reported to be between 3 and 10% in Europe and North America.
16,146,149,251
 Although there is 
controversy, likelihood ratios are generally considered to be less affected by disease 
prevalence than other measures of accuracy
282
 and therefore the accuracy estimated derived 
from these reviews can be cautiously translated into other settings where disease prevalence 
may differ. For a postmenopausal woman with vaginal bleeding with a 5% pre-test probability 
of endometrial cancer, her probability of cancer is approximately 80% following a positive 
EB or OPH and approximately 0.5% following a negative USS using a 4mm cut-off (0.8% 
using a 5mm cut-off). This is illustrated graphically in Figures 4-1 to 4-3.  
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The pre-test probability can be individualised in the presence of factors obtained from earlier 
in the clinical process. These will include adverse historical features (e.g. unopposed 
endogenous or exogenous oestrogen exposure, severity and duration of bleeding, family 
history) and adverse examination findings (e.g. obesity, immobile uterus).
272
 However, the 
absolute effect of such factors is unknown and thus difficult to quantify without further 
research (see section 4-10). 
 
 
 
 
131 
Figure  4-1 Pooled estimates of pretest probabilities, likelihood ratios and posttest 
probabilities for accuracy of outpatient endometrial biopsy in diagnosing 
endometrial cancer in women with postmenopausal bleeding 
(Nomogram reproduced with permission)118 
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Figure  4-2 Pooled estimates of pretest probabilities, likelihood ratios and posttest 
probabilities for accuracy of endometrial thickness measurement by 
pelvic ultrasound, using both a 4mm and 5mm cut-offs, in diagnosing 
endometrial cancer in women with postmenopausal bleeding. 
(Nomogram reproduced with permission)118  
     4mm cut-off       5mm cut-off 
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Figure  4-3 Pooled estimates of pretest probabilities, likelihood ratios and posttest 
probabilities for accuracy of hysteroscopy in diagnosing endometrial 
cancer in women with postmenopausal bleeding (Nomogram 
reproduced with permission)118 
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4.5 Economic evaluation 
 
These quantitative reviews provide precise estimates of accuracy of EB, USS and OPH in the 
diagnosis of endometrial cancer facilitating comparison between diagnostic performance. In 
order to further define the roles of respective tests and resolve the debate regarding the best 
sequence and combination of tests,
44
 a decision analysis was conducted based on this data. 
114,198,294
 The results of this economic approach show that survival is similar regardless of 
which initial diagnostic strategy is selected for the investigation of women with PMB for 
endometrial cancer. In contrast, costs varied between strategies, being more expensive when 
utilising combinations of tests from the outset. Postmenopausal bleeding is a common 
condition associated with high resource use,
1,89,310
 and under such circumstances, small 
differences in costs and outcome can be expected to affect healthcare expenditure and disease 
burden substantially.  
 
The balance between clinical benefit and economics (cost per life year gained) will influence 
recommendations for practice (see Figure 3-12).
40,65
 Cost-effectiveness analysis is an aid to 
decision making. As cost-effectiveness is relative, judicious interpretation involves describing 
competing interventions as being more or less cost-effective than others.
300
 No clear decision 
rule exists for cost-effectiveness analyses and therefore absolute statements about the cost-
effectiveness of a particular intervention should be viewed with caution. 
40
 However, absolute 
„threshold‟ values for determining cost-effectiveness that represent the willingness of society 
to pay for additional units of health benefit, are often used to make rationale decisions 
regarding the implementation of particular health care strategies.
41,65,73,203,249,274
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4.5.1 Base case analysis 
One such approach is to consider that a strategy is not cost-effective if the ICER is above a 
threshold, generally taken to be £30,000 per life-year gained.
274
 Application of this standard 
threshold suggests that all strategies are cost-effective compared to a policy of undertaking no 
initial investigation for first episode of PMB. Of the diagnostic modalities available, initial 
investigation with USS using a 5mm cut-off was the least expensive and no other strategy was 
found to be cost-effective compared to USS at this cut-off. However, the ICERs for USS 4mm 
(£37,652) and EB (£53,212) were close to the £30,000 ceiling. Compared to combination test 
strategies, initial investigation with USS 5mm alone remained the most cost-effective strategy 
for the diagnosis of endometrial cancer regardless of age at presentation. In women less than 
65 years of age, however, initial investigation with USS at a lower 4mm cut-off or EB may be 
considered cost-effective, although the additional cost is still over £20,000 to gain one 
additional year of life for the very young (aged 45 years) postmenopausal woman.   
 
4.5.2 Sensitivity analysis 
Sensitivity analyses showed that initial investigation with USS 4mm or EB were potentially 
cost-effective strategies compared to USS 5mm, if they performed at their most favourable 
estimates of diagnostic performance (accuracy and success). Despite obtaining precise 
estimates of diagnostic performance from high quality secondary research,
61-63,160,303
 the base 
case results were sensitive to small changes in these variables limiting the strength of any 
inferences regarding comparison of these three testing protocols. Variation in the prevalence 
of endometrial cancer also had an important influence of cost-effectiveness. At higher disease 
prevalence (10%), a strategy based on initial testing with EB was potentially more cost-
effective than strategies based on USS (ICER for EB strategy reduced to £1633 and £23,730 
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compared with USS 4mm and 5mm respectively). In contrast, at cancer prevalences below 
5% assumed in the base case analysis, USS strategies became more favourable on cost-
effectiveness grounds. The choice between initial testing with EB or USS at a 4 or 5mm cut-
off will therefore depend upon the nature of the clinician‟s practice (including the prevalence 
of endometrial cancer in the local population), the availability of high quality USS and patient 
preference
140
 
 
In contrast, the base case findings for combination strategies were robust to changes in the 
underlying model assumptions apart from if the effect on life expectancy of a delayed 
diagnosis was considered to be much greater than assumed in the base case. This is an 
example of uncertainty arising from the evaluative process
39
 i.e. the need to extrapolate from 
a clinical outcome (false negative diagnosis resulting in erroneous discharge) to a health 
outcome (reduced survival resulting from upstaging of endometrial cancer due to delayed 
diagnosis). However, it is doubtful that the additional proportion of women presenting with 
advanced extrauterine disease (i.e. greater than stage I localised disease), as a consequence of 
delayed diagnosis, would be significantly greater than 5%. This is because endometrial cancer 
presents with PMB in almost all cases and this alarming symptom will persist with an 
untreated endometrial tumour. Time to representation following erroneous discharge is 
therefore likely to be short, even when taking into account the impact of initial false 
reassurance, and so the effect of this delay on disease progression would be limited.  
 
In addition to its cost-effectiveness in terms of survival, there is consistent qualitative 
evidence showing ultrasound to be less invasive, better tolerated and preferred by women 
when compared with EB and OPH.
26,140,320
 Furthermore, the base case analysis assumed that 
an additional return visit was required following a positive USS in order to perform 
137 
endometrial sampling. However, USS is increasingly being performed by the consulting 
gynaecologist
280
 (this is common in much of Europe
46,180
) rather than radiologists or 
radiographers, and in such circumstances return visits for histological testing would not be 
necessary. This favours the initial independent USS strategies further as a result of reduced 
costs and convenience. This was confirmed by sensitivity analysis, where the ICER for the 
EB strategy was in excess of £100,000. An initial strategy employing USS is therefore 
recommended for the investigation of women with postmenopausal bleeding. There is 
insufficient data however, to recommend whether a 4 or 5mm endometrial thickness cut-off is 
preferred. In practice, the choice between initial testing with EB or USS at a 4 or 5mm cut-off 
will depend upon the nature of the clinician‟s practice, the availability of high quality USS 
and patient preference
140
 
  
 
4.6 Validity of economic evaluation 
 
An analytic approach was used to quantify decisions made within the clinical process for the 
diagnostic work up of women with PMB. This involved developing a clear decision making 
framework based on contemporary clinical practice.
114
 The design and reporting of the 
decision analysis is in keeping with current recommendations for a rigorous economic 
analysis.
87,98,99,111,253,300,301
 The research question, study design and perspective of 
analysis
47,225
 were clearly stated and the decision model described incorporating all alternate 
strategies.
99
 Outcomes of interest were identified and all supporting assumptions and 
estimates of test performance and costs comprehensively stated. A basic set of base case test 
results (discounted and non-discounted)
49
 including incremental cost-effectiveness ratios were 
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presented for all alternate non-dominated strategies
40,300
 and key sensitivity analyses 
presented to assess the stability of data assumptions.
39,99
 
 
Previous economic analyses evaluating the investigation of PMB have been of limited value 
because they have used imprecise and heterogeneous estimates of accuracy derived from 
particular primary studies published in the medical literature, in addition to evaluating 
outmoded tests.
119,167,257,337
 The economic analysis presented in this thesis used data on 
feasibility, accuracy and safety obtained from high quality systematic reviews
62,63,160,303
 and 
survival data from a recognised international source.
72
 In the few areas where explicit data to 
populate the decision tree was unavailable from the literature, probabilities of relevant 
outcomes (conditional estimates of test failure and accuracy) were independently estimated 
followed by consensus where disagreements arose. In this way it was hoped to represent the 
mainstream view.  
 
4.6.1 Limitations of economic analysis 
My approach could be criticised firstly in respect of test accuracy assessment. This stems 
from the fact that most published accuracy data looks at tests in isolation, but does not take 
into account the whole clinical context, such as information available from the preceding 
clinical history and examination. Consequently the usefulness of diagnostic tests may be 
overestimated
16,57
 increasing cost-effectiveness ratios to an unknown degree. Furthermore, 
without access to precise individual patient data, the accuracy of tests had to be estimated 
when used in combination as well as the changes in accuracy, which would be anticipated 
when conditional on a prior test result. Another potential limitation relates to the assumption 
that women with endometrial cancer who were erroneously discharged (false negatives) all 
139 
remained symptomatic and all represented within a short time frame where the error was 
always detected. Endometrial cancer presents with PMB in the vast majority of cases
250
 and 
so the assumption of persistent symptoms appears to be reasonable. However, the effect of 
false reassurance on the likelihood and timing of representation is unknown. We tried to 
account for this delay by assuming that some of these women would represent with higher 
stage disease. This approach has been used before.
119
 Sensitivity analysis around the 
proportion of women „upstaged‟ in this way increased costs. The strategies involving initial 
evaluation with EB or any two tests combined became more favourable in terms of cost-
effectiveness if the effect of a delayed diagnosis was assumed to have a greater impact on 
survival.  
 
A third area for possible criticism surrounds the identification, measurement and valuation of 
costs.
111,273
 Precise and comprehensive economic data is not readily available and so the best 
routine data that could be acquired from local and national sources was used.
247,252
  
It was felt reasonable to disregard indirect costs (e.g. patient transportation, time off work) as 
the viewpoint of this analysis was that of the hospital provider of health care within the 
United Kingdom National Health Service (NHS).
231
 Furthermore, all diagnostic strategies 
were based on outpatient investigation with comparably short „recovery times‟ and treatment 
following diagnosis (and thereby costs) were common to all strategies. Although microcosting 
was used to some extent, gross costing was used in most instances in keeping with available 
data sources (e.g. hospital costs at the level of healthcare resource groups).
252
 Where local 
costs were used, these often reflected charges as distinct from real costs.
273
 Potential litigation 
costs were not included for those women erroneously discharged. However, legal proceedings 
are likely to continue increasing in the future within the United Kingdom NHS and so such 
140 
costs may need to be taken into account. However, inferences are unlikely to be altered in 
such circumstances because USS has the lowest rate of false negative diagnosis.  
 
Uncertainty in parameters other than costs results from the fact that data are obtained from 
finite samples, and is therefore statistically uncertain. Data for the parameters diagnostic 
performance and treatment outcomes, were based upon precise confidence interval data 
derived from systematic reviews
62,63,160
 and high quality international cancer registry data 
respectively (FIGO).
72
 In contrast, unit costs for procedures at individual centres are likely to 
be known with reasonable certainty, but costs will vary between centres. Thus, it is 
appropriate to consider variation in cost parameters in a different way from uncertainty in 
other parameters. In effect, there is a new "base case" result for each centre, which is itself 
subject to sensitivity analysis on other parameters.  
 
The main results here apply to centres whose patterns of costs are similar to those at the 
Birmingham Women's Hospital (BWH). If the patterns of costs at another centre are 
substantially different, the analysis must be re-run. For examples of this, we ran the analysis 
for one centre whose costs were always at the bottom of the range given in Appendix 10, and 
separately for a centre whose costs were consistently at the top of the range. In each case, 
using the base case values for other parameters, the results show that EB dominates USS4mm, 
although this is not the case for the costs based on BWH. Similarly, the strategy EB 
dominated USS 5mm assuming high costs, but was also very cost-effective at low costs 
(£962/LYG). The ICER for USS 4mm compared with USS 5mm decreased (£26,129) at low 
assumed costs and increased slightly assuming high costs (£42,365). It should also be 
appreciated that a best (minimum costs) or worst (maximum costs) case scenario is likely to 
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overestimate any uncertainty associated with the results of economic evaluation, because cost 
components are unlikely to be perfectly correlated. 
39,41
 In view of the aforementioned, 
sensitivity analyses around cost data were not presented. As the results of this economic 
evaluation are limited to the NHS perspective, their use outside this setting would only be 
appropriate if the findings are maintained after application of more relevant local cost data 
(see section 4.7). This is also true for NHS centres with markedly different patterns of costs to 
those used in the base case analysis. 
 
 
4.7 Comparison with other economic evaluations and guidelines 
 
No study was identified that evaluated the cost-effectiveness of all contemporary outpatient 
modalities (i.e. EB, USS and OPH) used in sequence or combination for the investigation of 
postmenopausal bleeding for endometrial cancer (see section 1.5). The only identified 
guideline for the investigation of PMB (SIGN guideline)
293
 highlighted the need for a cost-
effectiveness analysis of different sequences of investigation using available tests and the 
effect of using different ultrasound endometrial thickness cut-offs.  
 
 
4.8 Applicability of economic evaluation 
 
The applicability of findings from this evaluation are limited geographically given that the 
perspective of this analysis is that of the United Kingdom National Health Service 
(NHS).
97,253
 However, one would expect that the twelve strategies defined within this decision 
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algorithm would encompass most clinical practices from Europe and North 
America.
3,59,70,99,251,296,326
  The application of more relevant local cost data to this model will 
facilitate translation of findings to different healthcare settings.
99,145
  
 
This analysis is confined to the initial investigation of women with PMB for endometrial 
cancer and did not look at women presenting with recurrent episodes of PMB. A recently 
published cohort study followed up women for 10 years or more that had been discharged 
after original presentation for PMB.
158
 They found that a quarter of the original cohort of 252 
women developed further PMB during this time. Of these symptomatic women, 11% had an 
underlying endometrial cancer, which is similar to the 5-10% prevalence generally quoted for 
endometrial cancer in first episode PMB.
16,146,149,251
 Reassuringly, no woman with 
endometrial cancer had an endometrial thickness less than 5mm on transvaginal ultrasound 
and no asymptomatic women developed endometrial cancer during the period of follow up.
158
 
The interval of recurrent bleeding was wide (2 months to 10 years), stages at diagnosis of the 
seven endometrial cancers were not given and data were missing in 14% of the original 
cohort. Thus inferences must be cautious. However, as longer periods before representation 
are more likely to signify new rather than existing pathology, it appears reasonable to consider 
women who develop a recurrent episode of PMB at an interval of at least 6 months or more to 
be at similar risk of endometrial cancer as if they presented with a first episode. The findings 
of the analysis are thus likely to be generalisable to recurrent PMB in this set of 
circumstances. 
 
The baseline estimates of accuracy cannot be reliably extrapolated to include those 
postmenopausal women with unscheduled bleeding on hormone replacement therapy (HRT). 
143 
However, such women bleeding on combined HRT regimens have a lower prior risk of 
endometrial cancer
16
 thereby more in keeping with the lower range of cancer prevalence (3%) 
used as part of a sensitivity analysis. This would appear to favour the use of USS, as 
competing strategies become less cost-effective at lower disease prevalence compared to 
those based on USS. However, optimal cut-offs for endometrial thickness measurement in 
women taking HRT are less well defined (false-positive rates are higher)
303
 
140,160
 and so 
alternative or additional testing with EB or OPH is likely to be necessary in the presence of 
this uncertainty. The accuracy of endometrial thickness measurement by USS is also less well 
defined in symptomatic women at risk of endometrial cancer due to tamoxifen therapy
29,108
 
and so additional testing is recommended
68
 In most cases, however, PMB results from benign 
endometrial or intra-cavity pathology,
60,278,342
  which does not require treatment unless 
symptoms persist.  
 
This analysis did not consider those women with less common malignant causes of PMB, 
such as non-uterine pelvic masses (vulvar, vaginal, cervical and ovarian cancers). More 
commonly these conditions are diagnosed after presentation with other symptoms such as 
pain or urinary and bowel problems.
251
 However, one should recommend a clinical 
gynaecologic examination in all women with PMB regardless of which diagnostic tests are 
used. The place of ultrasound is further strengthened as it is the only modality that has the 
advantage of allowing assessment of other pelvic organs
68
 and in particular opportunistic 
ovarian screening.  
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4.9 Recommendations for practice  
 
•  Women presenting for the first time with PMB should undergo initial evaluation with 
pelvic ultrasound as this represents the most cost-effective strategy for excluding 
endometrial cancer. A threshold of 4mm or 5mm with double layer endometrial 
thickness may be used to define abnormal results on pelvic ultrasound. Different 
approaches to enable the generation of practice recommendations exist, based on the 
methodological strength of evidence and the clinical outcomes and associated 
costs.
73,203,228,274
 Applying one such approach (the basis for recommendations about the 
use of interventions, treatments or services employed by the West Midlands Health 
Technology Assessment Collaboration) would rate the recommendation from this thesis 
as Evidence level II – Supported (£3000-£20,000 per life year). Details of this basis for 
recommendation are given in Appendix 28. 
 
 
•  Clinical guidelines should be developed and disseminated based on the results from this 
analysis.
208
 This should facilitate more effective and efficient delivery of 
gynaecological cancer services in line with current recommendations.
251
 I have prepared 
a West Midlands Health Technology Assessment Report for dissemination within the 
region (see Appendix 29). 
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4.10 Recommendations for future research  
 
The remit of any research has to be specified at the outset if it is to be successfully realised. 
Time restraints and the availability of resources limit the extent of research undertaken. 
Consequently, potentially important areas of research may be left unexplored. For example, in 
the reviews included as part of this thesis, it was not feasible to contact authors to acquire 
individual patient data. This would have strengthened the reviews by providing clinical data 
relating to patient history and examination findings, as well as data pertaining to individual 
tests and those used in combination. This would have allowed a more rigorous exploration of 
variation in results and more precisely determine the pre-test probability of endometrial 
cancer for a particular individual, which may then impact on the usefulness of tests in specific 
circumstances. Similarly, the economic analysis would have benefited from acquiring quality 
of life data so that non-monetary units of valuation could have been generated (quality 
adjusted life years or QALY).
137,253,324
 This would have then allowed a cost-per-QALY 
analysis to be performed taking into account quantitative and qualitative aspects of health. 
225
 
Moreover this approach enables the comparison of diverse competing health care 
interventions (allocative efficiency).
262
 A further improvement would have involved the 
acquisition of data about resource use associated with the treatment of endometrial cancer,
309
 
especially the follow up of women with advanced endometrial cancer, as this would have 
facilitated more precise estimation of costs. 
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4.10.1 Diagnostic accuracy 
 
•  Future research should be aimed at generating estimates of diagnostic test accuracy of 
test combinations from individual patient meta-analyses. Such analyses should take into 
account the whole clinical process so that the additional information provided by 
diagnostic testing is more accurately quantified in the clinical context.
16,57,183
 The 
analysis should be updated in the future to take into account the use of new diagnostic 
tools, such as 3D ultrasonography.
178
  
 
 The decision to treat or withhold treatment is determined by the estimated probability of 
disease (or not having disease) and the costs and benefits of subsequent clinical 
action.
236,264
 In clinical practice these factors are implicitly integrated into the clinical 
decision making process. Synthesizing the available diagnostic evidence in a clinician-
friendly manner
185
 (generation of pre and post-test probabilities) enables therapeutic 
recommendations to be made by explicit consideration of the available evidence, 
obviating the need for intuition.  However, even in the presence of robust evidence 
about disease probability and treatment costs and consequences, the threshold at which 
treatment decisions are made will vary between individual clinicians.
184
 Research 
determining the relative values assigned to these outcomes by clinicians will allow 
relevant decision frameworks to be produced for application in specific settings. 
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4.10.2  Economic evaluation 
 
•  Future decision-models may be improved by incorporation of new diagnostic tools and 
collecting data about resource use in treatment follow up and palliative care. The effect 
of staging endometrial cancer clinically (e.g. using magnetic resonance imaging), as 
opposed to surgically, on therapeutic outcomes may need to be explored if this method 
of staging becomes more established.
127,239
 If the ongoing Medical Research Council 
ASTEC trial shows benefit from routine pelvic node dissection, then the effects of this 
approach on costs and survival will need to be incorporated into the model.
239
 The 
design of disease specific quality of life instruments
58
 for women with PMB and 
endometrial cancer will allow the collection of meaningful utility data. This will 
improve the sensitivity of the model and the effects of a particular diagnostic and 
consequent therapeutic intervention will be more usefully and individually quantified in 
a cost-utility analysis.
208
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APPENDICES 
 
Appendix 1 Search strategy for economic evidence  
 
 
 
Medline (1966 – May 2002) and Embase (1982 – May 2002) 
 
PMB (tw) 
Endometrium [pathology]  
Endometrial neoplasms [diagnosis,economics] 
Uterine haemorrhage [diagnosis,economics] 
1 or 2 or 3 or 4 
Decision support techniques (tw) 
Costs 
Cost analysis (tw) 
Cost-benefit analysis (tw) 
Economics (tw) 
Economic evaluation (tw) 
Cost effectiveness  
Outcome assessment (health care) [economics] 
6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 
5 and 14 
 
 
Cochrane Library issue 3 (CCTR) 
 
Postmenopausal bleeding or endometrial cancer or cost-effectiveness or decision analysis 
 
 
NHS Economic Effectiveness Database, Centre for Reviews and Dissemination (NHS 
EED, June 2002) [Available at http://www1.york.ac.uk/inst/crd/welcome.htm 
Accessibility verified 13 June 2002] 
 
Postmenopausal bleeding or endometrial cancer or cost-effectiveness or decision analysis 
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Appendix 2 Economic evaluations in the diagnosis of endometrial cancer in postmenopausal bleeding 
    
Author (Year)  Study and Comparison Economic analysis Limitations 
    
    *Ong et al257 (1997)  
 
Retrospective non-randomised study with 
concurrent controls. 
Population: 498 women with suspected 
endometrial cancer.  
Intervention: EB vs. D&C. 
Outcome: rate of detection of endometrial cancer, 
benign abnormalities and complications   
Cost-effectiveness analysis 
Measure of benefit: complications avoided and 
additional cases of endometrial cancer detected. 
Finding: EB was found to be the dominant strategy 
(cheaper and associated with less complications) 
therefore a synthesis of benefits and costs not 
provided 
Selection bias (retrospective observational 
design). Failure rates of EB not accounted 
for (not intention to treat analysis). Short 
term (< 2 year), incomplete follow up – 
maybe undetected false negatives. No 
sensitivity analyses, discounted rates or 
cost data reported. 
    *Hidlebaugh
167
 
(1996) 
 
Retrospective cohort study with concurrent 
controls. 
Population: 568 women with abnormal uterine 
bleeding 
Intervention: OPH+ EB vs. IPH + D&C 
Outcome: adequacy of tissue sampling, clinical 
outcomes and success rates and complications 
Cost-effectiveness analysis 
Measure of benefit: additional successful cases and 
cases with adequate tissue sampling, complications 
avoided. 
Finding: OPH + EB found to be dominant strategy 
therefore a synthesis of benefits and costs not 
provided 
Selection bias (retrospective observational 
design). No estimates of diagnostic 
accuracy. Unclear length of follow up – 
maybe undetected false negatives. Not 
intention to treat analysis casting doubt 
over estimates of benefit. No sensitivity 
analyses.  
    *Feldman et al
119
 
(1993) 
 
Computer-based recursive decision tree model 
based on retrospective review of pathology reports 
Population: 287 women with PMB 
Intervention: Management pathways based on EB, 
D&C, TAH or observation at initial presentation 
Outcome: correct diagnosis of endometrial cancer 
or complex hyperplasia (with or without atypia). 
Cost-effectiveness analysis.  
Measure of benefit: life expectancy of the various 
strategies and their cost-effectiveness as a function of 
patient age and combined risk of cancer or complex 
hyperplasia. Sensitivity analyses performed. 
Finding: initial evaluation with EB was found to be 
the most cost-effective strategy. Cost, but not 
effectiveness (life expectancy) did vary markedly as a 
function of the strategy chosen. 
Diagnostic strategies did not include USS 
or OPH.  
    Weber et al
337
 
(1998) 
 
Comparison of two diagnostic algorithms 
Population: Computer simulation 
Intervention: Algorithms based on EB vs. USS at 
initial presentation 
Outcome: probability of non-diagnostic test and 
abnormal result (endometrial cancer, hyperplasia 
and benign abnormalities).  
Cost-analysis.  
Measure of benefit: Mean cost/completed diagnostic 
algorithm. No clinical benefits reported. Sensitivity 
analyses performed around these performance 
characteristics 
Finding: initial evaluation with USS was less costly 
than EB in the evaluation of women with PMB. 
Relative performance characteristics of EB 
and USS vary widely in the literature, 
often based on poor quality studies, which 
influence estimates of benefit. No 
estimates of diagnostic accuracy, 
complications or effectiveness data 
incorporated in the algorithms.  
*Less relevant study because a single outpatient strategy was compared with blind D&C, which is now outdated
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Appendix 3 Search strategy for Endometrial biopsy evidence 
 
 
 
Medline (1966 – December 1999) 
 
Endometrial biopsy 
Endometrial biop$.tw 
1 or 2 
Exp diagnosis 
Diagnos$.tw 
di.fs. 
4 or 5 or 6 
3 and 7 
limit 8 to human 
 
Embase (1982 – December 1999) 
 
Endometrial biopsy 
Endometrial biop$.tw 
1 or 2 
Exp diagnosis 
Diagnos$.tw 
di.fs. 
4 or 5 or 6 
3 and 7 
limit 8 to human 
 
 
Cochrane Library issue 3 (CCTR) 
 
Endometrial biopsy 
 
 
Hand searching 
 
Reference lists of included primary studies and review articles 
 
151 
Appendix 4  Search strategy for ultrasound endometrial thickness evidence 
 
 
 
Medline (1966 – December 2000) 
 
Ultrasound 
Sonography 
1 or 2 
Endometrial thickness 
3 and 4 
limit 5 to human 
 
 
Embase (1982 – December 1999) 
 
Ultrasound 
Sonography 
1 or 2 
Endometrial thickness 
3 and 4 
limit 5 to human 
 
 
Cochrane Library issue 3 (CCTR) 
 
Ultrasound or sonography 
 
 
Hand searching 
 
Reference lists of included primary studies and review articles 
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Appendix 5 Search strategy for hysteroscopy evidence  
 
 
 
Medline (1966 – December 2001) 
 
Exp hysteroscopy/ 
Hysteroscop$.ti,ab. 
Exp diagnosis 
Diagnos$.ti,ab. 
di.fs. 
or/ 1-2 
or/ 3-5 
6 and 7 
animal/ not human 
8 not 9 
 
Embase (1982 – December 2001) 
 
Exp hysteroscopy/ 
Hysteroscop$.ti,ab. 
Exp diagnosis 
Diagnos$.ti,ab. 
di.fs. 
or/ 1-2 
or/ 3-5 
6 and 7 
animal/ not human 
8 not 9 
 
 
Cochrane Library issue 4 (CCTR) 
 
Hysteroscopy 
 
 
Hand searching 
 
Reference lists of included primary studies and review articles 
Specialist journal Gynaecological Endoscopy 
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Appendix 6 Data collection checklist for review of outpatient endometrial biopsy 
 
 
Reviewer ID:………………   PaperNo:…………… 
 
Selection or rejection:  (must have all four as yes) 
a) population- (at risk of abnormal endometrial histology)    Y/N 
b) outpatient biopsy- test              Y/N 
c) histology- gold standard (obtained by method other than OPBx) Y/N 
d) can you construct 2x2 table (Ca vs. nonCa) (test vs. gold standard) Y/N 
  
Select this diagnostic test study?            Y/N   
if this is Y – complete the form 
if N must describe why not selected 
 
………………………………………………………………………………………..………… 
 
 
 
Data Collection   (if more than one population subgroups fill additional forms) 
 
Total number of patients recruited (n)        .……. 
 
Risk factors reported for population (n) a) PMB    (…….) 
             b) premenopausal (…….) 
             c) not described  (…….) 
 
Patient enrolment:         consecutive/ arbitrary/ unreported/ other 
 
Description of diagnostic test:     a) pipelle 
             b) vabra 
             c) other (state)………….. 
 
Blinding of test results from outcome:  yes/ no/ unreported 
 
Verification by reference standard   (complete/partial/differential)   
 
Completeness of follow-up: ………….  (>90/81-90/<81%) 
 
Legitimate exclusions: ……………….. 
 
Number of patients with data available: ……………… 
 
Failure rate of O/P Bx =      (…….) 
 
Insufficient sample of O/P Bx =    (…….) 
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Cancer in insufficient samples =   (…….) 
 
Hyperplasia in insufficient samples = (…….) 
 
Complications=       (…….) 
 
 
 
Endometrial cancer 
 
 
Test (=O/P BX) 
Cancer present Cancer absent Total 
 
POSITIVE    
NEGATIVE    
TOTAL    
 
 
Endometrial hyperplasia 
 
 
Test (=O/P BX) 
Hyperplasia present Hyperplasia absent Total 
 
POSITIVE    
NEGATIVE    
TOTAL    
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Appendix 7 Data collection checklist for review of pelvic ultrasound 
 
Reviewer:        Paper No: 
 
Type of study:       Diagnostic Yes/No 
 
    If so   Cohort/Case-control 
 
Ultrasound measurement of ET       Yes/No 
 
       If yes: Single layer/Double layer/Unreported 
 
 
If both yes: 
 
Total number recruited:_________  No of recruited patients on HRT: _____/unreported 
 
Inclusion criteria: 
 
 
 
Exclusion criteria: 
 
 
 
Patient enrollment:      Consecutive/Arbitrary/Unreported 
 
 
Description of diagnostic test:     Trans-vaginal ultrasound 
            Trans-abdominal ultrasound 
  Transducer frequency _________ Hz 
            Unreported 
 
Cut-off point for normality:      _______ mm is normal 
 
Risk factors for endometrial carcinorma reported for study population: Yes/No 
 
      If yes: Obesity/Diabetes mellitus/Hypertension 
 
Endometrial specimen obtained by:  D + C/Pipelle/Hysteroscopy/Hysterectomy 
 
Blinding of test results from outcome: Yes/No/Unreported 
 
Verification of pathology results:   Yes/No/Unreported 
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Appendix 7 continued 
 
 
Number of patients with data available:  ______________ 
 
Number of legitimate exclusions:     ______________ 
 
Follow-up rate:        > 90%/ 81-90%/ <80% 
 
 
 
 
CUT-OFF VALUE ____________________ MM 
 
 
Endometrial cancer 
 
 
 
TEST RESULT 
 
ENDOMETRIAL 
CA PRESENT 
 
ENDOMETRIAL 
CA ABSENT 
 
TOTAL 
 
POSITIVE 
 
 
 
 
 
 
 
NEGATIVE 
 
 
 
 
 
 
 
TOTAL 
 
 
 
 
 
 
 
 
Endometrial disease (i.e. endometrial cancer + all types of endometrial hyperplasia but 
excluding endometrial polyp and pyometra) 
 
 
 
TEST RESULT 
 
ENDOMETRIAL 
DIS PRESENT 
 
ENDOMETRIAL 
DIS ABSENT 
 
TOTAL 
 
POSITIVE 
 
 
 
 
 
 
 
NEGATIVE 
 
 
 
 
 
 
 
TOTAL 
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Appendix 8 Data collection checklist for review of hysteroscopy  
 
Reviewer ……        Paper No. …… 
 
 
 
i) population - abnormal uterine bleeding  yes / no 
ii) intervention – hysteroscopy      yes / no 
iii) reference standard – histology      yes / no 
iv)  2x2 table construction possible      yes / no 
 
Select this diagnostic test study (i-iv inclusive) yes / no   if no reject & specify reason  
 
……………………………………………………………………………………………………………… 
 
……………………………………………………………………………………………………………… 
 
 
 
Population: 
 
Study Design    Cohort / Cross-sectional / Case control / Other…………… 
 
Data Collection  Prospective / Retrospective / Unreported / Other…………. 
 
Patient Enrolment  Consecutive / Arbitrary / Unreported / Other…………….. 
 
Study Design Hierarchy  1 2   3  4  5  6 
 
No. patients recruited A original population     n=…… 
 
      B Pre-enrolment exclusions  n=……   
        (reasons eg population  characteristics)…………… 
 
        C actually recruited (A-B)    n=……    
     
        D post-enrolment exclusions  n=…… 
        (reasons eg missing data etc)….…………………… 
 
        E analysable data (C-D)   n=…… 
  
Completeness of Follow up (%)  >90 / 81-90 / <81  (FU% = E/C x 100% =…… %) 
 
Menopausal status (no. & %)   PMB n=……     HRT n=……  
           Pre-men n=……       Unreported =…… 
Selection criteria (diagnostic test 
study): 
Data Retrieval: 
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Appendix 8 continued 
 
Intervention: 
 
Description of technique Adequate / Inadequate 
 
Setting      outpatient  yes/no (dilatation n=…..anal/anaesn=…../…..) 
        inpatient  yes/no 
 
type        rigid…………… flexible…………… Other…………… 
 
manufacturer   …………………………….. 
 
diameter     …………………………….. 
 
angle      …………………………….. 
 
Medium (specify)  gas………….  fluid…………  Unreported…………. 
 
Video monitor   yes / no / unreported  
 
Menstrual phase  not timed / proliferative / secretory / preparation - (specify…) 
 
Complications (specify) major n=….. …………     minor n=…………… 
 
Levels of test abnormality() Cancer  ……. 
  Hyperplasia …… (specify if Atypia…Complex…Simple…) 
  Other …… 
 
test positive cases   n=……  
test negative cases   n=……  
 
Reference standard:   
 
Method      inpatient (specify hyst…. Dir Bx…. D&C…. OP device….) 
        outpatient (specify OP Device…Directed Bx… Other….) 
 
Partial verification  yes / no  (if yes specify & give %………………………) 
 
Differential verification yes / no   
        verification in test positive cases n =… % (>90 / 81-90 / <81) 
        verification in test negative cases n= …% (>90 / 81-90 / <81) 
 
Blinding of test result  yes / no / unreported   
 
Levels of Reference abnormality() Cancer  … 
           Hyperplasia … (specify Atypia…Complex…Simple…) 
    Other  … 
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Appendix 8 continued 
 
Outcome:  
 
Failure Rate      n / E  =….. 
 
Specify reason for failure  Technical n=…..  Inadequate view n=…..  
         Patient factor n=….. 
 
Failed hysteroscopies  Cancer  n=……  Hyperplasia n=…… 
 
Insufficient histology  n=……
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Appendix 8 continued 
 
2x2 Contingency tables (INcluding insufficient histology): 
 
Endometrial Cancer 
 
Reference Histology 
Hysteroscopy 
Cancer present Cancer absent Total 
Positive    
Negative    
Total    
 
 
Endometrial Hyperplasia 
 
ReferenceHistology 
Hysteroscopy 
Hyperplasia present Hyperplasia absent Total 
Positive    
Negative    
Total    
 
 
Endometrial Cancer + Hyperplasia 
 
ReferenceHistology 
Hysteroscopy 
Ca +H present Ca + H absent Total 
Positive    
Negative    
Total    
 
 
NB. If level of abnormality is different (ie more or less specific) from the above, then complete this table 
and specify the level 
 
ReferenceHistology 
Hysteroscopy 
Positive  […………] Negative […………] Total 
Positive [……………]    
Negative […………...]    
Total    
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Appendix 8 continued 
 
2x2 Contingency tables (EXcluding insufficient histology): 
 
Endometrial Cancer 
 
Reference Histology 
Hysteroscopy 
Cancer present Cancer absent Total 
Positive    
Negative    
Total    
 
 
Endometrial Hyperplasia 
 
ReferenceHistology 
Hysteroscopy 
Hyperplasia present Hyperplasia absent Total 
Positive    
Negative    
Total    
 
 
Endometrial Cancer + Hyperplasia 
 
ReferenceHistology 
Hysteroscopy 
Ca +H present Ca + H absent Total 
Positive    
Negative    
Total    
 
 
NB. If level of abnormality is different (ie more or less specific) from the above, then complete this table 
and specify the level 
 
ReferenceHistology 
Hysteroscopy 
Positive  
[…………………] 
Negative 
[…………………..] 
Total 
Positive [……………]    
Negative [……….…..]    
Total    
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Appendix 9 Probability estimates used and data sources for the decision  
     tree used for the investigation of postmenopausal bleeding  
 
Variable Baseline Sensitivity analysis (range) Source 
    
Failure rates    
Endometrial biopsy  0.12  (95% CI 0.09-0.15) SR
62
 
Ultrasound scan 0.0  (95% CI 0.0-0.02) SR
303
 
Outpatient hysteroscopy 0.05  (95% CI 0.04-0.07) SR
63
 
Ultrasound scan + outpatient hysteroscopy 0.04  (95% CI 0.03-0.06) EP 
Ultrasound scan + endometrial biopsy 0.12 (95% CI 0.09-0.17) EP 
Ultrasound scan + endometrial biopsy + outpatient 
hysteroscopy 
0.12 (95% CI 0.09-0.17) EP 
Endometrial biopsy after successful outpatient 
hysteroscopy 
0.07 (95% CI 0.05-0.10) EP 
Endometrial biopsy after successful ultrasound scan 0.12 (95% CI 0.09-0.15) EP 
    
Complication Rates    
Outpatient diagnostic procedures (EB, USS, OPH) - - SRs
61,63,160,303
 
Dilatation and curettage 0.014 - NR
152
 
    
True Positive Rates    
Endometrial biopsy 0.94 (95% CI 0.84-0.99) SR
62
 
Ultrasound scan 4mm 0.99 (95% CI 0.97-1.0) SR
160
 
Ultrasound scan 5mm 0.97 (95% CI 0.94-0.98) SR
160
 
Outpatient hysteroscopy 0.86 (95% CI 0.84-0.89) SR
63
 
Dilatation and curettage 0.96 (95% CI 0.82-1.0) EP 
    
Conditional True Positive Rates    
Endometrial biopsy if outpatient hysteroscopy positive 0.94 (95% CI 0.93-0.97) EP 
Endometrial biopsy if ultrasound positive 0.94 (95% CI 0.94-0.95) EP 
Outpatient hysteroscopy if endometrial biopsy negative 0.86 (95% CI 0.83-0.87) EP 
Outpatient hysteroscopy if ultrasound positive 0.86 (95% CI 0.86-0.87) EP 
Ultrasound scan 4mm if endometrial biopsy negative 0.99 (95% CI 0.82-0.99) EP 
Ultrasound scan 4mm if outpatient hysteroscopy negative 0.99 (95% CI 0.92-0.99) EP 
Ultrasound scan 5mm if endometrial biopsy negative 0.97 (95% CI 0.80-0.99) EP 
Ultrasound scan 5mm if outpatient hysteroscopy negative 0.97 (95% CI 0.91-0.99) EP 
    
False Positive Rates    
Endometrial biopsy 0.01 (95% CI 0.0-0.02) SR
62
 
Ultrasound scan 4mm 0.51 (95% CI 0.49-0.54) SR
160
 
Ultrasound scan 5mm 0.45 (95% CI 0.43-0.47) SR
160
 
Outpatient hysteroscopy 0.01 (95% CI 0.0-0.06) SR
63
 
Dilatation and curettage 0.01 (95% CI 0.0-0.03) EP 
    
Prevalence 0.05 (95% CI 0.03-0.10) PL
16,251
  
    
Surgical stage at hysterectomy (FIGO)    
Probability of stage I (First presentation) 0.7 0.6-0.8 FIGO
72
 
Probability of stage II-IV (First presentation) 0.3 0.2-0.4 FIGO
72
 
Probability of stage I (Representation) 0.65 0.4-0.7 EP 
Probability of stage II-IV (Representation) 0.35 0.3-0.6 EP 
    
EB = endometrial biopsy, EP = expert panel, FIGO = International Federation of Gynecology and Obstetrics, NR = narrative 
review, OPH = outpatient hysteroscopy, PL = published literature, SR = systematic review, USS = ultrasound scan
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Appendix 10  Direct medical costs used and data sources for decision tree for 
the investigation of postmenopausal bleeding (base case and 
sensitivity analyses) 
 
Variable Baseline (£)
$ 
Source Range (£)* Source 
     
Diagnosis     
Pelvic ultrasound scan 115 BWH 93-219 DoH 
Outpatient hysteroscopy 225 BWH 143-247 DoH 
Endometrial biopsy 186 BWH 126-195 DoH 
Pelvic ultrasound scan + outpatient 
hysteroscopy 
279 BWH 191-395 DoH†  
Pelvic ultrasound scan + endometrial 
biopsy 
240 BWH 174-343 DoH† 
Outpatient hysteroscopy + 
endometrial biopsy 
350 BWH 224-371 DoH† 
Pelvic ultrasound scan + outpatient 
hysteroscopy + endometrial biopsy 
404 BWH 272-519 DoH† 
Day-case hysteroscopy/D&C 360
#
 BWH 317-493 DoH 
GOPD FU 61 DoH 45-71 DoH 
Failed endometrial biopsy** 111 BWH 75-116 DoH 
Treatment     
Complex hysterectomy 2123 BWH 926-2773 DoH 
External beam radiotherapy 845 DoH 504-1756 DoH 
Chemotherapy 258 DoH 167-327 DoH 
Complications‡     
Co-amoxiclav 375mg tds (7 day 
course)  
3.30 BNF - - 
Inpatient stay (1 day)  620 BWH   
Unplanned laparotomy 2123 BWH 1121-2008 DoH 
     
 
*used for sensitivity analyses, ranges represent interquartile spread from National Schedule of Reference Costs (November 
2000), Department of Health. Includes cost of outpatient appointment (first visit) 
†adapted from national schedule of reference costs252 (November 2000), Department of Health, Interquartile ranges summed. 
‡ Incidence of major complications associated with Dilatation and curettage (D&C) applied to these costs and cost of 
inpatient hysteroscopy/D&C altered accordingly. See text)  
# includes £10 additional cost to account for complications incidence and cost i.e. 
cost of complication (infection, haemorrhage and perforation) x incidence = 623.3x1.3% + cost of unplanned laparotomy + 
incidence = 2123x0.1% = £8 therefore rounded up to £10 additional cost (£350 increased to £360) 
$ Where two diagnostic modalities used, the cost = sum of individual costs - £61 (cost of outpatient appointment), where 
three diagnostic modalities used, the cost = sum of individual costs - £61x2 (cost of outpatient appointments) 
** Minus histopathological examination of endometrial specimen costs 
BWH = Birmingham Women‟s Hospital standard charges for uncomplicated procedures 2000 
DoH = Department of Health, National Schedule of Reference Costs (November 2000)252 
BNF = British National Formulary 
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Appendix 11 Reference list of excluded studies from systematic reviews of e 
      endometrial biopsy  
 
 
 A1.  Guido R, Kanbour-Shakir A, Rulin M, Christopherson W. Pipelle endometrial 
sampling: sensitivity in the detection of endometrial cancer. J Reprod Med 
1995;40:553-55. 
 A2.  Stovall TG, Photopulos GJ, Poston WM, Ling FW, Sandles LG. Pipelle endometrial 
sampling in patients with known endometrial cancer. Obstet Gynecol 1991;77:954-56. 
 A3.  Zorlu CG, Cobanoglu O, Isik AZ, Kutluay L, Kuscu E. Accuracy of pipelle 
endometrial sampling in endometrial cancer. Gynecol Obstet Invest 1994;38:272-75. 
 A4.  Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and 
office endometrial biopsy in predicting final histopathologic grade in endometrial 
cancer. Obstet Gynecol 1995;86:38-42. 
 A5.  Larson DM, Krawisz BR, Johnson KK, Broste SK. Comparison of the Z-sampler and 
Novak endometrial biopsy instruments for in-office diagnosis of endometrial cancer. 
Gynecol Oncol 1994;54:64-67. 
 A6.  Bocanera AR, Roncoroni EC, Schlaen I, Ben J, Monteverde R, Gonzalez GM et al. An 
articulated rotating brush for office endometrial evaluation of climacteric outpatients. 
Maturitas 1994;19:67-76. 
 A7.  Ferry J, Farnsworth A, Webster M, Wren B. The efficacy of the pipelle endometrial 
biopsy in detecting endometrial cancer. Aust NZ J Obstet Gynaecol 1993;33:76-78. 
 A8.  Elpek G, Uner M, Elpek M, Sedele M, Karaveli S. The diagnostic accuracy of the 
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1998;18:274-75. 
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 A10.  Shipley CF, III, Simmons CL, Nelson GH. Comparison of transvaginal sonography 
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Ultrasound Med 1994;13:99-104. 
 A11.  Goldchmit R, Katz Z, Blickstein I, Caspi B, Dgani R. The accuracy of endometrial 
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Obstet Gynecol 1993;82:727-30. 
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 Appendix 12  Diagnostic accuracy of outpatient endometrial biopsy in detecting endometrial cancer and hyperplasia in 
women at risk of abnormal endometrial histology 
  
             
 Population  Intervention  Outcome 
    Menopausal Status (%)       
Study (Year Published)  Data 
Collection 
Patient 
Selection 
Quality 
Level 
Post Pre Unclear  Description 
of Technique 
 Reference 
Standard 
‡Level of test 
result reported 
Blinding 
of Results 
             
             
Accurette®             
Goldberg
138
 (1981)  Prospective Arbitrary 4 30 (100) - -  Adequate  †D&C H Unreported 
Gynoscann®             
Sun-Kuie
317
 (1992) Prospective Arbitrary 4 *5 (11) 41 (89) -  Adequate  †D&C C, H, N Unreported 
Novak Curette®             
Stovall
314
 (1989) Retrospective Arbitrary 4 - - 165(100)  Adequate  Hyst C. H Unreported 
Pipelle®             
Baruch
24
 (1994) Retrospective Arbitrary 4 *23 (52) 9 (20) 112 (28)  Adequate  †D&C/Hyst C Unreported 
Krampl
192
 (1997)   Retrospective Unreported 4 37 (12) 247(77)  35 (11)  Adequate  †TCRE/Hyst H, N Unreported 
Salet-Lizee
284
 (1993) Prospective Arbitrary 4 *41 (42) 57 (58) -  Inadequate  †D&C C, H, N Unreported 
De Silva
78
  (1997) Prospective Consecutive 1 35 (100) - -  Adequate  †D&C C Yes 
Van den Bosch
332 
(1995) Prospective Consecutive 3 138 
(100) 
- -  Adequate  Biopsy/Hyst C Unreported 
Gupta
161
 (1996) Prospective Arbitrary  54 (100) - -  Inadequate   †D&C C, H, N, A Unreported 
Batool
22
 (1994) Prospective  1 13 (100) - -  Adequate  †D&C C Yes 
Giannacopoulos
133
(1996) Prospective Arbitrary  - - 57 (100)  Inadequate  †D&C/Hyst C Unreported 
Vabra Aspiration®             
Goldberg
138
 (1981) Prospective Arbitrary 4 31 (100) - -  Adequate  †D&C C, H Unreported 
Stovall
314 
(1989) Retrospective Arbitrary 4 - - 62 (100)  Adequate  Hyst C, H Unreported 
Z-sampler®             
Etherington
117
 (1995) Prospective Consecutive 3 34 (100) - -  Adequate  †D&C C Unreported 
             
 
*Numbers of patients within respective menopausal status groups following exclusions for inadequate endometrial samples calculated from initial proportion of patients within these 
groups before such exclusions 
†D&C = dilatation of cervix and curettage of uterine cavity under anaesthesia, Hyst = hysterectomy, TCRE = transcervical resection of the endometrium 
‡ Level of test reported: H= hyperplasia, N= non-atypical hyperplasia, A= atypical hyperplasia
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Appendix 13  Procedure feasibility and diagnostic accuracy of outpatient endometrial biopsy in endometrial cancer and 
hyperplasia. 
 
          
Device (No. 
Evaluations)  
*Failure 
rate 
Inadequate 
rate 
Disease in 
failed  
Cancer Cases: Likelihood 
ratio for a 
Likelihood 
ratio for a  
Disease Cases: Likelihood 
ratio for a  
Likelihood 
ratio for a  
& Study (95% CI) (95% CI) biopsy 95% CI +ve test -ve test  positive test negative test +ve test -ve test positive test negative 
test 
(Year Published)    Ca Hyp  Sensitivity  1-Specificity  (95% CI) (95% CI) Sensitivity 1-Specificity  (95% CI) (95% CI) 
             
             
Accurette®             
Goldberg138 (1981)  5/40 
(13%) 
5/35 
(14%) 
0 1 3/3 (1.0) 0/27 (0.0) 49.0 
(3.1-783.4)  
0.1 
(0.01-1.7) 
5/5 
(1.0) 
0/25 
(0.0) 
47.6 
(3.0-749.9) 
0.1 
(0.01-1.2) 
Gynoscann®             
Sun-Kuie317 (1992) 8/70 
(11%) 
16/62 
(26%) 
0 0 2/2 (1.0) 0/44 (0.0) 75.0 
(4.6-1236.4) 
0.2 
(0.01-2.1) 
2/4 
(0.5) 
0/42 
(0.0) 
43.0 
(2.4-775.1) 
0.5 
(0.2-1.3) 
Novak Curette®             
Stovall314 (1989) 0/176 
(0%) 
11/176 
(6%) 
0 0 4/6 (0.67) 0/159 (0.0) 205.7 
(12.2-3458) 
0.3 
(0.1-1.0) 
8/16 
(0.5) 
4/149 
(0.03) 
18.6 
(6.3-55.1) 
0.5 
(0.3-0.8) 
Pipelle®             
Baruch24 (1994) 0/45 
(0%) 
1/45 
(2%) 
0 - 10/10 (1.0) 0/34 (0.0) 66.8 
(4.3-1050.5) 
0.1 
(0.00-0.7) 
- - - - 
Krampl192 (1997) 0/324 
(0%) 
5/324 
(2%) 
- 0 - - - - 14/35 
(0.4) 
24/284 
(0.0) 
4.7 
(2.7-8.3) 
0.7 
(0.5-0.9) 
Salet-Lizee284 
(1993) 
0/98 
(0%) 
0/98 
(0%) 
0 0 4/4 (1.0) 1/94 (0.01) 94.0 
(13.4-660.4) 
0.1 
(0.01-1.41) 
34/43 
(0.8) 
2/55 
(0.02) 
21.7 
(5.5-85.5) 
0.2 
(0.1-0.4) 
De Silva78  (1997) 9/50 
(18%) 
6/41 
(15%) 
1 - 1/1 (1.0) 1/34 (0.03) 34.0 
(1.7-666.1)  
0.5 
(0.1-0.9) 
- - - - 
Van den Bosch332 
(1995) 
2/140 
(1%) 
0/138 
(0%) 
0 - 6/7 (0.86) 0/131 (0.0) 214.5 
(13.2-3480) 
0.1 
(0.02-0.9) 
- - - - 
Gupta161 (1996) 15/69 
(22%) 
0/54 
(0%) 
0 0 2/2 (1.0) 1/52 (0.0) 52.0 
(7.5-362.2) 
0.2 
(0.01-2.15) 
6/10 
(0.6) 
1/44 
(0.02) 
26.4 
(3.6-195.6) 
0.4 
(0.2-0.9) 
Batool22 (1994) 15/70 
(21%) 
42/55 
(76%) 
0 - 3/3 (1.0) 0/10 (0.0) 19.3 
(1.3-296.2) 
0.1 
(0.01-1.8) 
- - - - 
Giannacopoulos133 
(1996) 
2/74 
(3%) 
15/72 
(21%) 
0 - 5/5 (1.0) 0/52 (0.0) 97.2 
(6.1-1549.5) 
0.1 
(0.01-1.2) 
- - - - 
Total 43/546 
(8%) 
64/503 
(13%) 
1 0 - - 64.6 
(22.3-187.1) 
0.1 
(0.04-0.28) 
54/88 
(0.6) 
27/383 
(0.07) 
9.9 
(5.5-17.6) 
0.5 
(0.4-0.6) 
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Device (No. 
Evaluations)  
*Failure 
rate 
Inadequate 
rate 
Disease in 
failed  
Cancer Cases: Likelihood 
ratio for a 
Likelihood 
ratio for a  
Disease Cases: Likelihood 
ratio for a  
Likelihood 
ratio for a  
& Study (95% CI) (95% CI) biopsy 95% CI +ve test -ve test  positive test negative test +ve test -ve test positive test negative 
test 
(Year Published)    Ca Hyp  Sensitivity  1-Specificity  (95% CI) (95% CI) Sensitivity 1-Specificity  (95% CI) (95% CI) 
             
             
Vabra 
Aspiration® 
            
Goldberg138 (1981) 0/64 
(0%) 
2/64 
(3%) 
0 0 1/1 (1.0) 0/61 (0.0) 93.0 
(5.3-1647.3) 
0.3 
(0.02-2.8) 
6/6 
(1.0) 
0/25 
(0.0) 
48.3 
(3.1-757.4) 
0.1 
(0.01-1.1) 
Stovall314 (1989) 5/40 
(13%) 
4/35 
(11%) 
0 0 3/3 (1.0) 0/28 (0.0) 50.8 
(3.2-812.1)  
0.1 
(0.01-1.7)  
7/7  
(1.0) 
7/55 
(0.13) 
18.6 
(6.3-55.1) 
0.1 
(0.0-1.1) 
Total 5/104 
(5%) 
6/99 
(6%) 
0 0 - - 59.4 
(6.8.-518.6) 
0.2 
(0.03-1.0) 
13/13  
(1.0) 
7/80 
(0.09) 
12.6 
(5.6-28.1) 
0.1 
(0.01-0.5) 
Z-sampler®             
Etherington117 
(1995) 
7/77 
(9%) 
36/70 
(51%) 
0 - 4/4 (1.0) 0/30 (0.0) 55.8 
(3.5-886.0)  
0.1 
(0.01-1.4) 
- - - - 
             
Endometrial 
cancer (13) 
68/1013 
6.7% 
(5.2-8.4%) 
138/945 
14.6% 
(12.4-17%) 
1/138  
0.7%  
(0.02-
4.0%) 
- 48/51 
 (0.94) 
3/756 
 (0.004) 
66.5 
(30.0-147.1)  
0.14 
(0.1-0.3) 
- - - - 
             
Endometrial 
hyperplasia (8) 
33/881 
3.7% 
(2.6-5.2%) 
43/848 
5.1% 
(3.7-6.8%) 
- 1/43  
2.3% 
(0.06-
12.3
%) 
- - - - 82/126 
(0.65) 
38/679 
(0.06) 
12.0 
(7.8-18.6) 
0.4 
(0.3-0.5) 
             
 
 
Ca = endometrial cancer, hyp = endometrial hyperplasia 
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Appendix 14  Studies included in systematic review of ultrasound measurement of endometrial thickness for predicting 
endometrial cancer and hyperplasia 
 
Study Population Diagnostic Test Outcome Quality 
Level* 
 
 
Patient 
selection 
Length of 
amenorrhoea 
Number of 
HRT users 
Method of 
scanning 
Transducer 
frequency 
Blinding of 
results 
Outcome 
measures 
 
Verification 
 
         
Measurement of both layers endometrial thickness      
3 mm          
Auslender et al
14
 1993 Consecutive 12 months None TVS 6.5 MHz Unreported Eca, Ehyp > 90% 4 
Zannoni et al
348
 1994 Unreported 6 months None TVS 5-6.5 MHz Unreported Eca > 90% 4 
          
4 mm          
Bakour et al
18
 1999
a
 Unreported 6 months 46/96 TVS 6.5 MHz Unreported Eca, Ehyp > 90% 4 
Botsis et al
36
 1992
p
 Unreported Unreported None TVS Unreported Unreported Eca, Ehyp > 90% 4 
Fistonic et al
122
 1997
a
 Unreported 12 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Garuti et al
130
 1999
a
 Unreported 12 months 51/419 TVS 7.5 MHz Unreported Eca, Ehyp > 90% 4 
Granberg et al
147
 1997
p
 Unreported Unreported 351/1168 TVS 5-7.5 MHz Unreported Eca, Ehyp > 90% 4 
Guner et al
159
 1996
p
 Unreported Unreported  Unreported  TVS 5-7.5 MHz Unreported Eca, Ehyp > 90% 4 
Haller et al
164
 1996
a
 Unreported Unreported None TVS 5.5 MHz Unreported Eca, Ehyp > 90% 4 
Tsuda et al
328
 1997
p
 Unreported 12 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Varner et al
334
 1991
p
 Unreported 6 months 9/15 TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
          
5 mm          
Abu-Ghazzeh et al
4
 1999
a
 Unreported 6 months Unreported TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Briley et al
42
 1998
a
 Unreported Unreported Unreported TVS 5, 7.5 MHz Unreported Eca, Ehyp < 80% 4 
Cacciatore et al
48
 1994
p
 Unreported Unreported  Unreported TVS 5-6.5 MHz Unreported Eca > 90% 4 
DeSilva et al
78
 1997
p
 Consecutive Unreported 6/50 TVS 7.5 MHz Unreported Eca, Ehyp > 90% 3 
Granberg et al
146
 1991
p
 Unreported Unreported 30/205 TVS 7 MHz Unreported Eca, Ehyp > 90% 4 
Grigoriou et al
151
 1996
p
 Unreported Unreported None TVS 5 MHz Yes Eca, Ehyp > 90% 2 
Gu et al
155
 1994
p
 Unreported 12 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Gupta et al
161
1996
p
 Unreported 12 months None TVS 6.5 MHz Yes Eca, Ehyp > 90% 2 
Hänggi et al
165
 1995
a
 Consecutive Unreported Unreported TVS 6.5 MHz No Eca, Ehyp < 80% 5 
Ivanov et al
172
 1998
p
 Unreported 6 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
172 
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Study Population Diagnostic Test Outcome Quality 
Level* 
 
 
Patient 
selection 
Length of 
amenorrhoea 
Number of 
HRT users 
Method of 
scanning 
Transducer 
frequency 
Blinding of 
results 
Outcome 
measures 
 
Verification 
 
          
Karlsson et al
179
 1993
a
 Unreported Unreported Unreported TVS 7 MHz Unreported Eca, Ehyp > 90% 4 
Loverro et al
216
 1999
p
 Unreported Unreported None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Malinova et al
224
 1996
a
 Unreported 24 months None TVS 7.5 MHz Unreported Eca, Ehyp > 90% 4 
Merz et al
234
 1990
p
 Unreported Unreported > 8 TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Nasri et al
243
 1989
p
 Unreported 12 months None ABS 3.5 MHz Yes Eca, Ehyp > 90% 2 
Nasri et al
244
 1991
p
 Unreported 6 months 3/103 TVS 5 MHz Unreported Eca, Ehyp 81-90% 5 
Pertl et al
269
 1996
p
 Unreported Unreported 35/169 TVS 5 MHz Unreported Eca, Ehyp 81-90% 5 
Suchocki et al
316
 1998
p
 Unreported Unreported None TVS+ABS 5, 6, 7.5 MHz Unreported Eca, Ehyp > 90% 4 
Taviani et al
321
 1995
p
 Unreported 12 months Unreported TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Weber et al
338
 1998
a
 Unreported 12 months None TVS 5, 7.5 MHz Unreported Eca > 90% 4 
Wolman et al
345
 1996
a
 Unreported 12 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
          
6 mm          
Moreles et al
237
 1998 Unreported 12 months Unreported TVS 5, 6, 7.5 MHz Unreported Eca, Ehyp < 80% 5 
Rudigoz et al
281
 1993 Unreported Unreported None TVS 5-7.5 MHz Unreported Eca, Ehyp > 90% 4 
          
8 mm          
Todorova et al
323
 1998 Unreported Unreported Unreported TVS 7.5 MHz No Eca > 90% 4 
          
15 mm          
Gruboeck et al
154
 1996 Unreported 6 months None TVS 7.5 MHz Unreported Eca > 90% 4 
          
Single Layer endometrial thickness measurement      
2 mm          
Chan et al
54
 1994 Unreported 12 months None TVS 5 MHz Unreported Eca, Ehyp 81-90% 5 
Degenhardt et al
85
 1991 Unreported Unreported 2/137 TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Dijkhuizen et al
94
 1996 Consecutive 12 months None TVS 5 MHz Yes Eca, Ehyp > 90% 2 
          
3 mm          
Brolmann et al
43
 1993 Arbitrary Unreported 11/65 TVS 5 MHz Yes Eca, Ehyp > 90% 4 
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Study Population Diagnostic Test Outcome Quality 
Level* 
 
 
Patient 
selection 
Length of 
amenorrhoea 
Number of 
HRT users 
Method of 
scanning 
Transducer 
frequency 
Blinding of 
results 
Outcome 
measures 
 
Verification 
 
Ceccini et al
53
 1996 Unreported 12 months Unreported TVS+ABS 6, 3.5 MHz Unreported Eca > 90% 4 
Masearetti et al
227
 1993 Unreported 24 months Unreported TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Mortakis et al
238
 1997 Unreported 12 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Schramm et al
290
 1995 Unreported Unreported None TVS 5-7.5 MHz Yes Eca, Ehyp > 90% 4 
Smith et al
304
 1991
 
Arbitrary Unreported Unreported TVS 5 MHz Yes Eca, Ehyp > 90% 2 
          
4 mm          
Osmers et al
258
 1992 Unreported 24 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Seelbach-Göbel et al
295
 1995 Unreported 6 months Unreported TVS 5-7.5 MHz Unreported Eca, Ehyp > 90% 4 
          
10 mm          
Altuncu et al
9
 1992 Unreported Unreported 13/68 TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
          
Unreported number of layers for endometrial thickness measurement      
4 mm          
Archer et al
13
 1999 Unreported Unreported 38/38 TVS 5-7.5 MHz Unreported Ehyp > 90% 4 
Dorum et al
96
 1993 Consecutive 12 months Unreported TVS 7 MHz Unreported Eca > 90% 4 
Gerber et al
132
 1999 Unreported Unreported None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
Li et al
205
 1997 Unreported 12 months None TVS 3.5 MHz Unreported Eca, Ehyp > 90% 4 
Salmaggi et al
285
 1997 Unreported Unreported Unreported TVS + ABS 3.5, 5 MHz Unreported Eca, Ehyp > 90% 4 
          
5 mm          
Goldstein et al
142
 1990 Unreported Unreported 18/30 TVS 5, 7.5 MHz Unreported Eca, Ehyp > 90% 4 
Malinova et al
223
 1995 Unreported 24 months None TVS 7.5MHz Unreported Eca, Ehyp > 90% 4 
          
6 mm          
Mateos et al
229
 1997 Unreported 6 months None TVS 5 MHz Unreported Eca, Ehyp > 90% 4 
          
7 mm          
Guisa-Chiferi et al
135
 1996 Unreported Unreported Unreported TVS 5 MHz Unreported Eca > 90%  4 
TVS = transvaginal USS, ABS = abdominal USS, HRT = hormone replacement therapy, Eca = endometrial cancer, Ehyp = endometrial hyperplasia, a = cut-off for abnormality 
determined a priori, p = cut-off for abnormality determined post hoc, * see Methods section for details of quality 
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 Appendix 16  Likelihood ratios (LR) for predicting endometrial cancer in primary 
studies 
 
   
Method of measurement and 
cut-off level for abnormality 
Positive test results Negative test results 
TPR FPR LR (95% CI) FNR TNR LR (95% CI) 
    
    
Measurement of both layers of endometrial thickness    
3 mm       
Auslender et al
14
 1993 16/16 55/113 2.05 (1.70-2.48) 0/16 58/113 0.06 (0.00-0.88) 
Zannoni et al
348
 1994 55/56 331/705 2.09 (l.92-2.28) 1/56 374/705 0.03 (0.00-0.24) 
       
4 mm       
Bakour et al
18
 1999 11/11 43/85 1.98 (l.60-2.44) 0/11 42/85 0.08 (0.01-1.28) 
Botsis et al
36
 1992 8/8 14/112 8.00 (4.90-13.06) 0/8 98/112 0.06 (0.00-0.94) 
Fistonic et al
122
 1997 14/14 72/89 1.24 (l.12-1.37) 0/14 17/89 0.17 (0.01-2.70) 
Garuti et al
130
 1999 59/60 240/359 1.47 (l.36-1.59) 1/60 119/359 0.05 (0.01-0.35) 
Granberg et al
147
 1997 114/114 480/996 2.08 (l.95-2.21) 0/114 516/996 0.01 (0.00-0.13) 
Guner et al
159
 1996 19/19 92/173 1.88 (l.64-2.16) 0/19 81/173 0.05 (0.00-0.83) 
Haller et al
164
 1996 16/16 48/65 1.35 (l.17-1.56) 0/16 17/65 0.11 (0.01-1.75) 
Tsuda et al
328
 1997 14/15 56/151 2.52 (l.96-3.22) 1/15 95/151 0.11 (0.02-0.71) 
Varner et al
334
 1991 2/2 6/13 2.17 (l.20-3.90) 0/2 7/13 0.31 (0.02-4.09) 
       
5 mm       
Abu-Ghazzeh et al
4
 1999 1/1 60/97 1.62 (l.38-1.89) 0/1 37/97 0.65 (0.06-7.30) 
Briley et al
42
 1998 5/5 85/172 2.02 (1.74-2.35) 0/5 87/172 0.16 (0.01-2.35) 
Cacciatore et al
48
 1994 4/4 30/41 1.37 (l.14-1.64) 0/4 11/41 0.37 (0.03-5.30) 
DeSilva et al
78
 1997 1/3 12/47 1.31 (0.24-6.96) 2/3 35/47 0.90 (0.40-2.03) 
Granberg et al
146
 1991 8/8 47/197 4.19 (3.27-5.38) 0/8 150/197 0.07 (0.00-1.08) 
Grigoriou et al
151
 1996 24/24 75/226 3.01 (2.50-3.63) 0/24 151/226 0.03 (0.00-0.47) 
Gu et al
155
 1994 7/7 16/22 1.38 (l.06-1.78) 0/7 6/22 0.22 (0.01-3.50) 
Gupta et al
161
 
1996 
2/3 26/72 1.85 (0.78-4.35) 1/3 46/72 0.52 (0.10-2.61) 
Hänggi et al
165
 1995 18/21 15/70 4.00 (2.47-6.47) 3/21 55/70 0.18 (0.06-0.52) 
Ivanov et al
172
 1998 10/10 31/74 2.39 (l.83-3.12) 0/10 43/74 0.08 (0.01-1.18) 
Karlsson et al
179
 1993 14/15 31/88 2.65 (l.94-3.63) 1/15 57/88 0.10 (0.02-0.69) 
Loverro et al
216
 1999 25/25 13/81 6.23 (3.79-10.25) 0/25 68/81 0.02 (0.00-0.36) 
Malinova et al
224
 1996 69/69 43/85 2.35 (l.75-3.14) 0/69 42/85 0.02 (0.00-0.24) 
Merz et al
234
 1990 14/14 24/42 1.75 (l.35-2.27) 0/14 18/42 0.08 (0.00-1.21) 
Nasri et al
243
 1989 7/7 19/56 2.95 (2.05-4.25) 0/7 37/56 0.10 (0.01-1.40) 
Nasri et al
244
 1991 6/6 32/83 2.59 (l.98-3.40) 0/6 51/83 0.12 (0.01-1.69) 
Pertl et al
269
 1996 18/19 96/131 1.29 (1.11-1.50) 1/19 35/131 0.20 (0.03-1.36) 
Suchocki et al
316
 1998 28/28 89/101 1.13 (l.06-1.22) 0/28 12/101 0.14 (0.01-2.31) 
Taviani et al
321
 1995 2/2 18/39 2.17 (l.54-3.04) 0/2 21/39 0.31 (0.02-3.96) 
Weber et al
338
 1998 61/62 59/97 1.62 (l.37-1.90) 1/62 38/97 0.04 (0.01-0.29) 
Wolman et al
345
 1996 4/4 18/50 2.78 (l.92-4.02) 0/4 32/50 0.16 (0.01-2.19) 
       
6 mm       
Moreles et al
237
 1998 20/22 70/178 2-31 (l.85-2.90) 2/22 108/178 0.15 (0.04-0.56) 
Rudigoz et al
281
 1993 7/9 12/46 2.98 (l.64-5.43) 2/9 34/46 0.30 (0.09-1.03) 
       
8 mm       
Todorova et al
323
 1998 2/2 4/8 2.00 (l.00-4.00) 0/2 4/8 0.33 (0.02-4.55) 
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Appendix 16 continued 
     
   
Method of measurement and 
cut-off level for abnormality 
Positive test results Negative test results 
TPR FPR LR (95% CI) FNR TNR LR (95% CI) 
    
       
15 mm       
Gruboeck et al
154
 1996 9/11 10/86 7.04 (3.69-13.42) 2/11 76/86 0.21 (0.06-0.72) 
       
Single  layer endometrial thickness measurement    
2 mm       
Chan et al
54
 1994 17/17 19/50 2.63 (l.85-3.75) 0/17 31/50 0.04 (0.00-0.70) 
Degenhardt et al
85
 1991 32/37 33/96 2.52 (l.86-3-41) 5/37 63/96 0.21 (0.09-0.47) 
Dijkhuizen et al
94
 1996 8/8 31/61 1.97 (l.54-2.52) 0/8 30/61 0.11 (0.01-1.69) 
       
3 mm       
Brolmann et al
43
 1993 10/10 26/55 2.12 (l.60-2.80) 0/10 29/55 0.09 (0.01-1.31) 
Ceccini et al
53
 1996 15/16 101/352 3.27 (2.65-4.02) 1/16 251/352 0.09 (0.01-0.59) 
Masearetti et al
227
 1993 3/3 8/19 1.98 (l.60-2.44) 0/3 11/19 0.01 (0.00-0.23) 
Mortakis et al
238
 1997 7/7 30/71 2.37 (l.80-3.11) 0/7 41/71 0.11 (0.01-1.60) 
Schramm et al
290
 1995 18/29 83/166 1.24 (0.90-1.71) 11/29 83/166 0.76 (0.46-1.24) 
Smith et al
304
 1991
 
4/4 19/41 2.16 (l.55-3.00) 0/4 22/41 0.19 (0.01-2.63) 
       
4 mm       
Osmers et al
258
 1992 27/27 103/206 2.00 (l.74-2.29) 0/27 103/206 0.04 (0.00-0.56) 
Seelbach-Göbel et al
295
 1995 37/39 109/193 1.68 (l.45-1-94) 2/39 84/193 0.12 (0.03-0.46) 
       
10 mm       
Altuncu et al
9
 1992 5/6 1/35 29.17 (4.09-
208.03) 
1/6 34/35 0.17 (0.03-1.03) 
       
Unreported number of layers for endometrial thickness measurement    
4 mm       
Dorum et al
96
 1993 11/13 35/87 2.10 (l.49-2.97) 2/13 52/87 0.26 (0.07-0.93) 
Gerber et al
132
 1999 148/154 375/725 1.86 (l.72-2.01) 6/154 350/725 0.08 (0.04-0.18) 
Li et al
205
 1997 59/62 56/130 2.21 (l.80-2.71) 3/62 74/130 0.09 (0.03-0.26) 
Salmaggi et al
285
 1997 4/4 13/21 1.62 (l.15-2.26) 0/4 8/21 0.26 (0.02-3.78) 
       
5 mm       
Goldstein et al
142
 1990 1/1 16/27 1.69 (1.23-2.31) 0/1 11/27 0.61 (0.05-6.99) 
Malinova et al
223
 1995 57/57 26/61 2.38 (l.40-4.02) 0/57 35/61 0.22 (0.02-2.99) 
       
6 mm       
Mateos et al
229
 1997 18/18 43/140 3.26 (2.54-4.18) 0/18 97/140 0.04 (0.00-0.59) 
       
7 mm       
Guisa-Chiferi et al
135
 1996 19/19 23/61 2.65 (l.92-3.66) 0/19 38/61 0.04 (0.00-0.63) 
       
 
LR = likelihood ratio, CI = confidence interval,  
TPR = True positive rate, FPR = False positive rate, FNR = False negative rate, TNR = True negative rate 
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Appendix 17  Likelihood ratios (LR) for predicting endometrial disease 
(hyperplasia and/or cancer) in primary studies 
 
 
Method of measurement and 
cut-off level for abnormality 
 
Positive test results 
 
Negative test results 
TPR FPR LR (95% CI) FNR TNR LR (95% CI) 
 
    
Measurement of both layers of endometrial thickness    
 3 mm       
Auslender et al
14
 1993 32/32 39/97 2.49 (l.95-3.17) 0/32 58/97 0.03 (0.00-0.40) 
       
 4 mm       
Bakour et al
18
 1999 13/14 41/82 1.86 (l.43-2.41) 1/14 41/82 0.14 (0.02-0.96) 
Botsis et al
36
 1992 18/18 4/102 25.50 (9.76-66.64) 0/18 98/102 0.03 (0.00-0.42) 
Fistonic et al
122
 1997 51/51 35/52 1.49 (l.23-1.80) 0/51 17/52 0.03 (0.00-0.47) 
Garuti et al
130
 1999 103/106 196/313 1.55 (l.42-1.70) 3/106 117/313 0.08 (0.02-0.23) 
Granberg et al
147
 1997 220/226 374/884 2.30 (2.12-2.49) 6/226 510/884 0.05 (0.02-0.10) 
Guner et al
159
 1996 50/50 61/142 2.33 (l.93-2.81) 0/50 81/142 0.02 (0.00-0.27) 
Haller et al
164
 1996 30/32 34/49 1.35 (1.10-1.66) 2/32 15/49 0.20 (0.05-0.83) 
Tsuda et al
328
 1997 26/27 44/139 3.04 (2.36-3.93) 1/27 95/139 0.05 (0.01-0.37) 
Varner et al
334
 1991 5/5 3/10 3.33 (l.29-8.59) 0/5 7/10 0.12 (0.01-1.79) 
       
 5 mm       
Abu-Ghazzeh et al
4
 1999 3/3 58/95 1.64 (l.39-1.92) 0/3 37/95 0.32 (0.02-4.33) 
Briley et al
42
 1998 13/15 77/162 1.82 (l.41-2.36) 2/15 85/162 0.25 (0.07-0.93) 
DeSilva et al
78
 1997 3/6 10/44 2.20 (0.84-5.79) 3/6 34/44 0.65 (0.29-1.46) 
Granberg et al
146
 1991 21/21 34/184 5.41 (4.00-7.33) 0/21 150/184 0.03 (0.00-0.43) 
Grigoriou et al
151
 1996 69/69 30/181 6.03 (4.35-8.37) 0/69 151/181 0.01 (0.00-0.14) 
Gu et al
155
 1994 10/10 13/19 1.46 (l.08-1.98) 0/10 6/19 0.14 (0.01-2.26) 
Gupta et al
161
 1996 6/7 22/68 2.65 (l.68-4.19) 1/7 46/68 0.21 (0.03-1.31) 
Hänggi et al
165
 1995 21/25 12/66 4.62 (2.69-7.92) 4/25 54/66 0.20 (0.08-0.48) 
Ivanov et al
172
 1998 17/17 24/67 2.79 (2.03-3.85) 0/17 43/67 0.04 (0.00-0.67) 
Karlsson et al
179
 1993 24/25 21/78 3.57 (2.45-5.18) 1/25 57/78 0.05 (0.01-0.38) 
Loverro et al
216
 1999 25/28 13/78 5.36 (3.21-8.94) 3/28 65/78 0.13 (0.04-0.38) 
Malinova et al
224
 1996 80/80 32/74 2.31 (l.78-3.00) 0/80 42/74 0.01 (0.00-0.17) 
Merz et al
234
 1990 17/19 21/37 1.58 (l.14-2.17) 2/19 16/37 0.24 (0.06-0.95) 
Nasri et al
243
 1989 10/10 16/53 3.31 (2.20-4.99) 0/10 37/53 0.07 (0.00-0.99) 
Nasri et al
244
 1991 16/16 22/73 3.32 (2.34-4.71) 0/16 51/73 0.04 (0.00-0.65) 
Pertl et al
269
 1996 46/52 68/98 1.27 (l.08-1.50) 6/52 30/98 0.38 (0.17-0.85) 
Suchocki et al
316
 1998 90/90 27/39 1.44 (l.17-1.78) 0/90 12/39 0.02 (0.00-0.29) 
Taviani et al
321
 1995 4/4 16/37 2.31 (1.60-3.35) 0/4 21/37 0.18 (0.01-2.49) 
Wolman et al
345
 1996 10/11 12/43 3.26 (l.95-5.45) 1/11 31/43 0.13 (0.02-0.82) 
       
 6 mm       
Moreles et al
237
 1998 24/59 66/141 0.87 (0.61-1.24) 35/59 75/141 1.12 (0.86-1.45) 
Rudigoz et al
281
 1993 17/19 2/36 16.1 (4.15-62.48) 2/19 34/36 0.11 (0.03-0.41) 
       
Single layer endometrial thickness measurement    
 2 mm       
Chan et al
54
 1994 23/23 13/44 3.38 (2.14-5.34) 0/23 31/44 0.03 (0.00-0.47) 
Degenhardt et al
85
 1991 39/46 26/87 2.84 (2.01-4.00) 7/46 61/87 0.22 (0.11-0.44) 
Dijkhuizen et al
94
 1996 15/15 24/54 2.25 (l.67-3.03) 0/15 30/54 0.06 (0.00-0.87) 
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Method of measurement and 
cut-off level for abnormality 
 
Positive test results 
 
 
 
Negative test results 
 TPR FPR LR (95% CI) FNR TNR LR (95% CI) 
 
       
 3 mm       
Brolmann et al
43
 1993 11/12 25/53 1.94 (l.39-2.71) 1/12 28/53 0.16 (0.02-1.05) 
Masearetti et al
227
 1993 5/6 6/16 2.22 (l.07-4.60) 1/6 10/16 0.27 (0.04-1.66) 
Mortakis et al
238
 1997 11/12 26/66 2.33 (l.65-3.28) 1/12 40/66 0.14 (0.02-0.91) 
Schramm et al
290
 1995 68/103 33/92 1.84 (l.35-2.50) 35/103 59/92 0.53 (0.39-0.72) 
Smith et al
304
 1991
 
8/8 15/37 2.47 (l.67-3.64) 0/8 22/37 0.09 (0.01-1.41) 
       
 4 mm       
Osmers et al
258
 1992 35/35 95/198 2.08 (l.80-2.41) 0/35 103/198 0.03 (0.00-0.42) 
Seelbach-Göbel et al
295
 1995 59/62 87/170 1.86 (l.59-2.18) 3/62 83/170 0.10 (0.03-0.30) 
       
 10 mm       
Altuncu et al
9
 1992 6/15 0/26 21.94 (l.32-364.10) 9/15 26/26 0.60 (0.40-0.91) 
       
Unreported number of layers for endometrial thickness measurement    
 4 mm       
Gerber et al
132
 1999 203/213 320/666 1.98 (l.82-2.16) 10/213 346/666 0.09 (0.05-0.17) 
Li et al
205
 1997 77/80 38/112 2.84 (2.18-3.69) 3/80 74/112 0.06 (0.02-0.17) 
Salmaggi et al
285
 1997 7/7 10/18 1.80 (l.19-2.72) 0/7 8/18 0.14 (0.01-2.14) 
       
 5 mm       
Goldstein et al
142
 1990 4/4 13/24 1.85 (l.28-2.67) 0/4 11/24 0.22 (0.02-3.12) 
Malinova et al
223
 1995 64/64 19/54 2.84 (l.98-4.08) 0/64 35/54 0.01 (0.00-0.19) 
       
 6 mm       
Mateos et al
229
 1997 35/35 26/123 4.73 (3.36-6.66) 0/35 97/123 0.02 (0.00-0.28) 
       
 
LR = likelihood ratio, CI = confidence interval 
TPR = True positive rate, FPR = False positive rate, FNR = False negative rate, TNR = True negative rate 
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Appendix 19 Diagnostic accuracy of hysteroscopy in detecting endometrial cancer and hyperplasia in women at risk of 
abnormal endometrial histology: Methodological details 
 
         
Study (Year  Data  Patient  Study  Bleeding Type / Menopausal Status (%) Method(s) of obtaining  Timing of  Completeness  Follow  
Published) Collection Selection Quality     endometrial histology Verification§ of Verification Up 
   Level Post HRT   Pre †Other (Reference Standard)    
            
            
Alexopoulos7(1999) Unreported Unreported 5 861 (33) 40 (2) 1647(64) 33 (1) OB Simultaneous Partial 49% >90 
Altaras8 (1993) Prospective Unreported 4 39 (100) - - - OB Simultaneous Complete >90 
Azzena15 (1999) Prospective Unreported 2 *9 (18) - 11 (22) 30 (60) DB Sequential Complete >90 
Bakour17 (1999)  Prospective Unreported 4 35 (14) 77 (31) 136 (45) - D&C, OB Simultaneous Complete >90 
Bocanera32 (1994) Unreported Consecutive  5 72 (46) - 84 (54) - Hyst / D&C / OB Sequential Complete‡ <81 
Bucholz45 (1988) Retrospective Unreported 4 168(100 - - - D&C Simultaneous Complete >90 
Cacciatore48 (1994) Prospective Unreported 4 25 (56) 20 (44) - - D&C Simultaneous Complete >90 
Cameron50 (2001) Unreported Unreported 4 *12 (35) 21 (65) - - Hyst / OB Sequential Complete 81-90 
Caserta52 (1999) Unreported Unreported 4 - - - 222 (100) DB Simultaneous Complete >90 
Dargent74 (1983) Unreported Unreported 4 63 (33) - 143 (75) - OB Simultaneous Complete >90 
Davydov75 (1989) Unreported Unreported 4 46 (100) - - - D&C Simultaneous Complete >90 
De Jong76 (1990) Unreported Unreported 5 62 (39) - 87 (54) 11 (7) D&C/OB Simultaneous Partial 74% >90 
De Mendonca77 (1994) Unreported Unreported 4 158(100 - - - Unreported Simultaneous Complete >90 
De Silva78 (1997) Prospective Consecutive 3 44 (88) 6 (12) - - Hyst / D&C Sequential Complete >90 
De Vivo79 (1986) Unreported Unreported 4 - - 18 (36) 32 (64) Unreported Unreported Unreported >90 
Decloedt81 (1999) Retrospective Unreported 4 204 (30) - 469 (70) OB Sequential  Complete >90 
Descargues90 (2001) Prospective Consecutive 4 8 (21) 1 (3) 29 (76) - DB / D&C / OB Simultaneous Complete >90 
Elewa112(2001) Unreported Unreported 4 20 (40)   30 (60) DB / D&C Simultaneous Complete >90 
Epstein115 (2001) Prospective Consecutive 3 #77(73) 28 (27) - - Hyst / DB / D&C Sequential Complete >90 
Gabrys129 (1994) Unreported Unreported 4    63 (100) DB Simultaneous Complete >90 
Garuti131 (2001) Retrospective Consecutive 3 *523(34  - 607 (41) 370 (25) Hyst/DB/D&C/OB Sequential  Complete >90 
Gorostiaga144 (2001) Prospective Consecutive 3 100(100 - - - OB Simultaneous Complete >90 
Grosdanov153 (1988) Unreported Unreported 4 - - - 631 (100) DB Unreported Complete >90 
Gucer156 (1996) Unreported Unreported 4 74 (72) 13 (13) 16 (15) - D&C Simultaneous Complete >90 
Gupta161 (1996) Prospective Unreported 4 73 (100) - - - D&C Simultaneous Complete >90 
Haller164 (1996) Prospective Unreported 4 81 (100) - - - D&C Simultaneous Complete >90 
Iossa169 (1991) Retrospective Consecutive 5 - - - 815 (100) D&C / OB Simultaneous Partial 37% >90 
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Study (Year  Data  Patient  Study  Bleeding Type / Menopausal Status (%) Method(s) of obtaining  Timing of  Completeness  Follow  
Published) Collection Selection Quality     endometrial histology Verification§ of Verification Up 
   Level Post HRT   Pre †Other (Reference Standard)    
            
            
Itzkowic171 (1990) Unreported Consecutive 3 6 (12) - 43 (86) 1 (2) OB Simultaneous Complete >90 
Kovar191 (2000) Retrospective Unreported 4 *391(36  206 (19) 495 (45) - D&C Simultaneous Complete >90 
Krampl193 (2001) Prospective Consecutive 3 5 (5) 6 (6) 89 (89) - DB Simultaneous Complete >90 
#Kun197 (1999) Prospective Consecutive 3 63 (20) - 180 (80) - D&C / DB Simultaneous Complete >90 
La Sala200 (1987) Unreported Unreported 5 317 (33) - 415 (43) 244 (25) Hyst / DB / OB Sequential Partial 38% >90 
Litta210 (1996) Unreported Unreported 4 251 (40) - 378 (60) - DB Simultaneous Complete >90 
Liu211 (1995) Unreported Unreported 4 130(100 - - - Unreported Sequential Complete >90 
Lo212 (2000) Retrospective Unreported 4 503 (31)  - 950 (59)  147 (10) DB / D&C / OB Simultaneous Partial 74% >90 
Loverro217 (1996) Unreported Unreported 4 455 (46) - 525 (54) - DB / OB  Simultaneous Complete >90 
Loverro216 (1999) Prospective Unreported 4 106(100 - - - DB / OB Simultaneous Complete >90 
Luo218 (1989) Unreported Unreported 4 125(100 - - - D&C Sequential Complete >90 
Madan220 (2001) Retrospective Unreported 4 76 (13) - 480 (77) 64 (10) D&C Simultaneous Complete 81-90 
Maia221 (1996) Unreported Unreported 4 16 (34) 15 (32) - 16 (32) OB Simultaneous Complete >90 
Maia222 (1998) Retrospective Unreported 4 - 143(100) - - Hyst / DB / OB  Sequential Complete >90 
Mencaglia233 (1987) Unreported Unreported 5 NR NR NR 638(100) NS  OB Simultaneous Partial 33% >90 
Nagele241 (1996) Unreported Unreported 5 202 (8) - 1925(77) 373 (15) DB / OB Simultaneous Partial 68% >90 
Neis246 (1986) Prospective Unreported  4 NR NR NR 307(100) NS  D&C Sequential Complete <81 
Neumann248 (1994) Unreported Unreported 4 54 - 31 - D&C Simultaneous  Complete >90 
Ohad255 (1998) Retrospective Consecutive 3 173 (46) - - 200(54) NS D&C Simultaneous Complete >90 
Okeahialam256 (2001) Retrospective Unreported 4 - 190(100) - - DB / OB Simultaneous Complete >90 
Paschpoulos263 (1997) Prospective Unreported 4 - - - 235(73) NS 
89 (37) 
DB Simultaneous Complete >90 
Paya265 (1998) Retrospective Unreported 4 866 (54) 109 (6) 641 (40) - Unreported Simultaneous Complete >90 
Perez-Medina266 (1994) Prospective Unreported 4 *80 (65) - 53 (35) - D&C / DB Sequential Complete >90 
Possati270 (1994) Unreported Unreported 4 78 (78) - - 22 (22) Unreported Simultaneous Complete >90 
Raju275 (1986) Unreported Unreported  4 49 (70) 7 (10) 14 (20) - DB / D&C Simultaneous Complete >90 
Salet-Lizee284 (1993) Prospective Unreported 4 43 (24) 32 (18) 103 (58) - D&C Simultaneous Complete >90  
Sanfeliu286 (1990) Retrospective Unreported 4 127 (26) - 482 (74) - OB Unreported Complete >90 
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Study (Year  Data  Patient  Study  Bleeding Type / Menopausal Status (%) Method(s) of obtaining  Timing of  Completeness  Follow 
Published) Collection Selection Quality     endometrial histology Verification§ of Verification Up 
   Level Post HRT   Pre †Other (Reference Standard)    
            
            
Scwarzler291 (1998) Unreported Consecutive 3 29 (30) - 69 (70) - D&C Simultaneous Complete >90 
Sevcik297 (1998) Unreported Unreported 4 34 (47) - - 39 (53) DB / D&C Simultaneous Complete >90 
Simon302 (1993) Retrospective Unreported 4 *15 (14) - - 91 (86) Hyst Sequential Complete <81 
Sousa308 (2001) Prospective Consecutive 1 75 (85) 13 (15) - - Hyst/DB/OB Sequential Complete >90 
Tahir320 (1999) Prospective Consecutive 3 123 (31) - 277 (69) - D&C / OB Simultaneous Complete >90 
Todorova323 (1998) Prospective Unreported 4 10 (50) - 10 (50) - Unreported Simultaneous Complete >90 
Uhiara329 (1999) Retrospective Unreported 5 *61 (32) 8 (5) 81 (43) 38 (20) OB Simultaneous Partial 36% >90 
Valli330 (1995) Prospective Unreported 5 *162(17) - 233 (25) 538 (58) DB Simultaneous Partial 26% >90 
Vercellini335 (1997) Unreported Consecutive 5 - - 793(100) - OB Simultaneous Partial 98% >90 
Vigada336 (1995) Unreported Unreported 4 49 (58) - 23 (28) 12 (14) OB Simultaneous Complete >90 
Widrich343 (1995) Prospective Unreported  5 29 (22) 5 (4) 88 (68) 8 (6) OB/surgery - NS Sequential Partial 49% >90 
            
 
*Numbers calculated from initial proportion of patients within these groups before missing outcome data or duplicate testing was excluded  
† Other refers to proportion of women included in the study who did not have abnormal uterine bleeding as an indication for hysteroscopy 
‡ Incomplete reporting of endometrial cancer (i.e. not all histologically confirmed cases included in study analysis) 
§Timing of verification of diagnosis refers to when verification of diagnosis following hysteroscopy was performed, at the same time (simultaneous) or after a short delay sequential). 
¶ Proportion of successful hysteroscopies for which outcome data was available 
# All patients had endometrium thickness >5mm on transvaginal ultrasound 
NS = not specified (refers to proportion of women included in the study where the type of abnormal uterine bleeding was not specified)  
D&C = dilatation of the cervix and curettage of the endometrium, DB = directed biopsy, OB = outpatient biopsy (blind), Hyst = hysterectomy specimen 
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Appendix 20 Procedure feasibility and diagnostic accuracy of hysteroscopy in endometrial cancer and endometrial disease 
(cancer and hyperplasia) 
 
        
Study  *Failure rate Disease in failed Inadequate rate    Cancer Cases:       Disease Cases:  
(Year published)  Hysteroscopy 
Cancer    Hyper 
 +ve test 
(Sensitivity) 
-ve test  
(1-Specificity) 
+ve test 
(Sensitivity) 
-ve test  
(1-Specificity) 
        
        
Alexopoulos
7
(1999) 83/2581 0 - 165/2498 6/11 (0.55) 13/2322 (0.006) 6/11 (0.55) 13/2322 (0.006) 
Altaras
8
 (1993) 0/39 0 - 0/39 3/3 (1.0) 0/36 (0.0) 3/3 (1.0) 0/36 (0.0) 
Azzena
15
(1999) 3/50 - 0 0/47 - - 9/10 (0.9) 2/37 (0.05) 
Bakour
17
 (1999) †0/248 - 0 0/248 - - 4/14 (0.29) 1/230 (0.004) 
Bocanera
32
 (1994) 7/156 0 3 6/149 10/11 (0.91) 0/132 (0.0) 23/29 (0.79) 15/114 (0.13) 
Bucholz
45
 (1988) 0/168 0 0 0/168 12/12 (1.0) 4/156 (0.03) 23/23 (1.0) 3/145 (0.02) 
Cacciatore
48
 (1994) 2/45 0 - 0/43 2/4 (0.50) 0/39 (0.0) 2/4 (0.50) 0/39 (0.0) 
Cameron
50
 (2001) 3/33 - 0 0/30 - - 1/2 (0.50) 0/28 (0.0) 
Caserta
52
 (1999) 0/222 0 - 0/222 6/6 (1.0) 0/216 (0.0) 6/6 (1.0) 0/216 (0.0) 
Dargent
74
 (1983) 0/191 0 - 31/191 4/15 (0.27) 1/145 (0.007) 4/15 (0.27) 1/145 (0.007) 
Davydov
75
 (1989) 0/46 0 0 0/46 11/11 (1.0) 0/35 (0.0) 14/14 (1.0) 1/32 (0.03) 
De Jong
76
 (1990) 8/160 1 - 19/152 5/5 (1.0) 5/128 (0.04) 5/5 (1.0) 5/128 (0.04) 
De Mendonca
77
 (1994) 0/158 0 - 0/158 14/15 (0.93) 17/143 (0.12) 14/15 (0.93) 17/143 (0.12) 
De Silva
78
 (1997) 1/50 1 - 25/49 2/2 (1.0) 0/22 (0.0) 2/2 (1.0) 0/22 (0.0) 
DeVivo
79
(1986) 0/50 - 0 0/50 - - 1/1 (1.0) 0/49 (0.0) 
Decloedt
81
 (1999) 37/673 0 - 0/636 9/9 (1.0) 0/627 (0.0) 9/9 (1.0) 0/627 (0.0) 
Descargues
90
 (2001) 1/38 0 0 0/37 2/2 (1.0) 1/35 (0.03) 10/10 (1.0) 6/27 (0.22) 
Elewa
112
(2001) 0/50 0 0 0/50 3/3 (1.0) 0/47 (0.0) 26/26 (1.0) 3/24 (0.13) 
Epstein
115
 (2001) 0/105 0 - 0/105 21/25 (0.84) 12/80 (0.15) 21/25 (0.84) 12/80 (0.15) 
Gabrys
129
 (1994) 0/63 0 - 5/63 1/1 (1.0) 0/57 (0.0) 1/1 (1.0) 0/57 (0.0) 
Garuti
131
 (2001) †‡0/1050 0 0 43/1457 85/102 (0.83) 7/1355 (0.005) 208/287 (0.73) 91/869 (0.09) 
Gorostiaga
144
 (2001) 4/100 0 - 41/96 6/6 (1.0) 0/49 (0.0) 6/6 (1.0) 0/49 (0.0) 
Grosdanov
153
 (1988) 0/461 0 - 0/461 67/67 (1.0) 6/394 (0.02) 67/67 (1.0) 6/394 (0.02) 
Gucer
156
 (1996) 5/103 0 - 0/98 8/9 (0.89) 2/89 (0.02) 8/9 (0.89) 2/89 (0.02) 
Gupta
161
 (1996) 4/73 - 0 35/69 - - 5/11 (0.46) 0/23 (0.0) 
Haller
164
 (1996) 5/81 1 4 0/76 8/15 (0.53) 0/61 (0.0) 16/27 (0.59) 9/49 (0.18) 
Iossa
169
 (1991) 196/2007 1 - 26/1811 22/29 (0.76) 13/1756 (0.007) 22/29 (0.76) 13/1756 (0.007) 
Itzkowic
171
 (1990) 2/50 0 - 1/48 1/1 (1.0) 0/46 (0.0) 1/1 (1.0) 0/46 (0.0) 
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Study  *Failure rate Disease in failed Inadequate rate    Cancer Cases:       Disease Cases:  
(Year published)  Hysteroscopy 
Cancer    Hyper 
 +ve test 
(Sensitivity) 
-ve test  
(1-Specificity) 
+ve test 
(Sensitivity) 
-ve test  
(1-Specificity) 
        
         
Kovar
191
 (2000) 0/1092 0 - 0/690 13/26 (0.50) 6/1174(0.005) 13/26 (0.50) 6/1174(0.005) 
Krampl
193
 (2001) 1/100 0 0 0/99 1/1 (1.0) 0/98 (0.0) 2/9 (0.22) 11/90 (0.12) 
Kun
197
 (1999) 1/318 0 - 2/317 5/5 (1.0) 1/310 (0.003) 5/5 (1.0) 1/310 (0.003) 
La Sala
200
 (1987) 87/976 0 0 0/889 32/33 (0.97) 4/856 (0.005) 105/105 (1.0) 26/784 (0.03) 
Litta
210
 (1996) †0/629 0 0 0/629 35/42 (0.83) 0/587 (0.0) 128/162 (0.79) 54/467 (0.12) 
Liu
211
 (1995) 0/130 0 0 24/130 9/11 (0.82) 4/95 (0.04) 17/22 (0.77) 7/84 (0.08) 
Lo
212
 (2000) 132/1600 3 - 0/1468 10/17 (0.59) 38/1451 (0.03) 10/17 (0.59) 38/1451 (0.03) 
Loverro
217
(1996) 0/980 - 0 90/980 - - 102/102 (1.0) 47/788 (0.06) 
Loverro
216
 (1999) 0/106 0 - 0/106 25/25 (1.0) 2/81 (0.03) 25/25 (1.0) 2/81 (0.03) 
Luo
218
 (1989) 0/125 0 - 0/125 13/13 (1.0) 2/112 (0.02) 13/13 (1.0) 2/112 (0.02) 
Madan
220
 (2001) 39/556 0 10 82/517 2/7 (0.29) 2/428 (0.005) 49/122 (0.40) 53/313 (0.17) 
Maia
221
 (1996) 0/47 0 - 5/47 5/5 (1.0) 0/37 (0.0) 5/5 (1.0) 0/37 (0.0) 
Maia
222
(1998) 0/143 - 0 2/143 - - 4/69 (0.06) 0/72 (0.0) 
Mencaglia
233
 (1987) 20/638 0 0 0/618 59/60 (0.98) 7/558 (0.01) 124/149 (0.83) 28/469 (0.06) 
Nagele
241
 (1996) 91/2500 0 - 392/2409 11/11 (1.0) 0/2006 (0.0) 11/11 (1.0) 0/2006 (0.0) 
Neis
246
 (1986) 0/307 0 0 0/307 44/48 (0.92) 0/259 (0.0) 70/76 (0.92) 9/231 (0.04) 
Neumann
248
 (1994) 4/89 0 0 0/85 4/5 (0.80) 0/80 (0.0) 17/18 (0.94) 3/67 (0.04) 
Ohad
255
 (1998) 25/373 0 0 33/348 2/10 (0.20) 0/305 (0.0) 42/65 (0.65) 105/250 (0.42) 
Okeahialam
256
 (2001) 0/190 0 0 37/190 2/3 (0.66) 5/150 (0.03) 5/8 (0.63) 2/181 (0.01) 
Paschpoulos
263
 (1997) 12/324 0 0 0/312 12/12 (1.0) 0/300 (0.0) 119/128 (0.93) 9/184 (0.05) 
Paya
265
 (1998) 30/1616 0 0 0/1586 84/85 (0.99) 2/1501 (0.001) 256/311 (0.82) 69/1275 (0.05) 
Perez-Medina
266
 (1994) 5/123 1 0 28/118 8/9 (0.89) 0/81 (0.0) 14/15 (0.93) 10/75 (0.13) 
Possati
270
(1994) 0/100 - 0 0/100 - - 23/23 (1.0) 0/77 (0.0) 
Raju
275
 (1986) 0/70 0 0 17/70 14/14 (1.0) 0/39 (0.0) 25/25 (1.0) 0/28 (0.0) 
Salet-Lizee
284
 (1993) 0/195 0 0 0/195 7/8 (0.88) 2/187 (0.01) 56/70 (0.8) 5/125 (0.04) 
Sanfeliu
286
 (1990) 0/609 0 0 0/609 14/15 (0.93) 1/594 (0.001) 51/59 (0.86) 20/550 (0.04) 
Scwarzler
291
 (1998) 0/98 0 0 0/98 3/3 (1.0) 0/95 (0.0) 9/10 (0.9) 0/88 (0.0) 
Sevcik
297
 (1998) 0/73 0 0 0/73 1/4 (0.25) 0/69 (0.0) 4/8 (0.5) 0/65 (0.0) 
Sousa
308
 (2001) 15/84 0 0 12/69 8/9 (0.89) 1/48 (0.02) 9/11 (0.82) 0/46 (0.0) 
Simon
302
 (1993) 0/106 0 0 0/106 6/8 (0.75) 0/98 (0.0) 16/20 (0.8) 8/86 (0.09) 
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Study  *Failure rate Disease in failed Inadequate rate    Cancer Cases:       Disease Cases:  
(Year published)  Hysteroscopy 
Cancer    Hyper 
 +ve test 
(Sensitivity) 
-ve test  
(1-Specificity) 
+ve test 
(Sensitivity) 
-ve test  
(1-Specificity) 
        
         
Tahir
320
 (1999) 7/400 0 - 30/393 8/11 (0.73) 0/352 (0.0) 8/11 (0.73) 0/352 (0.0) 
Todorova
323
 (1998) 0/20 - 0 0/20 - - 4/6 (0.67) 2/14 (0.14) 
Uhiara
329
 (1999) 14/188 0 0 0/174 1/2 (0.50) 0/172 (0.0) 6/10 (0.6) 8/164 (0.05) 
Valli
330
 (1995) 47/933 0 0 18/886 18/18 (1.0) 9/850 (0.01) 95/103 (0.92) 99/765 (0.13) 
Vercellini
335
 (1997) 23/793 0 0 17/770 2/2 (1.0) 0/751 (0.0) 32/68 (0.47) 48/685 (0.07) 
Vigada
336
 (1995) 13/84 0 0 10/71 1/2 (0.5) 0/59 (0.0) 9/9 (1.0) 9/52 (0.17) 
Widrich
343
 (1995) 10/130 0 0 0/120 1/1 (1.0) 0/119 (0.0) 4/8 (0.5) 0/112 (0.0) 
        
Endometrial disease 
studies (65) 
937/26346 
3.6% (3.3-
3.8%) 
25/937 
2.7% (1.7-3.9%) 
1196/25409 
4.7% (4.5-5.0%) 
- - 2004/2570 900/21643 
        
Endometrial cancer 
studies (56) 
927/24649  
3.8% (3.6-
4.0%) 
8/927 
0.8% (0.4-1.7%) 
1069/23722 
4.5% (4.3-4.8%) 
768/889 167/21764 - - 
        
 
* Failed outpatient hysteroscopic procedures included technical aspects (e.g. cervical stenosis, anatomical factors), inadequate visualization (e.g. obscured by bleeding) or patient factor 
(e.g. pain)  
†Failed outpatient hysteroscopies, which were successfully performed subsequently as an inpatient NOT included in the failure rates  
‡ 128 „unsatisfactory hysteroscopies‟ but all included in results 
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Appendix 21 Life expectancies of United Kingdom women stratified by age, surgery 
and presence of endometrial cancer  
 
      
Life Expectancy Age 45 years Age 55 years Age 65 years Age 75 years Age 80+ years 
      
    
General    
Non-discounted 36.11 26.94 18.51 11.40 8.49 
Discounted 27.37 21.68 15.76 10.22 7.79 
General + abdominal hysterectomy    
Non-discounted 36.11 26.92 18.45 11.31 8.39 
Discounted 27.37 21.66 15.72 10.14 7.70 
    
Endometrial Cancer (Immediate Diagnosis)    
Non-discounted 30.00 (18.02) 19.95 (16.02) 13.54 (8.02) 9.26 (4.80) 5.48 (2.31) 
Discounted 22.98 (14.33) 16.33 (13.32) 11.73 (7.23) 8.38 (4.53) 5.13 (2.25) 
    
Endometrial Cancer (Delayed Diagnosis)    
Non-discounted 29.19 (17.59) 19.23 (15.47) 13.04 (7.79) 8.97 (4.71) 5.33 (2.28) 
Discounted 22.40 (14.01) 15.77 (12.89) 11.32 (7.03) 8.14 (4.45) 5.00 (2.23) 
      
 
The values were derived from United Kingdom life tables for females
177
, data from the International Federation 
of Gynaecology and Obstetrics (FIGO),
72
 the West-Midlands Cancer Intelligence Unit (WMCIU) and Wingo et 
al.
344
 Discounted values are shown at 1.5% per year. Survival times for delayed diagnosis relate to times from 
initial investigation. The lower ranges of values used in sensitivity analyses are shown in parentheses. See text 
for further details. 
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Appendix 22 Investigation of postmenopausal bleeding: Base-case results for the
      decision model with a starting age of 65 years 
 
    
Strategy Average cost per 
patient (£) 
Expected survival per 
patient (years)* 
Dominated by 
    
    
No investigation 146.27 15.538200  
USS 5mm 358.20 15.556677  
USS 4mm 371.84 15.557039  
EB 378.16 15.557045  
OPH 385.58 15.554847 USS (either) or EB 
USS5+EB 517.96 15.557906  
USS4+EB 529.33 15.557924  
USS5+OPH 533.18 15.558053  
EB+OPH 545.32 15.557931 USS5mm+OPH 
USS4+OPH 545.34 15.558083  
USS+EB+OPH 599.32 15.557931 USS+OPH 
    
 
EB = endometrial biopsy, OPH = outpatient hysteroscopy, USS = transvaginal ultrasound.  
*It is not claimed that the model can predict even a population average survival accurately to 6 decimal places, the numbers 
are quoted in that form to show how little difference the various strategies make to the expected survival. 
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Appendix 23 Incremental cost-effectiveness ratios for diagnostic strategies,  
compared to ultrasound (5mm cut-off) assuming endometrial biopsy is 
performed at the same visit following a positive ultrasound or 
outpatient hysteroscopy 
 
     
Strategy Incremental 
cost (£) 
Life Years 
Gained (LYG) 
Average days 
extra survival 
per patient 
ICER (£/LYG) 
     
     
USS 4mm 10.09 0.000362 0.13 27,873 
EB 48.99 0.000368 0.13 133,125 
OPH 53.37 -0.00183 -0.67 D 
USS 5mm+EB 188.79 0.001229 0.45 153,613 
USS 4mm+EB 200.17 0.001246 0.45 160,650 
USS 5mm+OPH 204.01 0.001376 0.50 148,263 
EB+OPH 216.15 0.001254 0.46 172,368 
USS 4mm+OPH 216.17 0.001405 0.51 153,858 
USS 4mm+EB+OPH  270.15 0.001254 0.46 215,431 
     
 
Survival discounted at a rate of 1.5% 
D = dominated by alternate strategy 
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Appendix 24 Investigation of postmenopausal bleeding at different ages of  
presentation: Non-discounted incremental cost-effectiveness ratios of 
strategies compared to ultrasound (5mm cut-off)  
 
 
  
Strategy ICER compared to USS5mm for starting age (years) 
 45 55 65 75 80+ 
      
      
USS 4mm 17,858 20,434 31,195 61,407 161,595 
EB 17,426 21,848 D(USS4mm) D(USS5mm) D(USS5mm) 
OPH D(USS5mm) D(USS5mm) D(USS5mm) D(USS5mm) D(USS5mm) 
USS5+EB 55,907 65,615 110,317 290,752 D(USS5mm) 
USS4+EB 59,157 69,395 116,442 304,691 D(USS5mm) 
USS5+OPH D(USS5mm+EB) D(USS4mm+EB) 104,050 183,487 370,562 
EB+OPH 64,291 75,422 D(USS5mm+OPH) D(USS5mm+OPH) D(USS5mm) 
USS4+OPH D(EB+OPH) 74,049 109,302 D(EB+OPH) D(USS5mm+OPH) 
      
 
D(X)  =  dominated by strategy X 
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Appendix 25 Sensitivity analysis for the diagnostic strategy ultrasound using a 4mm  
      cut-off compared to ultrasound using a 5mm cut-off  
(When varying the test characteristics for ultrasound, low and high values were 
taken for both cut-off points simultaneously) 
 
    
Variable Value Survival gain (days 
per 1000 patients 
Extra cost  
(£ per patient) 
    
    
Base  132 13.63 
    
Adjustment for conditional probability EBtpr after USS* 0 -8 13.65 
Probability of upstaging cancer 0.3 834 13.51 
Probability D&C fpr 0 133 13.49 
Probability D&C fpr 0.03 130 13.92 
Probability D&C tpr 0.82 130 13.64 
Probability D&C tpr 1 133 13.63 
Probability EB fpr 0 139 12.57 
Probability EB fpr 0.02 125 14.7 
Probability EB tpr 0.84 119 13.66 
Probability pEB tpr 0.99 139 13.62 
Probability USS fpr low 132 13.63 
Probability USS fpr high 131 15.93 
Probability USS tpr low 202 13.57 
Probability USS tpr high 132 13.63 
Probability USS success 0.98 129 13.36 
Probability pUSS success 1 132 13.63 
Probability of endometrial cancer (prevalence) 0.03 76 13.97 
Probability of endometrial cancer (prevalence) 0.1 273 12.78 
    
 
* Adjustment made to account for lack of complete test independence 
Survival discounted at a rate of 1.5% 
D&C = dilatation and curettage, EB = endometrial biopsy, fpr = false positive rate, OPH = outpatient hysteroscopy, tpr = true 
positive rate, USS = transvaginal ultrasound.  
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Appendix 26 Sensitivity analysis for the diagnostic strategy endometrial biopsy   
       compared to ultrasound using a 5mm cut-off  
 
    
Variable Value Survival gain (days 
per 1000 patients 
Extra cost  
(£ per patient) 
    
    
Base case  134 19.95 
    
Adjustment for conditional probability EBtpr after USS* 0.01 69 20.12 
Probability of upstaging cancer 0 -76 19.98 
Probability Upstage 0.3 1187 19.78 
Probability D&C fpr 0 143 18.62 
Probability D&C fpr 0.03 116 22.62 
Probability D&C tpr 0.82 130 19.96 
Probability D&C tpr 1 135 19.95 
Probability EB fpr 0 201 10.19 
Probability EB fpr 0.02 67 29.71 
Probability EB tpr 0.84 115 20.00 
Probability pEB tpr 0.99 144 19.93 
Probability USS fpr 0.43 131 24.54 
Probability USS fpr 0.47 137 15.37 
Probability USS tpr 0.94 345 19.76 
Probability USS tpr 0.98 64 20.02 
Probability EB success 0.85 139 30.74 
Probability EB success 0.91 130 9.16 
Probability USS success 0.98 129 14.64 
Probability pUSS success 1 134 19.95 
Probability of endometrial cancer (prevalence) 0.03 48 22.69 
Probability of endometrial cancer (prevalence) 0.1 349 22.69 
    
 
* Adjustment made to account for lack of complete test independence 
Survival discounted at a rate of 1.5% 
D&C = dilatation and curettage, EB = endometrial biopsy, fpr = false positive rate, OPH = outpatient hysteroscopy, tpr = true 
positive rate, USS = transvaginal ultrasound.  
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Appendix 27 Sensitivity analysis for the diagnostic strategy endometrial biopsy  
      compared to ultrasound using a 4mm cut-off  
 
    
Variable Value Survival gain (days 
per 1000 patients 
Extra cost  
(£ per patient) 
    
    
Base  2 6.32 
    
Adjustment for conditional probability EBtpr after USS* 0.01 -63 6.49 
Probability of upstaging cancer 0 -68 6.33 
Probability Upstage 0.3 353 6.26 
Probability D&C fpr 0 10 5.14 
Probability D&C fpr 0.03 -14 8.7 
Probability D&C tpr 0.82 1 6.32 
Probability D&C tpr 1 3 6.32 
Probability EB fpr 0 62 -2.37 
Probability EB fpr 0.02 -58 15.01 
Probability EB tpr 0.84 -4 6.34 
Probability pEB tpr 0.99 5 6.31 
Probability USS fpr 0.49 -1 10.91 
Probability USS fpr 0.54 6 -0.56 
Probability USS tpr 0.97 143 6.19 
Probability USS tpr 1 -68 6.39 
Probability EB success 0.85 7 17.11 
Probability EB success 0.91 -2 -4.47 
Probability USS success 0.98 0 1.29 
Probability pUSS success 1 2 6.32 
Probability of endometrial cancer (prevalence) 0.03 -27 8.72 
Probability of endometrial cancer (prevalence) 0.1 76 0.34 
    
 
* Adjustment made to account for lack of complete test independence 
Survival discounted at a rate of 1.5% 
D&C = dilatation and curettage, EB = endometrial biopsy, fpr = false positive rate, OPH = outpatient hysteroscopy, tpr = true 
positive rate, USS = transvaginal ultrasound.  
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Appendix 28 Basis for recommendations about the use of interventions, treatments or service 
 
Code for categorising the quality of the evidence*: 
 
I  At least one properly designed randomised controlled trial  
  
  (High quality studies with a blind comparison of test to reference standard in an appropriate population spectrum)* 
 
 
II  Well-designed controlled trials or well-designed cohort or case-control analytic studies, preferably from more than one centre or  
  research group or multiple time-series or dramatic results in uncontrolled experiments  
  
  (Any one of the following is present in the study: narrow population spectrum, differential use of reference standard, reference  
 standard not blind, case-control design)* 
 
 
III  Opinions of respected authorities based on clinical evidence, descriptive studies or reports of expert committees  
  
  (Any three or more of the above)* 
 
 
IV  Evidence inadequate owing to problems of methodology (e.g. sample size, length or comprehensiveness of follow up) or conflicts of 
evidence  
  
  (Expert opinion)* 
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Appendix 28 continued 
 
 
 
Evidence <£3000 per QALY £3000 - £20,000 per 
QALY 
£20,000 - £30,000 per 
QALY 
>£30,000 per QALY Negative QALYs 
 
I Strongly Supported Strongly Supported Supported Borderline Not Supported 
II Strongly Supported Supported Borderline Borderline Not Supported 
III Supported Borderline Borderline Borderline Not Supported 
IV Not Proven Not Proven Not Proven Not Proven Not Proven 
 
 
* The levels of evidence are not suitable for assessing test accuracy studies, so a grading system devised by the NHS Centre for Reviews 
and Dissemination
187
 has been used to adapt the code for categorising the quality of evidence. 
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Appendix 29 Publications from the thesis 
 
 
1. Clark TJ, Mann CH, Shah N, Song F, Khan KS, Gupta JK. Accuracy of outpatient 
endometrial biopsy in the diagnosis of endometrial hyperplasia: A systematic review. Acta 
Obstet Gynecol Scand 2001; 80(9): 784-793. 
 
2. Clark TJ, Mann CH, Shah N, Song F, Khan KS, Gupta JK. Accuracy of outpatient 
endometrial biopsy in the diagnosis of endometrial cancer: A systematic review. Br J 
Obstet Gynecol 2002; 109: 313-321. 
 
3. Clark TJ, Bakour SH, Khan KS, Gupta JK. Evaluation of outpatient hysteroscopy and 
ultrasonography in the diagnosis of endometrial disease. Obstet Gynecol 2002; 99: 1001-
1007. 
 
4. Gupta JK, Chien PFW, Voit D, Clark TJ, Khan KS. Ultrasonographic endometrial 
thickness for diagnosing endometrial pathology in women with postmenopausal bleeding: 
A meta-analysis. Acta Obstet Gynecol Scand 2002;81:799-816. 
 
5. Clark TJ, Voit D, Gupta JK, Hyde C, Song FS, Khan KS. Accuracy of hysteroscopy in the 
diagnosis of endometrial cancer and hyperplasia: a systematic quantitative review. JAMA 
2002,288:1610-22. 
 
6. Clark TJ, Khan KS, Gupta JK. The diagnosis of intrauterine pathology in postmenopausal 
women: An evidence-based approach. Reviews in Gynaecological Practice 2002; 2 : 109-
116.  
 
7. Clark TJ, Gupta JK. Endometrial sampling of gynaecological pathology. Obstetrician and 
Gynaecologist 2002;4:169–174. 
 
8. Clark TJ, Gupta JK. Outpatient Hysteroscopy. Obstetrician and Gynaecologist 
2002;4:217-221. 
 
9. Bachmann LM, Clark TJ, ter Riet G, Gupta JK, Khan KS. Probability analysis for 
diagnosis of endometrial hyperplasia and cancer in postmenopausal bleeding: An 
approach for a rational diagnostic workup. Acta Obstet Gynecol Scand 2003; 82: 1-6. 
 
10. Clark TJ, Barton PM, Gupta JK, Khan KS. Ambulatory diagnosis of endometrial cancer in 
women with postmenopausal bleeding. (ISBN) West Midlands Health Technology 
Assessment Collaboration Report 2003University of Birmingham [in press, will be 
available at http://www.publichealth.bham.ac.uk] 
 
11. Clark TJ, Khan KS, Ter Riet G, Gupta JK. Bias associated with delayed verification in 
test accuracy studies: Accuracy of tests for endometrial hyperplasia may be much higher 
than we think! BMC Med Res Methodol 2003 (submitted) 
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